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Summary 
Malaria is an infectious disease caused by protozoan pathogens of the genus 
Plasmodium. The most important species affecting humans is P. falciparum 
transmitted by the bite of female Anopheles mosquitoes during a blood meal. About 
40% of the world’s population is exposed to the parasite and 350 to 500 million cases 
of disease and more than one millions deaths are reported every year. Almost 80% 
of these cases occur in sub-Saharan Africa, where mainly children younger than five 
years and pregnant women are affected. Due to problems with arising resistance of 
mosquitoes against insecticides and parasites against drugs, the development of a 
malaria vaccine is an urgent need. It has been shown more than 30 years ago that 
sterile protection against malaria infection is feasible by vaccination with irradiated 
sporozoites. Since then many malaria vaccine candidates have been developed but 
there is no vaccine on the market to date.  
We have established a strategy to develop synthetic peptides of P. falciparum 
antigens for inclusion in a multi-stage multivalent malaria subunit vaccine based on 
the immunopotentiating reconstituted influenza virosome (IRIV) technology. IRIVs are 
an already registered delivery/adjuvant system based on liposomes incorporating 
influenza surface proteins hemagglutinin and neuraminidase. IRIVs enhance and 
facilitate the delivery of antigens to antigen presenting cells. This technology allows a 
stepwise lead peptide optimization based on parasite-binding properties of antibodies 
elicited after immunization of experimental animals with virosomally-formulated 
peptide-phospholipid conjugates. In this thesis the development steps of three 
peptide antigens are described: UK-39 a peptide derived from the sporozoite antigen 
circumsporozoite protein (CSP), AMA49-CPE derived from the blood-stage protein 
apical membrane antigen 1 (AMA-1) and FB-23 derived from the blood-stage protein 
serine repeat antigen 5 (SERA5). All optimized peptides induced parasite cross-
reactive antibodies in experimental animals. Virosomal formulations of the antigens 
UK-39 and AMA49-CPE were carried into a phase 1 clinical trial. Both vaccine 
components were safe and immunogenic in malaria-naïve volunteers. Two 
immunizations with appropriate doses of UK-39 or AMA49-CPE were enough to 
induce high titers of parasite-binding antibodies. Combined delivery of the two 
peptides did not interfere with the development of an antibody response to either of 
the two antigens. The antibody responses were affinity maturated and long-lived, 
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indicating the formation of B cell memory. Purified total IgG from UK-39 immunized 
volunteers inhibited sporozoite migration, invasion and development in a dose 
dependent manner. Further clinical trials with this two-component vaccine candidate 
are ongoing and new peptide candidates like FB-23 have been developed and are 
now ready for preclinical and clinical profiling. 
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Zusammenfassung 
Malaria ist eine Infektionskrankheit die durch Protozoen des Genus Plasmodium 
verursacht wird. Die bedeutendste, den Menschen befallende Spezies, ist P. 
falciparum, welche durch den Biss einer blutsaugenden Anopheles Mücke 
übertragen wird. Etwa 40% der Weltbevölkerung lebt in Gebieten, in denen der 
Parasit vorkommt und jährlich werden zwischen 350 und 500 Millionen 
Krankheitsfälle und mehr als eine Million Todesfälle gemeldet. Fast 80% aller Fälle 
treten in Afrika südlich der Sahara auf, wo vor allem Kleinkinder jünger als 5 Jahre 
und schwangere Frauen betroffen sind. Ein Malaria-Impfstoff wird dringend benötigt, 
da sich Medikamenten-resistente Parasiten und Insektizid-resistente Mücken 
ausbreiten. Vor mehr als 30 Jahren wurde gezeigt, dass Menschen eine sterile 
Immunität entwickeln können, wenn sie mit durch Bestrahlung abgeschwächten 
Sporozoiten geimpft werden. Seither sind viele Malaria Impfstoffkandidaten 
entwickelt worden, aber es gibt bis heute keinen effizienten Impfstoff. 
Wir haben eine Strategie zur Entwicklung von künstlichen Peptiden, abgeleitet von P. 
falciparum Antigenen, etabliert, die zusammen mit der Virosomen-Technologie 
(Immunopotentiating Reconstituted Influenza Virosomes=IRIV) zur Herstellung eines 
multi-Stadien multivalenten Malaria Impfstoffes ermöglichen soll. Virosomen sind ein 
registriertes Verabreichungs-/Adjuvanssystem, das auf Liposomen, welche die 
Influenza Proteine Hämagglutinin und Neuraminidase auf der Oberfläche tragen 
basiert. Virosomen verstärken und erleichtern die Aufnahme von Antigenen durch 
Antigen-präsentierende Zellen. Phopshpolipid-Konjugate von Fremdpeptiden können 
in der Virosomen Membran verankert und so dem Immunsystem präsentiert werden. 
Diese Technologie erlaubt eine schrittweise Entwicklung und Verbesserung von 
Peptidantigenen. Als Auswahlkriterium dient hierbei die Fähigkeit der virosomal 
formulierten Peptide, Parasiten-Bindende Antikörper hervorzurufen. In dieser 
Dissertation beschreiben wir Entwicklungsschritte von drei Peptid-Antigenen: UK-39 
ein Peptid, das vom Sporozoiten Antigen Circumsporozoite Protein (CSP) abgeleitet 
ist, AMA49-CPE, abgeleitet vom Blutstadien Protein Apical Membrane Antigen 1 
(AMA-1) und FB-23 abgeleitet vom Blutstadienprotein Serine Repeat Antigen 
(SERA5). Alle optimierten Peptide induzierten Parasiten-Bindende Antikörper in 
Tieren. Virosomale Formulierungen der Peptide UK-39 und AMA49-CPE wurden in 
einem Phase 1 klinischen Versuch in Malaria-naiven Freiwilligen getestet. Beide 
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Impfstoff-Komponenten waren immunogen, ungefährlich und wurden gut toleriert. 
Zwei Immunisierungen mit einer adäquaten Dosis UK-39 oder AMA49-CPE waren 
genug, um hohe Parasiten-bindende Antikörper Titer hervorzurufen. Kombinierte 
Impfung mit UK-39 und AMA49-CPE hatte keinen negativen Einfluss auf die 
Entwicklung einer Antikörper Antwort gegen die einzelnen Komponenten. Die 
Antikörper Antworten zeigten Affinitätsreifung und waren langlebig, was für die 
Entwicklung von langlebigen Gedächtnis B-Zellen spricht. Gereinigtes IgG von UK-39 
immunisierten Freiwilligen hemmte abhängig von der Antikörper Konzentration 
Migration, Invasion und Wachstum von P. falciparum Sprozoiten in vitro. Weitere 
klinische Versuche mit diesen beiden Kandidaten sind im Gange und geplant und 
weitere Komponenten, wie FB-23, stehen bereit für eine detaillierte präklinische und 
klinische Charakterisierung 
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1.1 Plasmodium and Malaria 
1.1.1 General 
Malaria is due to infection with a protozoan of the genus Plasmodium, transmitted by 
a female Anopheles mosquito. Plasmodium belongs to the phylum of the 
Apicomplexa that contains other human and veterinary pathogens like Toxoplasma, 
Cryptosporidium, Eimeria, Babesia and Theileria. Apicomplexa are characterized by 
the presence of an apical complex, which contains an apicoplast, a structure in 
juxtaposition to the nucleus and related to the chloroplast, a polar ring organizing the 
microtubules, and vesicles called micronemes, rhoptries and dense granules. These 
vesicles contain proteins involved in parasite motility, adhesion to host cells, invasion 
of host cells, and establishment of the parasitophorous vacuole (PV), which are 
sequentially released during infection of a host cell1. The genus Plasmodium contains 
more than 100 species of which four infect humans: Plasmodium falciparum, the 
most important pathogen for humans, P. vivax, P. ovale, and P. malariae. Other 
species that infect monkeys (e.g. P. knowlesi, P. cynomolgi) or rodents (P. yoelii, P. 
berghei, P. chabaudi, P. vinckei) are studied and used as animal models. 
Malaria remains the most frequent parasitic disease in the world: About 40% of the 
world’s population is exposed to the parasite and 350 to 500 million cases of disease 
are reported every year. Almost 80% of these cases occur in sub-Saharan Africa, 
where mainly children younger than five years and pregnant women are affected. 
With over one million deaths, malaria has one of the highest mortalities of all 
infectious diseases (WHO World Malaria Report 2005). Moreover malaria is a major 
social and economic burden in endemic areas2. There are multiple channels by which 
malaria impedes development, including effects on fertility, population growth, saving 
and investment, worker productivity, absence, premature mortality and medical costs. 
1.1.2 Life Cycle of Plasmodium 
The life cycle of Plasmodium is complex (Figure 1). It involves two hosts, a female 
mosquito of the genus Anopheles and a vertebrate (e.g. a human). The cycle can be 
divided into three consecutive phases of multiplication: Two phases of schizogony 
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(asexual multiplication) in the vertebrate host first in hepatocytes then in erythrocytes 
and one phase of sporogony (sexual multiplication) in the mosquito. The vertebrate 
host gets naturally infected by the bite of a mosquito injecting the parasite in the 
sporozoite form. Sporozoites rapidly migrate to the liver via the blood circulation. 
They invade hepatocytes where they develop into hepatic schizonts3,4. Every 
schizont produces up to 10,000 merozoites in a few days, which are released into the 
blood stream where they infect erythrocytes. In the erythrocyte they multiply giving 
raise to up to 25 merozoites, which are released and again invade erythrocytes 
thereby maintaining the erythrocytic cycle. In parallel a few parasites differentiate into 
male or female sexual forms called gametocytes. Once ingested by a blood sucking 
mosquito gametocytes give rise to sexual gametes, which fuse in the midgut lumen. 
The zygotes formed by this fertilization develop into motile ookinetes, which invade 
and traverse the midgut epithelium. Diploid ookinetes undergo meiosis and, on 
reaching the basal side of the midgut, transform into oocysts, thereby undergoing 
several rounds of mitosis as they mature. Each oocyst releases thousands of haploid 
sporozoites into the mosquito hemocoel, from where they are transported through the 
hemolymph and invade the salivary glands. Sporozoites are finally transmitted to a 
new vertebrate host during an infective bite5.  
The life cycle of Plasmodium thus consists of three invasive stages: the ookinetes 
traversing the intestinal cells in the mosquito, the sporozoites infecting the mosquito 
salivary gland, and the vertebrate hepatocytes, and the merozoites infecting the 
vertebrates’ erythrocytes. The sporozoites and the hepatic stages are called the pre-
erythrocytic stages. The hepatic stage is asymptomatic in humans and takes 
approximately one week in the case of P. falciparum. Clinical symptoms that can be 
very severe are solely due to infection of erythrocytes. Almost all antimalarial drugs 
currently in use are directed against this stage6. 
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Figure 1. Life cycle of P. falciparum (Source Wirth 2002)7 
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1.2 Sporozoite Biology 
1.2.1 General 
Sporozoites represent a special life stage of the parasite as they interact with both 
the mosquito and the vertebrate host. In the mosquito the sporozoites are formed in 
the oocysts in the midgut cell wall, then infect the salivary glands and once injected 
into the vertebrate host they rapidly reach the liver and infect hepatocytes. 
Sporozoites are polarized, elongated cells (Figure 2) measuring about 10µm in length 
and 1µm in width, and have an apical complex. Until recently the only well 
characterized sporozoite proteins have been the circumsporozoite protein (CSP) and 
the thrombospondin-related adhesive protein (TRAP). These two proteins are on the 
sporozoite surface and contain typical adhesion motifs implicated in ligand receptor 
interactions in mammals3,8. 
 
Figure 2. A: Schematic representation of a Plasmodium sporozoite showing some of 
its organelles and sub-cellular structures (Source: Kappe et al. 2004)4. B: P. 
falciparum sporozoite isolated from the salivary glands of an infected mosquito, 
stained with antibodies against circumsporozoite protein (orange) and Hoechst Dye 
No. 33256 (nucleus in blue) (Photo S. Okitsu). 
1.2.2 Circumsporozoite Protein 
CSP is expressed only in Plasmodium sporozoites and cannot be found in other 
Apicomplexa. It is a major surface protein encoded by a single copy gene and covers 
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the entire surface of the sporozoite4,9. CSP is also present in the micronemes10 from 
where it is continuously secreted to the anterior pole of the parasite surface and 
transported to the sporozoites posterior end, where it is released11. Due to its 
abundance, surface localization, immunogenicity and key role in parasite invasion, 
CSP is one of the leading candidate molecules for the development of malaria pre-
erythrocytic vaccines. CSPs from different Plasmodium spp. display common 
structural features, including a signal peptide, a central domain composed mostly of 
amino acid repeats, and a C-terminal hydrophobic sequence (Figure 3)12. 
 
 
 
Figure 3.  Schematic representation of CSP. 
 
 
The central repeats are formed by a variable number of in-tandem repeats that 
contain immunodominant B cell epitopes13. The sequence of the CSP repeats is 
species specific. In P. falciparum the repetitive unit consists of tandem repeats of the 
tetrapeptide NANP interspersed with four copies of NVDP. The repeat motif adopts a 
type-I b-turn, which is stabilized by hydrogen bonding14. The function of these 
repeats is unknown. They are flanked by two conserved regions called region I, 
region II-plus and region III. Region I consists of a pentapeptide KLKQP involved in 
the attachment to the mosquito salivary glands and was shown to be the recognition 
site for proteolytical cleavage upon contact with hepatocytes15. Region II-plus is an 
18-amino acid sequence containing a thrombospondin repeat (TSR) type I domain. 
The TSR is an ancient eukaryotic domain found in a superfamily of adhesive proteins 
related to thrombospondin. These proteins are involved in immunity, cell adhesion, 
angiogenesis, and the development of the nervous system (Adams &Tucker Dev.Dyn 
2000). The TSR domain mediates adhesion to heparan sulfate proteoglycans 
(HSPGs) of the liver16 and is important for sporozoite motility and infectivity17. Region 
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III is predicted to form an amphipathic a-helix that may provide the proper framework 
for the neighboring region II-plus adhesion motif4. The C-terminus of CSP consists of 
a hydrophobic stretch of residues that typically encodes a 
glycosylphosphatidylinositol (GPI) attachment signal, but this has not been formally 
demonstrated. Recent results in our laboratory have shown that anti-GPI mabs 
recognize CSP in Western blot with sporozoite lysate (M. Tamborrini personal 
communication). 
 
1.2.3 Gliding Motility 
Most apicomplexan invasive stages, called zoites are motile. These parasites have a 
particular way of moving, called gliding motility, which allows them to glide rapidly (1-
10µm/s) on solid substrates and actively invade target cells in a matter of seconds. 
Gliding motility is based on the redistribution (capping) of adhesion molecules called 
invasins from the anterior to the posterior end of the parasite. The invasins linking the 
intracellular actin-myosin motor and the extracellular substrate belong to the TRAP 
family18 and act like a tank’s caterpillar tracks. The molecular motor pulls the invasins 
backward, and as the extracellular portion of the protein is anchored to a fixed 
substrate, this leads to a forward movement of the parasite.  
During sporozoite gliding a fragment of TRAP containing only the extracellular portion 
is left behind as a trail19. Large amounts of CSP are also continuously released at the 
posterior end of the parasite during gliding20. As CSP seems to be attached to the 
parasite membrane via a GPI anchor, it has no cytoplasmic domain and cannot be 
directly coupled to the actin-myosin motor. It is probably attached to the motor 
through another transmembrane protein, which might be TRAP although an 
interaction between these two could not been shown by immunoprecipitation. 
Supporting such a functional coupling, deletion of region II in the TSR of CSP 
induces the same phenotype as observed after deletion of TRAP17. 
 
1.2.4 Invasion of Host Cells 
The first ultrastructural analyses on the invasion of host cells by zoites has shown 
that merozoites enter erythrocytes via formation of a moving junction21. A tight 
junction between the apical end of the parasite and the target cell surface is formed 
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after initial contact. This junction is moving to the posterior end like a ring around the 
zoite, which enters into a vacuole in the host cell cytoplasm. This tight junction 
formation has been observed in several other Apicomplexa22. Internalization only 
takes some seconds and is based on a mechanism similar to gliding motility. Ligands 
are secreted to the surface of the parasite at the anterior pole, attach to the surface 
of the host cell and are redistributed to the back (Figure 4). This process does not 
rupture the integrity of the host cells plasma membrane23.  
 
Figure 4. Invasion of a host cell by a zoite. After attachment the zoite establishes a 
tight junction between micronemal proteins, the neck of the rhoptries and the target 
cell. The redistribution of this moving junction (MJ) to the posterior end of the zoite 
moves the parasite forward. This forward movement leads to the formation of an 
invagination, which gives raise to the parasitophorous vacuole (PV) surrounded by a 
parasitophorous vacuole membrane (PVM). Once the redistributed proteins reach the 
posterior pole of the parasite they are proteolytically cleaved and shed into the 
medium (Source: Alexander et al. 2005)24. 
1.2.5 From the Mosquito to the Liver 
In their search for capillaries, infected mosquitoes probe the skin of the host and 
deposit saliva containing vasodilators, anticoagulants, and Plasmodium sporozoites. 
Although one mosquito can harbor thousands of sporozoites, they normally only 
inject a low number (10-200) during a blood meal25. Intravital microscopy with 
transgenic parasites expressing GFP has shown that parasites in the skin are highly 
motile and migrate through the cutaneous tissue before actively penetrating through 
the vascular endothelium to reach the blood circulation26. The presence of anti-
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sporozoite antibodies in the skin of mice immunized with irradiated sporozoites can 
reduce or even block the observed motility of the parasites.  
Once in the blood stream the sporozoites reach the liver within some minutes27. Most 
circulating sporozoites are arrested in the liver after a single passage, suggesting 
that specific receptors are present on the cells lining the liver sinusoids (Figure 5). As 
CSP covers the entire sporozoite plasma membrane, it is very likely that it contains 
the postulated liver ligand(s). Numerous observations indicate that the ligand is 
contained in the stretch of positively charged residues of region II-plus (TSR) of CSP, 
and that the binding sites in the liver sinusoids are heparan sulfate proteoglycans 
(HSPGs) from the extracellular matrix, protruding through fenestrations into the 
sinusoids17,28.  
 
 
Figure 5. Sporozoite arrest in the liver, passage of the sinusoidal barrier and invasion 
of hepatocytes (Source Kappe et al. 2003)29. 
 
To reach the hepatocytes, sporozoites have to traverse the sinusoidal barrier built by 
endothelial cells and Kupffer cells (Figure 5). Kupffer cells are macrophages of the 
liver involved in removal of foreign and degraded substances from the blood stream. 
Studies in Brown Norway rats and intravital microscopy in mice have shown that P. 
berghei sporozoites traverse Kupffer cells in a vacuole, which does not fuse with 
lysosomes to reach the underlying hepatocytes30.  
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1.2.6 Hepatocyte Infection 
According to the current model of hepatocyte infection by Plasmodium sporozoites, 
the parasite migrates through several hepatocytes by disrupting the cell’s plasma 
membrane, i.e. without vacuole formation, before infecting a cell by tight junction and 
vacuole formation. Migration triggers the secretion of the content of the secretory 
vesicles at the apical pole of the parasite, needed for tight junction formation between 
the sporozoite and its target cell and successful infection by vacuole formation31. 
Migration through hepatocytes also induces the release of hepatocyte growth factor 
(HGF) by wounded cells. HGF-MET signaling in neighboring cells protects them from 
apoptosis, thereby allowing successful establishment of infection by the parasite32. It 
has to be taken into account that most of these studies have been done in in vitro or 
artificial murine model systems and have not been confirmed in vivo or with P. 
falciparum so far.  
Once inside a PV in the hepatocyte, the sporozoites differentiate into hepatic 
schizonts, also called exo-erythrocytic forms (EEFs). Within 2 days in rodent and 6 to 
7 days in primate parasites the schizonts grow to a size bigger than the initial size of 
the hepatocyte containing thousands of merozoites capable of infecting erythrocytes 
(Figure 6). The merozoites are released to the blood stream in a mechanism not yet 
completely understood. A recent study with P. berghei shows that parasites induce 
the death and the detachment of their host hepatocytes, followed by the budding of 
parasite-filled vesicles (merosomes) into the sinusoid lumen33. 
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Figure 6. In vitro development of P. falciparum exo-erythrocytic forms in primary 
human hepatocytes. A. Intrahepatic parasites, indicated by an arrow, have been 
stained with an anti-Plasmodium HSP70 antibody (green), and the nuclei of the 
hepatocyte and the parasite with DAPI (blue). B. Mature schizonts 9 days after 
infection, stained with an anti-RAP1 (rhoptry associated protein 1) antibody (red) and 
DAPI (blue) (Photos O. Silvie). 
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1.3 Vaccine Development 
“… let me be permitted to use the word ‘vaccinate’ to express the act of 
inoculating a chicken with the attenuated virus” 
Louis Pasteur, 1880 
 
1.3.1 General 
Vaccination is an elegant way to induce an adaptive immune response in non-
immune individuals by confronting the immune system with important antigenic 
determinants of a pathogen without the deleterious effects of disease. Some of the 
first hints of the use of vaccines date back to the eleventh century when variolation 
(blowing variola crusts into the nostril to immunize against smallpox) was practiced in 
China. By the end of the 18th century Edward Jenner discovered that cowpox, a mild 
illness in humans, could prevent smallpox. A more rational attempt of vaccine design 
began in the 19th century in the laboratory of Louis Pasteur. He discovered 
attenuation to reduce the virulence of a pathogen, a cornerstone in modern vaccine 
development34. 
Advanced vaccine technologies together with the knowledge provided by modern 
immunology formed the basis for more deliberate and sophisticated vaccines. 
Nowadays there are three main approaches for vaccine development: live vaccines, 
nonliving or subunit vaccines, and vaccines based on genetic engineering. 
 
1.3.2 Live Vaccines 
After first methods for attenuation like heat, oxygenation, chemical agents, aging, or 
passage in animal hosts, it was mainly the development of cell culture leading to 
advances in the field of attenuated live vaccines34,35 (Table 1).  
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Table 1. Live vaccines and their approximate times of availability 
(Adapted from Plotkin 2005)34 
Development strategy Date Vaccine or target 
Use of related animal virus 1798 Smallpox 
Chemical attenuation 1885 Rabies 
 1881 Anthrax 
Passage in vitro 1927 BCG 
 1935 Yellow fever 
Cell culture passage 1963 Measles 
 1995 Varicella 
 2005 Rotavirus 89-12 
Cell culture passage with cold adaptation 1969 Rubella 
 2003 Live influenza 
Auxotrophy 1989 Ty21a typhoid 
Use of reassortants 1970s Inactivated influenza seed 
  2005 Rotavirus bovine-human 
 
1.3.3 Nonliving and Subunit Vaccines 
Table 2 outlines the strategies for the development of inactivated vaccines. The 
discovery of extracellular bacterial toxins by Roux, Yersin, Behring and Kisato 
permitted the development of toxoids (inactivated toxins)36. As technology advanced, 
it became possible to separate and use subunits of organisms in the form of extracts 
of infected tissue (e.g. rabies), capsular polysaccharides (e.g. typhoid Vi and 
pneumococci) and proteins (e.g. acellular pertussis). Late in the twentieth century 
conjugation of proteins by polysaccharides became important in vaccines against 
encapsulated bacteria (e.g. Haemophilus influenza type b)37. The use of peptides as 
vaccines has been slowed by the need for strong adjuvants, but is still a focus of 
research. 
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Table 2. Nonliving vaccines and their approximate times of availability  
(Adapted from Plotkin, 2005)34 
Vaccine strategy Date Vaccine or target 
Inactivated whole organisms 1896 Typhoid 
 1896 Cholera 
 1897 Plague 
 1926 Whole-cell pertussis 
 1938 Influenza 
 1995 Hepatitis A 
Use of extracts and subunits 1944 Japanese encephalitis 
 1970s Influenza 
 1960 Anthrax 
 1976 Cell-culture rabies 
Use of toxoids 1923 Diphtheria 
 1927 Tetanus 
Use of capsular polysaccharides 1977 Pneumococcal 
 1974 Meningococcal 
 1995 Typhoid 
Use of protein-conjugated capsular 1987 H. influenzae type b 
polysaccharides 2002 Pneumococcal 
 2002 Meningococcal 
Use of purified or recombinant proteins 1986 Hepatitis B 
 1996 Acellular pertussis 
 1998 Lyme disease 
 
1.3.4 Vaccine Development Based on Genetic Engineering  
Advances in molecular biology and genetic engineering have had a dramatic effect 
on vaccine development, providing greater opportunities for construction of 
inactivated antigens and for rational attenuation of organisms through directed 
mutation. Several recombinant strategies are possible. To develop live recombinants, 
genes from heterotypic viruses can be inserted into an attenuated virus. Genes can 
also be inserted into animal, plant, bacterial, viral, or yeast cells for expression of 
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proteins used for immunization. Bacterial DNA plasmids containing foreign genes can 
induce antigen production in muscle cells, inducing a cytotoxic immune response38. 
Another powerful strategy to induce cellular responses uses vectors, microbes that 
are naturally or artificially attenuated for humans, in which foreign genetic information 
has been inserted39. These vectors have often been employed in a prime-boost 
configuration, so called because the immune system is primed with proteins 
expressed by injected DNA plasmids or vector, and then boosted with the same 
proteins in soluble form or expressed by another vector40. The latest approach for 
vaccine development is called ‘reverse vaccinology’.  The availability of microbial 
genome sequences allows for in silico search and identification of new protective 
factors. Candidate genes are recombinantly expressed and used for immunological 
studies. Another use of the genome information is the generation of mutants to get 
genetically attenuated organisms as described above. One example is a P. berghei 
knockout for a gene called uis341. The mutant sporozoites infect hepatocytes but are 
unable to establish blood-stage infections in vivo, and thus do not lead to disease. 
 
1.3.5 Immunopotentiating Reconstituted Influenza Virosomes (IRIVs) 
IRIVs are a liposomal carrier system characterized as spherical, unilammelar vesicles 
with a mean diameter of approximately 150 nm. They consist of 70% egg yolk 
phosphatidylcholine (EYPC), 20% phosphatidylethanolamine (PE) and 10% envelope 
phospholipids originating from H1N1 influenza virus (A/Singapore/6/86) (Figure 7A 
and B). In contrast to liposomes, influenza hemagglutinin (HA) and neuraminidase 
(NA) are intercalated into the lipid bilayer, which give them their fusogenic activity 
and thereby play a key role in the mode of action of these virosomes42. Virosomes 
are prepared by detergent removal43. Specifically, like native influenza virus, 
influenza-derived virosomes enter cells through receptor-mediated endocytosis and 
subsequently fuse with the endosomal membrane (Figure 7A and B). 
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Figure 7. Immunopotentiating reconstituted influenza virosomes (IRIVs). A. Structure 
and mode of action of virosomes with antigen presented on the surface (exogenous). 
B. Structure and mode of action of virosomes with antigen encapsulated in the 
virosome (Adapted from Westerfeld and Zurbriggen, 2005)44. 
 
Influenza viruses use a membrane fusion strategy to deliver their genomes to the 
cytosol of target cells. Hemagglutinin binds to sialic acid residues on glycoproteins or 
glycolipids on the host cell surface45. Receptor binding initiates the uptake of the 
virus through receptor-mediated endocytosis. In this process, virus particles are 
engulfed by the host cell plasma membrane. The vesicles thus formed subsequently 
fuse with endosomes (Figure 7B)46,47. The low pH inside the endosomes (pH 5–6) 
triggers a fusion reaction between the viral envelope and the endosomal membrane, 
which delivers the viral core to the host cell cytosol46,48.  
Hemagglutinin and neuraminidase spikes protruding from the virosomal membrane, 
as well as foreign antigens that may be coupled to the surface of the virosomes via 
lipid anchors, can be recognized by membrane-associated immunoglobulin receptor 
molecules on B lymphocytes (Figure 7A)49. The repetitive arrangement of the 
antigens on the virosomal surface presumably enables cross-linking of these 
immunoglobulin receptors on the B cells which is known to be an exceptionally strong 
activation signal50. The strong immune response induced by peptides presented on 
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the surface of virosomes is predominantly humoral, whereas a supplementary T-
helper immune response is evoked by virosomal influenza-specific glycoproteins44,51.  
Antigen molecules inside virosomes are delivered to the cytoplasm after fusion of the 
virosomes to the endosomal membrane (Figure 7B). This leads to degradation of the 
antigen within the cytoplasm by the proteosome and subsequent transport of the 
antigen peptides into the endoplasmic reticulum (ER) and loading onto MHC class I. 
Peptide-loaded MHC class I molecules reach the cell surface of the antigen 
presenting cell and interact with CD8+ T- cells to induce a cytotoxic T-cell 
response52. 
The virosome-based technology is validated by two marketed products. These 
products are registered for human use in more than 38 countries, and were 
administered to more than 20 million individuals44. 
 
1.3.6 Malaria Vaccine Development 
Malaria vaccine development started in the middle of the 20th century. It is based on 
the observation that a protective immune response eventually develops in people 
who survive repeated attacks of malaria during early childhood53. Older people in 
endemic areas, although almost always harboring the parasite in the blood during 
seasons of high transmission, rarely become clinically ill. This immunity primarily 
impacts the severity of clinical disease, and appears to be linked to continuous 
antigenic stimulation, waning rapidly when exposure ceases. Moreover passive 
transfer of purified immunoglobulins from semi-immune adults can protect malaria-
naïve children54.  
The first success in malaria vaccine development was in 1973, when Clyde et al. 
reported that immunization with sporozoites attenuated by irradiation can protect 
healthy volunteers against infection55. The next milestone was Spf66, a hybrid 
polymer vaccine combining four different antigens from P. falciparum. Spf66 is up to 
now the only malaria vaccine candidate tested in phase III field trials but failed to 
show efficacy (summarized in Graves and Gelband, 2006)56. During the past 5 years 
many vaccine approaches have been tested in clinical trials and many potential 
candidates are now ready for preclinical and clinical assessment (WHO Initiative for 
Vaccine Research). The most advanced vaccine RTS,S/AS02A is based on 
recombinant CSP and was the first pre-erythrocytic vaccine candidate to show 
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protection against malaria in the field57. However, key obstacles to the development 
of a malaria vaccine include the lack of immune correlates of protection, the lack of 
reliable and predictive animal models, and the developmental and antigenic diversity 
and variability of the parasite.  
The traditional approach to develop malaria vaccines has been the targeting of the 
different stages of parasite development (pre-erythrocytic, asexual and sexual 
stages) (Figure 1). Pre-erythrocytic vaccine strategies aim at generating an antibody 
response, which neutralizes sporozoites and prevents them from invading the 
hepatocyte, and/or at eliciting a cell-mediated immune response attacking intra-
hepatic parasites. This type of vaccine would be ideal for travelers because it should 
convert sterile immunity, preventing clinical disease. 
Asexual blood-stage (erythrocytic) vaccine strategies mainly aim at eliciting 
antibodies that will inactivate merozoites and/or target malarial antigens expressed 
on the erythrocyte surface, thus inducing antibody-dependent cellular cytotoxicity and 
complement lysis. This type of vaccine would mostly serve as a disease-reduction 
vaccine in endemic countries by decreasing the exponential multiplication of blood-
stage parasites. 
Vaccines targeting the sexual stage of the parasite, also called transmission-blocking 
vaccines, do not intend to prevent illness or infection in the vaccinated individual, but 
to prevent or decrease transmission of the parasite to new hosts. Other novel 
approaches include the development of multi-stage multi-component vaccines, a 
commercial irradiated sporozoite vaccine58, and an anti-parasite toxin vaccine59. This 
type of potential anti-disease vaccine targets parasite toxins contributing to the 
disease, such as the glycosylphosphatidylinositol (GPI) anchor. 
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Chapter 2: Goal and Objectives 
2.1 Goal 
To contribute to the development of a malaria vaccine by developing and establishing 
a technology platform to choose and optimize P. falciparum-derived antigens for 
inclusion in a multivalent virosomal subunit vaccine. 
 
2.2 Objectives 
1. To optimize and characterize synthetic peptides derived from P. falciparum 
antigens 
2. To evaluate virosomal formulations of candidate peptides in experimental 
animals 
3. To show that virosomally formulated synthetic peptides are safe and 
immunogenic in humans 
4. To analyze the human immune response to virosomally formulated 
synthetic peptides 
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Summary 
The circumsporozoite protein (CSP) of Plasmodium falciparum is a leading candidate 
antigen for inclusion in a malaria subunit vaccine. We describe here the design of a 
conformationally constrained synthetic peptide, designated UK-39, which has 
structural and antigenic similarity to the NPNA-repeat region of native CSP. NMR 
studies on the antigen support the presence of helical turn-like structures within 
consecutive NPNA motifs in aqueous solution. Intramuscular delivery of UK-39 to 
mice and rabbits on the surface of immunopotentiating reconstituted influenza virus-
like particles (IRIV) elicited high titers of sporozoite cross-reactive antibodies. 
Influenza virus proteins were crucially important for the immunostimulatory activity of 
the IRIV-based antigen delivery system, since a liposomal formulation of UK-39 was 
not immunogenic. IgG antibodies elicited by UK-39 loaded virosomes inhibited 
invasion of hepatocytes by P. falciparum sporozoites, but not by antigenically distinct 
P. yoelii sporozoites. This approach to optimized IRIV-formulated synthetic peptide 
vaccines should be generally applicable and amenable for other infectious and non-
infectious diseases. 
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Introduction 
Malaria is the most important parasitic disease in people and may cause as many as 
2.5 million deaths per annum [1]. Vaccine development against both Plasmodium 
falciparum and P. vivax is ongoing [2] and one candidate vaccine, RTS,S/AS02A 
demonstrated 30% protection against the first episode of malaria and 58% protection 
against severe malaria in a clinical trial in Mozambican children [3]. Nevertheless, it is 
assumed that it will take at least another decade until a malaria vaccine will be 
available that is more effective and more cost effective than current malaria control 
tools, such as insecticide treated bed nets and intermittent preventive treatment in 
infants [4-6]. 
 Apart from plans to develop a radiation-attenuated sporozoite vaccine [7], 
vaccine development against malaria is focusing largely on subunit vaccine 
technologies [8]. It is thought that an effective malaria subunit vaccine will have to 
incorporate antigens against several developmental stages of the parasite. A 
combination of actions against sporozoites, infected liver cells, merozoites and 
infected red blood cells may be required to achieve substantial protective activity [8]. 
The fact that most vaccines currently available are based on attenuated or 
inactivated whole pathogens or material derived directly from them demonstrates that 
the technological problems associated with peptide and protein subunit vaccine 
design are still incompletely solved. Major obstacles include difficulties to retain the 
native conformation of key antibody epitopes and the need for an effective but safe 
human-compatible exogenous adjuvant in order to achieve efficient immune 
responses [9]. 
 We are addressing the problem of protein subunit vaccine design by 
developing synthetic peptide structures that elicit antibodies against surface epitopes 
of native malaria antigens [10-12], and coupling them to the surface of 
immunopotentiating reconstituted influenza virosomes (IRIVs) as a liposomal carrier 
system [12, 13]. IRIVs are spherical, unilammelar vesicles, prepared by detergent 
removal from a mixture of natural and synthetic phospholipids and influenza surface 
glycoproteins. The hemagglutinin membrane glycoprotein of the influenza virus is a 
fusion-inducing component, which facilitates antigen delivery to immunocompetent 
cells. IRIVs represent a universal antigen-delivery system for multi-component 
subunit vaccines, since antigens can be either attached to their surface to elicit 
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antibody responses or encapsulated in their lumen to elicit CD8 T cell responses. 
They have an excellent safety profile and are already registered for human use [14]. 
 Sequential rounds of optimization of synthetic peptide structures, as typically 
applied in drug research, may ideally lead to vaccine candidate antigens, which elicit 
primarily or exclusively antibodies that contribute to immune protection. In the case of 
the central repeat region (NPNA)≈37 of the circumsporozoite protein (CSP) of P. 
falciparum sporozoites, results of clinical trials with a linear (NANP)3 peptide 
conjugated to tetanus toxin in alum [15, 16] were disappointing. We have previously 
described the synthesis and immunological properties of template-bound NPNA 
peptides, which were superior to their linear counterparts in eliciting sporozoite-
binding antibodies [10-12]. Building on NMR and modeling studies we designed and 
synthesized an improved cyclic NPNA-repeat region mimetic peptide (designated 
BP-65), which has been shown to efficiently elicit anti-sporozoite antibody responses 
in mice [11]. Here we describe functional properties of monoclonal antibodies (mAbs) 
elicited by BP-65, and the properties and preclinical profiling of a synthetically more 
accessible derivative (UK-39). An IRIV-based formulation of this peptide, designated 
PEV302, is currently being tested in human clinical trials. 
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 RESULTS 
Sporozoite-inhibitory activity of anti-BP-65 mAbs 
Two mAbs (designated EP3 and EP9) specific for the synthetic compound BP-65 
(Figure 1) were generated from spleen cells of mice immunized with BP-65-loaded 
IRIVs. Both mAbs bind to sporozoites in IFA, and functional inhibitory activity was 
assessed by performing in vitro invasion inhibition assays with P. falciparum 
sporozoites and primary human hepatocytes. At a concentration of 200 µg/ml mAb 
EP3 caused 82% and mAb EP9 100% invasion inhibition (Figure 2A). The inhibitory 
activity decreased in a dose dependent manner, when increasing concentrations of 
BP-66 were added to the antibody-parasite mixture (Figure 2B) confirming the 
specificity of the inhibitory activity of the mAbs. 
 
Design of UK-40 and its phosphatidylethanolamine (PE)-conjugate UK-39 
In an attempt to minimize the size of the synthetic vaccine antigen, a derivative of 
BP-65, called BP-125, without the C-terminal PNA  and N-terminal NPNA portions 
was produced and tested for reactivity with the sporozoite-inhibitory anti-BP-65 mAbs 
EP3 and EP9. Only a strongly diminished reactivity was observed (Figure S1), 
indicating that BP-65 represents the minimal essential structure. 
 In BP-65 the folded conformation of the peptide is stabilized by cross-linking 
an amino group at the ß-position of Pro6 to a spatially adjacent side chain carboxyl of 
Glu as a replacement for Ala16 [11]. Since limited availability of orthogonally protected 
(2S,3R)-3-aminoproline required for the synthesis of BP-65 represented an obstacle 
for up-scaling of the synthesis for clinical grade material, we synthesized derivatives 
of BP-65 designated UK-40 and UK-39 (PE- conjugate of UK-40), in which this 
building block is replaced by (2S,4S)-4-aminoproline (Figure 1). The required 
orthogonally protected N(α)-Fmoc(2S,4S)-4-(Boc)aminoproline ((2S,4S)-Boc-4-
amino-1-Fmoc-pyrrolidine-2-carboxylic acid) is commercially available. 
 
NMR studies of UK-40 
The solution structure of UK-40 was investigated in water (90% H2O, 10% D2O, pH 
5.0, 293 K) by 1H NMR spectroscopy. The 1H NMR spectrum of UK-40 indicated the 
existence of a major and two minor forms in a ratio of 14:3:1, which interconvert 
slowly on the NMR timescale, caused by cis-trans isomerism at Asn-Pro peptide 
bonds. Similar cis-trans rotamers were found in BP-66 in earlier work [11], and in 
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linear peptides containing multiple NPNA-repeats [17]. The major form can be 
assigned the all trans conformation on the basis of observed NOE connectivities. 
Resonance overlap prevented an assignment of the minor forms to specific peptide 
bond rotamers. Chemical shift assignments for the major rotamer (Table S1) were 
made using standard 2D NMR methods [18]. Side chain proton frequencies in UK-40 
exhibited major spectral overlap, although this problem was not as severe as seen in 
linear peptides containing multiple tandem NPNA-repeats. This is illustrated in Figure 
S2, where HN-C(α)H cross peaks from 2D DQF-COSY spectra are shown for UK-40 
and the peptide Ac-(NPNA)3-NH2. Notable in the spectrum of UK-40 are the 
significantly upfield shifted amide HN resonances of Asn9 and Ala12. The amide 
proton chemical shift temperature coefficients were measured and are given in 
Figure S3. Notable are the low values for both Ala8 and Asn9, suggesting that both 
these amide NHs are involved in intramolecular hydrogen bonding. A low value is 
also seen for Ala12, but not for Asn13. 
 2D NOESY spectra of UK-40 showed dNN (i, i+1) NOE connectivities between 
amide protons of Asni+3, Alai+4 and Asni+5 within each NAN motif, as shown in Figure 
S3 and Figure S4. The same pattern of NOE interactions was also found earlier in 
BP-66 [11]. Furthermore, characteristic medium range dαN (i, i+2) NOEs were found 
between Asn7 and Asn9, Asn9 and Asn11, Pro10 and Ala12, Pro14 and Glu16 in UK-40. 
Weak NOE contacts between side chains of the first Asn and the Ala of each NPNA 
motif are also seen, as predicted in the structure model of an NPNA motif in a helical 
turn conformation (vide infra) (Figure 3A). No other medium/long range NOEs were 
observed in NOESY spectra. 
 Using the available short and medium range NOE connectivities, average 
solution structures for UK-40 were calculated using DYANA. The final ensemble of 
20 structures (see Table S2) is shown in Figure 3B. The backbone atoms of residues 
6-16 enclosed within the macrocyclic ring can be superimposed with an rmsd of 1.6 
Å, whereas the remaining residues at the N- and C-termini show much greater 
conformational diversity. When each tetrapeptide motif within the macrocycle are 
considered, the highest structural similarity both to the ANPNA crystal structure and 
to a model helical turn conformation is seen in the first (N5-A8) and in particular the 
central (N9-A12) tetrapeptide motifs (Figure 4), suggesting that helical turns are 
significantly populated in this portion of the molecule. Within the third unit N13-E16, 
Chapter 3: Development and Characterization of a CSP-derived peptide 
 
 32 
however, the helical turn conformations are adopted much less frequently, or not at 
all, in the 20 lowest energy DYANA structures, suggesting either that the turn is not 
significantly populated or, as seems more likely, that the average NMR structures do 
not represent accurately these regions of the macrocycle due to the presence of 
multiple rapidly interconverting helical and extended conformations. The low number 
and weak intensity of many NOEs are indicative of significant backbone flexibility. 
Moreover, the occurrence of significant restraint violations, such as from the Glu16 
C(α)H to Asn17 HN  NOE, indicate also the presence of extended (ß) chain forms. 
 
Antigenic properties 
The antigenic properties of virosomally formulated UK-39 were compared to those of 
BP-65 and two previously described [12] template-bound peptides (JL-934 and JL-
1036) (see Figure 1). Panels of CSP repeat region specific sporozoite-binding mAbs 
obtained after immunization of mice with either NPNA peptides or with P. falciparum 
sporozoites were tested in ELISA for cross-reactivity with the first to fourth generation 
compounds (Table 1). The results demonstrate that antibodies with a range of 
different fine-specificities can bind to the native CSP on the sporozoite surface. Thus 
mAb 1.26 the only sporozoite cross-reactive mAb elicited by the antigen JL-934 [12] 
did not bind to the other peptide antigens and only three of the four sporozoite-
binding mAbs elicited by the peptide antigen JL-1036 [12] cross-reacted with the  
antigens BP-65 and UK-39. Cross-reactivity analysis with a set of twelve CSP repeat 
region specific mAbs raised against P. falciparum sporozoites demonstrated that only 
two of these mAbs cross-reacted with JL-934, five with JL-1036 and all 12 with BP-65 
and UK-39. While cross-reactivity of mAbs Sp4-7H1 and Sp4-1B4 with the antigen 
BP-65 was only weak, all twelve anti-sporozoite mAbs cross-reacted strongly with 
UK-39, indicating that this compound better reflects the native structure of the CSP 
repeat region. 
 
Immunogenicity of virosomally formulated UK-39  
Already one immunization of BALB/c mice with UK-39-loaded IRIV elicited detectable 
titers of anti-UK-39 IgG in ELISA (Figure 5A) and sporozoite cross-reactive IgG in IFA 
(Figure 5B). While a second immunization led to a strong titer increase, a third 
immunization had only a moderate further booster effect. In Western blots with a 
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lysate of salivary glands of P. falciparum infected mosquitoes, anti-UK-39 IgG stained 
a characteristic CSP double-band of 50-55 kDa (not shown).  
 Comparison of immune responses elicited by a liposomal and an IRIV-based 
formulation of UK-39 demonstrated the importance of influenza virus proteins for the 
immunopotentiating activity of IRIVs (Figure 5C). The strong immunogenicity of 
virosomally formulated UK-39 is virtually abolished when the peptide is presented on 
liposomes, lacking influenza derived hemagglutinin and neuraminidase. Also no 
parasite cross-reactive IgG was detected in IFA (not shown). Already one dose of 
IRIV formulated UK-39 elicited high ELISA and IFA IgG titers in rabbits (Figure S5). 
Additional immunizations had only a minor booster effect. IgG from immunized 
animals stained the CSP double-band in Western blots (not shown). 
 
Generation of sporozoite inhibitory antibodies by UK-39 
Total IgG purified from UK-39-immunized rabbits showed at a concentration of 1 
mg/ml of total IgG, inhibitory activity in sporozoite in vitro invasion inhibition assays 
(Figure 6A). Inhibition decreased in a dose dependent manner. Control IgG 
preparations from rabbits immunized with empty IRIVs had no inhibitory activity. Sera 
inhibiting invasion of P. falciparum sporozoites did not inhibit invasion of P. yoelii into 
murine hepatocytes (not shown), demonstrating specificity of the inhibitory activity. 
 Purified IgG from rabbits immunized with UK-39 inhibited parasite gliding 
motility, as demonstrated by immunofluorescence analysis of the trails of CSP shed 
by P. falciparum sporozoites gliding on glass slides [19]. At a concentration of 1 
mg/ml of total IgG, traces were reduced (Figure 6B). Furthermore, CSP was 
precipitated at the apical ends of the sporozoites as described [20] and sporozoites 
were agglutinated. Serum of rabbits immunized with empty IRIVs had no effect on 
gliding motility or on parasite morphology. 
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Discussion 
An important goal here was the design of a conformationally constrained 
peptidomimetic of the immunodominant NPNA repeat region of the CS protein, which 
could be delivered to the immune system on the surface of immunopotentiating 
reconstituted influenza virus-like particles (IRIVs). Linear peptides are generally 
unsuitable as immunogens, due to their inherent conformational flexibility. As a 
result, there are many different ways that linear peptides can be recognized (by B-
cell receptors), correlating with the number of accessible conformational states 
available to the peptide chain. Only a small subset of these will be relevant for cross-
recognition of the cognate folded protein. A peptide chain restrained into the 
biologically relevant backbone conformation, on the other hand, should be a more 
effective immunogen, since it should be recognized preferentially in a conformation 
that promotes cross-reaction with the folded protein. There is the further advantage 
that linear peptides are usually degraded by proteolysis within minutes in biological 
fluids, which limits the window of accessibility to B-cell receptors. 
 Our strategy for the design of a multi-stage multi-component subunit malaria 
vaccine is to focus immune responses onto protection-relevant structural elements of 
key parasite proteins. Moreover, synthetic peptides and proteins with native-like folds 
can be presented to the immune system on IRIVs, thereby bypassing many of the 
problems associated with the production of stable recombinant protein-based vaccine 
formulations. A key parameter used for selecting vaccine candidates was the cross-
reactivity of elicited antibodies with the native target antigen on the cell surface of the 
parasite. IRIV formulations of the peptide antigens evaluated here were immunogenic 
in mice and rabbits when coupled to virosomes. The optimized structure, UK-39, has 
remarkable structural and antigenic similarity with the native repeat region of the key 
sporozoite vaccine antigen CSP and is suitable for large scale GMP production.  
 Key structural information used to guide the design of UK-39 came from 
earlier NMR and modeling studies [11]. Already NMR studies on linear peptides 
containing one or several tandemly linked NPNA motifs suggested the presence of 
turn-like structures based on the NPNA cadence, stabilized by hydrogen bonding, but 
in rapid dynamic equilibrium with extended chain forms [17]. Recently, an X-ray 
crystal structure was reported of the pentapeptide Ac-ANPNA-NH2, which confirmed 
that the NPNA unit adopts a type-I ß-turn conformation in aqueous solution [21]. 
Nevertheless, a key question remains how individual ß-turns in a longer (NPNA)n 
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oligomer might be interconnected to form a repeat structure. In earlier work, we were 
strongly influenced by the observation in NOESY spectra of various (NPNA)n-
containing cyclic and linear peptides, of strong sequential backbone NH-NH NOEs 
between both Asni+2 and Alai+3 as well as Alai+3 and Asni+4. This led us to consider 
backbone conformations of extended (NPNA)n oligomeric peptides, in which Proi+1, 
Asni+2 and Alai+3 are in the α-helical region, leaving only Asni in the ß-region of φ/ψ 
space; a combination called here a helical-turn. A computer model of such a turn is 
shown in Figure 3A, where the close approach of the backbone amide NHs of  Asni+2 
and Alai+3 as well as Alai+3 and Asni+4 can be seen. With these φ/ψ angles for each 
NPNA motif, and assuming trans peptide bonds, a cross-linked peptidomimetic was 
designed using a computer model of an extended (NPNA)n-oligomer, as described 
earlier [11]. In our first effort, (2S,3R)-3-aminoproline was used to synthesize the 
mimetic BP-66, and the phospholipid conjugate BP-65. Here, we have investigated 
the related peptidomimetics UK-39 and UK-40 (Figure 1), which use instead the 
synthetically more accessible (2S,4S)-4-aminoproline. 
 NMR studies on UK-40 in aqueous solution provide insights into the preferred 
backbone conformations of this mimetic, and confirm a close similarity to those 
deduced earlier for BP-66 [11]. As expected, the residues contained within the 
macrocyclic ring of UK-40 are more restrained in their conformation than the NPNA 
units outside the macrocycle at the N- and C-termini (Figure 3B). The Asn5-Ala8 and 
Asn9-Ala12 motifs, in particular, appear to populate helical turns, as seen in the 
average solution structures calculated using NOE-derived distance restraints (Figure 
4). However, especially the Asn13-Glu16 motif within the macrocycle appears to be 
more disordered and to exist in dynamic equilibrium with extended forms. It is less 
clear what role (if any) the observed minor cis-(Asn-Pro) peptide bond conformers 
might play in eliciting antibodies cross-reactive with the CS protein 
 As far as the antigenic properties are concerned, UK-39 was recognized by all 
tested CSP repeat region specific mAbs elicited by sporozoite-immunization of mice, 
and by the majority of sera from human donors living in malaria endemic regions 
(data not shown). One major limitation in using peptide antigens as vaccine 
components is their poor immunogenicity. We demonstrate here that presentation of 
UK-39 on the surface of virus-like particles elicited a strong parasite cross-reactive 
antibody response both in mice and in rabbits. Lack of immunogenicity of a liposomal 
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formulation demonstrated the importance of influenza protein antigens for the 
immunopotentiating activity of IRIVs. We have observed better immune responses 
with liposomal formulations of PE-conjugates of larger peptides, but also in these 
cases IRIV formulations were far superior (unpublished results). While two 
immunizations were needed to reach high IgG titers in mice, one immunization was 
sufficient in rabbits. Seroconversion was not only observed in all inbred mice, but 
also in all rabbits with diverse immunogenetic backgrounds. Genetic restriction of the 
response in humans may therefore not represent a serious limitation for IRIV-based 
peptide vaccines. As previously observed for other antigens [13, 22], pre-
immunization of animals with an influenza vaccine improved the titers of antibodies 
elicited by the IRIV formulation (data not shown). Possible explanations for this 
phenomenon are (i) opsonization of IRIVs with pre-existing anti-influenza antibodies, 
leading to enhanced uptake by antigen presenting cells and (ii) activation of 
influenza-specific memory T cells, providing T cell help to UK-39-specific B cells. 
Results of the animal immunogenicity studies described here suggested that two 
immunizations with a 10 µg dose of UK-39 will elicit a potent antibody response in 
influenza pre-exposed humans, irrespective of their immunogenetic background. 
Preliminary immunogenicity data of clinical trials with two IRIV-based malaria vaccine 
components, UK-39 and a peptide loop derived from the P. falciparum Apical 
Membrane Antigen-1 [10, 22] support this assumption and the general concept of 
delivering peptides as IRIV-bound phosphatidylethanolamine (PE)-conjugates to the 
human immune system. Widespread outbreaks of influenza have been reported for 
Africa [23], making the virosomal antigen delivery system applicable in malaria 
endemic areas of Africa. 
 Antibodies against BP-65 and its easier to synthesize derivative UK-39 
inhibited sporozoite invasion into hepatocytes in vitro. Inhibition with mAbs against 
BP-65 was up to 100% whereas only lower levels of inhibition were observed with 
purified IgG from UK-39-immunized rabbits. This reduced effect can be explained by 
the fact that we used total IgG from immunized animals. Thus, despite using high 
concentrations of IgG (1 mg/ml), only a minor fraction of the antibodies is specific for 
the NPNA repeats. Additionally, physiological serum IgG concentrations of rabbits 
are higher than 1 mg/ml, pointing towards an increased inhibitory effect in vivo. 
 The mechanism of this inhibition is not clearly understood. The observed 
inhibition of gliding motility suggests interference with parasite motility, which is 
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necessary to invade the target cell, as described before [24]. Whether the gliding 
inhibition is based on a specific block of the mechanism promoting movement or just 
the result of steric hindrance remains to be elucidated, as the involvement of CSP in 
the process of gliding motility is still controversial [25]. The protective potential of anti-
CSP repeat antibodies has been shown in vivo with passive transfer of anti-CSP 
repeat antibodies, which can protect mice from experimental sporozoite challenge 
[26]. The mechanism of this protection is at least in part due to antibody-mediated 
immobilization of sporozoites in the skin after injection by the mosquito [27].  
 It is not likely that antibodies against UK-39 alone would result in complete 
protection against malaria. However, in the context of a multi-stage vaccine, they 
may reduce the number of sporozoites entering liver cells and thus support immune 
protection elicited by components directed against the liver and blood stages of the 
malaria parasite. Moreover it is thought that reduction of the number of merozoites 
released from the liver by anti-pre-erythrocytic vaccination [3] or reduction of the 
sporozoite inoculum by the use of insecticide treated bed-nets [28] can reduce the 
incidence of severe malaria.  
The universal IRIV-based antigen delivery platform described in this report is highly 
suitable for combining antigens specific for the different development stages of the 
parasite into a multi-component malaria subunit vaccine. 
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Significance 
With increasing global prevalence of malaria and emerging resistance of P. 
falciparum to drug treatment, the need for an efficient malaria vaccine is greater than 
ever. Although it was shown more than 30 years ago that man can be protected 
against malaria by vaccination [29], a safe, effective and affordable vaccine is still 
many years away [4]. Especially the lack of safe and potent adjuvant/delivery 
systems and the technical and regulatory problems associated with recombinant 
protein production has hampered vaccine development. We have developed a 
technology platform based on the design of conformationally constrained synthetic 
peptides and the IRIV delivery system, which allows for the rational development of a 
malaria vaccine. The parasite-binding capacity of antibodies elicited by immunization 
of mice was used as a key indicator for the optimization of peptide antigens. The 
universal IRIV-based antigen delivery platform is highly suitable for combining 
antigens specific for the different development stages of the parasite into a multi-
component malaria subunit vaccine. As the IRIV system is already registered for use 
in humans, this platform can contribute to the rapid development of a safe, efficient 
and cost-effective malaria vaccine. 
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Experimental procedures 
Synthesis of peptides 
Synthesis of JL-934, JL-1036 and BP-65 has been described previously [11, 12, 30]. 
For UK-40, a linear peptide was first assembled on Rink Amide MBHA resin (0.73 
mM/g) (Novabiochem) using an Applied Biosystems ABI433A peptide synthesizer, 
and Fmoc-protected amino acids (Fmoc-Asn(Mtt)-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, 
Fmoc-Glu(tBu)-OH and Fmoc-(4S,2S)-4-aminoproline(Boc)-OH) and HBTU/HOBt (4 
eq.) for activation. After cleavage of the linear peptide from the resin with 95% TFA, 
2.5% TIS and 2.5% water over 3 h, the peptide was precipitated using iPr2O and 
dried. The linear peptide was then stirred overnight with HATU (4eq.) and HOAt (4 
eq.) in DMF with 1 % v/v iPr2EtN (2 mg/ml peptide). After drying in vacuo the peptide 
was stirred in 20 % piperidine in DMF for 15 min. The solvent was evaporated and 
peptide was precipitated using iPr2O, dried in vacuo, and then purified by reverse 
phase HPLC (C18 column using a gradient of MeCN/H2O (+0.1% TFA; 5 to 95% 
MeCN ; tR = 11 min). ES-MS m/z: 2276 (M+H)+.  
 The cyclic peptide (40 mg) was coupled to PE-CO-(CH2)2-COOH (PE-
succinate; 4 eq.) in DMF (5 ml), CH2Cl2 (5 ml) and 1% iPr2EtN using HATU and HOAt 
with stirring overnight at rt. The solvent was then removed and the product purified by 
reverse phase HPLC (C4 column Vydac 214 TP 1010, 25cmx10mm) using a gradient 
of 50 % ethanol in water to 100 % ethanol (+0.1% TFA) over 15 min. UK-39 appears 
as a broad peak at about 90 % ethanol. ES-MS m/z: 1427 (M+2H)2+. Alternatively, 
the cyclic peptide was acetylated with acetic anhydride in MeOH and NH4HCO3 
buffer and UK-40 was purified by reverse phase HPLC (C18 column Vydac) using a 
gradient of 0 to 100% MeCN in water. ES-MS m/z: 1049 (M+2H)2+. 
 
NMR studies 
For NMR studies, UK-40 was dissolved in 90%H2O/10%D2O, pH 5.0, at a 
concentration of ca. 10 mg/ml. 1D and 2D 1H NMR spectra were recorded at 600 
MHz (Bruker AV-600 spectrometer). Water suppression was by presaturation. The 
sequential resonance assignments were based on DQF-COSY, TOCSY and NOESY 
spectra. Distance restraints were obtained from NOESY spectra with mixing times of 
80 and 250 ms. Spectra were collected with 1024 x 256 complex data points zero-
filled prior to Fourier transformation to 2048 x 1024, and transformed with a cosine-
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bell weighting function. Data processing was carried out with XWINNMR (Bruker) and 
XEASY. [31] 
 The structure calculations were performed by restrained molecular dynamics 
in torsion angle space by applying the simulated annealing protocol implemented in 
the program DYANA. [32] Starting from 100 randomized conformations a bundle of 
20 conformations were selected with the lowest DYANA target energy function. The 
program MOLMOL [33] was used for structure analysis and visualization of the 
molecular models. 
 
Preparation of peptide-loaded virosomes 
For the preparation of IRIV loaded with phosphatidylethanolamine (PE)-peptide 
conjugates, a solution of purified Influenza A/Singapore hemagglutinin (4 mg) in 
phosphate buffered saline (PBS) was centrifuged for 30 min at 100 000 g and the 
pellet was dissolved in PBS (1.33 ml) containing 100 mM 
octaethyleneglycolmonodecylether (PBS-OEG). Peptide-PE conjugates (4 mg), 
phosphatidylcholine (32 mg; Lipoid, Ludwigshafen, Germany) and PE (6 mg) were 
dissolved in a total volume of 2.66 ml of PBS-OEG. The phospholipid and the 
hemagglutinin solutions were mixed and sonicated for 1 min. This solution was then 
centrifuged for 1 hour at 100 000 g and the supernatant was filtered (0.22 µm) under 
sterile conditions. Virosomes were then formed by detergent removal using BioRad 
SM BioBeads (BioRad, Glattbrugg, Switzerland). 
 
Mouse immunogenicity studies 
BALB/c mice were pre-immunized intramuscularly with 0.1 ml of the commercial 
whole virus influenza vaccine Inflexal BernaTM (Berna Biotech, Bern, Switzerland). At 
least three weeks later they were immunized with PE-peptide conjugate-loaded IRIVs 
(containing 10 µg PE-peptide) in intervals of at least two weeks. Blood was collected 
before each immunization and two weeks after the final injection. 
 
 
Generation of hybridomas and production of mAbs 
Hybridomas were generated from spleen cells of mice three days after a booster 
immunization with BP-65 loaded IRIVs using PAI mouse myeloma cells as a fusion 
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partner. Hybrids were selected in HAT medium and cells that secreted anti-BP-65 
mAbs were identified by ELISA. For large-scale mAb production, hybridoma cell lines 
were cultured in 175 cm2 flasks and mAbs were purified by protein A or G affinity 
chromatography (Protein A SepharoseTM CL4B or HiTrapTM Protein G HP, 
Piscataway, NJ). Purified mAbs were dialyzed against PBS, aliquoted and stored at -
80°C. Generation of anti-P. falciparum sporozoite mAbs has been described 
previously [34]. 
 
Rabbit immunogenicity studies 
Rabbits were pre-immunized intramuscularly with 0.5 ml of the commercial whole 
virus influenza vaccine Inflexal BernaTM (Berna Biotech, Bern, Switzerland). At least 
three weeks later they were immunized with peptide-loaded IRIVs (containing 10 µg 
PE-peptide) in intervals of at least two weeks. Blood was collected before each 
immunization and two weeks after the final injection. Rabbit IgG was purified from 
immune sera by protein A affinity chromatography. 
 
ELISA 
ELISA analyses with peptide-PE conjugates were performed essentially as described 
before [10]. Briefly, PolysorpTM plates (Nunc, Fisher Scientific, Wohlen, Switzerland) 
were coated overnight at 4°C with 100 µl of a 10 µg/ml solution of UK-39 in PBS (pH 
7.2). After three washings with PBS containing 0.05% Tween-20 wells were blocked 
with 5% milk powder in PBS for 30 min at 37°C and washed three times again. Plates 
were then incubated with serial dilutions of anti-peptide mouse or rabbit sera or anti-
peptide mAbs in PBS containing 0.05% Tween-20 and 0.5% milk powder for 2 h at 
37°C. After washing, plates were incubated with alkaline phosphatase-conjugated 
goat anti-mouse IgG (Fc-specific) antibodies (Sigma, St. Louis, Mo) for 1 h at 37°C. 
After washing again, phosphatase substrate solution (1 mg/ml p-nitrophenyl 
phosphate (Sigma, St. Louis, Mo) in a pH 9.8 buffer solution containing 10% [vol/vol] 
diethanolamine and 0.02% MgCl2) was added and the plates were incubated in the 
dark at room temperature until the colorimetric reaction had progressed sufficiently. 
The optical density was measured at 405 nm on a Titertek Multiscan MCC/340 
reader (Labsystems, Helsinki, Finland). For experiments with rabbit sera, horseradish 
peroxidase-conjugated goat anti-rabbit IgG heavy and light chain antibodies (Bio-Rad 
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Laboratories, Hercules, CA) were used as secondary antibody. The TMB microwell 
peroxidase substrate system (KPL, Gaithersburg, MD) was used according to the 
manufacturer and optical density was measured at 650 nm. After stopping the 
reaction by addition of 50 µl 1N HCl per well OD was measured at 450nm.  
 
Indirect immunofluorescence assay (IFA) 
Air-dried unfixed P. falciparum (strain NF54) salivary gland sporozoites attached to 
microscope glass slides were incubated for 15 min at room temperature with 25 µl 
blocking solution containing 1% fatty acid-free bovine serum albumin (BSA) in PBS. 
Immunostaining was performed by incubating the wells with 25 µl of an appropriate 
serum dilution in blocking solution in a humid chamber for 1 h at room temperature. 
After five washes with blocking solution 25 µl of 5 µg/ml cyanine dye (Cy3)-
conjugated affinity-pure F(ab´)2 fragment goat anti-mouse IgG (Fc-specific) 
antibodies (Jackson Immuno Research Laboratories, West Grove, Pa.) or Cy3-
conjugated donkey anti-rabbit IgG heavy and light chain antibody (Jackson Immuno 
Research Laboratories, West Grove, PA), diluted in blocking solution containing 0.01 
mg/ml Hoechst dye no. 33256 (Sigma, St. Louis, Mo) were added to the wells and 
incubated for 1 h at room temperature. Finally, wells were washed five times with 
PBS, mounted with mounting solution (90% [vol/vol] glycerol containing 0.1 M Tris-
Cl, pH 8.0 and 2 mg/ml o-phenylenediamine) and covered with a coverslip. Antibody 
binding and DNA staining were assessed by fluorescence microscopy on a Leitz 
Dialux 20 fluorescence microscope and documented with a Leica DC200 digital 
camera system. 
 
SDS-PAGE and immunoblotting 
100 µl of an Anopheles stephensi salivary gland lysate containing about 100’000 P. 
falciparum sporozoites were diluted with an equal volume of 2x loading buffer (1.7ml, 
0.5M Tris-HCl pH 6.8, 2 ml glycerol, 4.5 ml 10% SDS, 1 ml β-mercaptoethanol, 0.8 
ml 0.3% w/v bromophenol blue) and heated to 95°C for 10 minutes. Proteins were 
separated on a 10% SDS PAGE mini-gel. Separated proteins were 
electrophoretically transferred to a nitrocellulose filter (Protran® Nitrocellulose, BA85, 
Schleicher & Schuell) by semi-dry blotting. Blots were blocked with PBS containing 
5% milk powder and 0.1% Tween-20 over night at 4°C. The filter was cut into strips 
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and incubated with appropriate dilutions of immune sera in blocking buffer for 2 h at 
room temperature. Filter strips were then washed three times for 10 minutes in 
blocking buffer and incubated at room temperature for 1 h with alkaline peroxidase-
conjugated goat anti-mouse IgG (Fc-specific) antibodies (Sigma, St. Louis, Mo) 
diluted 1:30’000 in blocking buffer or horseradish peroxidase-conjugated goat anti-
rabbit IgG heavy and light chain antibodies (Bio-Rad Laboratories, Hercules, CA) 
diluted 1:6’000 in blocking buffer. After washing again, blots were finally developed 
using ECLTM Western blotting detection (Amersham Biosciences, Buckinghamshire, 
England) reagents to visualize bands.  
 
P. falciparum and P. yoelii in vitro invasion inhibition assay 
Inhibition assays were performed as described before [35, 36]. Briefly, primary 
human or mouse hepatocytes were isolated as described [37, 38], and inoculated 
with P. falciparum (NF54 strain) or P. yoelii (265BY strain) sporozoites (1 x 
105/Labtek well) obtained from salivary glands of infected Anopheles stephensi 
mosquitoes. After 3 h at 37°C, the cultures were washed, further incubated in fresh 
medium for 3 days (P. falciparum) or 2 days (P. yoelii) before fixation in methanol. 
Quantification of exoerythrocytic forms was done by immunofluorescence. To 
determine the effects of anti-CSP antibodies on sporozoite infectivity, sporozoites 
were incubated with hepatocytes in the presence of increasing concentrations of 
mAbs or purified polyclonal rabbit IgG from immunized animals. The percentage of 
inhibition was determined in comparison to PBS control. 
 
Gliding inhibition 
To analyze sporozoite motility, 30,000 sporozoites were deposited on multispot glass 
slide wells precoated with anti-P. falciparum CSP (PfCSP) mAb E9 (100 µg/ml 1 h at 
37 °C) and incubated at 37 °C for 1 h. The slides were then washed, and the 
deposited CSP trails were fixed with 4% paraformaldehyde for 15 min. The trails 
were then labeled using the anti-PfCSP mAb E9 conjugated to Alexa Fluor® 488 and 
visualized under a fluorescence microscope. 
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Figure legends 
 
Figure 1. Structures of peptidomimetics discussed in the text. 
 
Figure 2. Hepatocyte invasion inhibition by anti-BP-65 mAbs. A: Inhibition of parasite 
invasion into primary human hepatocytes by mAb EP3 and mAb EP9. Shown is the 
mean percentage of inhibition compared to PBS control ± SD deviation for duplicates. 
B: Competition of invasion inhibition by increasing concentrations of BP-66 peptide 
(BP-65 without PE). Inhibitory mAbs were used at a constant concentration of 20 
µg/ml. 
 
Figure 3. A: An NPNA motif is depicted in a helical turn conformation (see text). N-
atoms dark blue, O-atoms red, C-atoms grey, amide H-atoms light white, H-bonds 
pale blue broken line. Here the first Asn has φ/ψ angles in the ß-region, and the 
following Pro, Asn and Ala in the α-region. A green ribbon traces the backbone. B: 
Superimposition of the final 20 DYANA structures for UK-40. The backbone only is 
represented, superimposed using all heavy atoms from Apro6 to Glu16 (region in 
blue). 
 
Figure 4. Backbone superimposition of the 20 DYANA structures of UK-40 with a 
helical turn conformation (red, A - C), and with the ANPNA crystal structure (green, D 
- F). In A and D only residues 5-8 in UK-40 were used for the superimposition, for B 
and E only residues 9-12, and for C and F only residues 13-16. 
 
Figure 5. Immunogenicity of virosomal and liposomal formulations of UK-39 in mice. 
A: Anti-UK-39 IgG response in ELISA after immunization with IRIV-formulated UK-39. 
Shown are mean ELISA readouts ± SD obtained with serial dilutions of mouse sera 
taken pre-immune and two weeks after the first, second and third immunization. Sera 
from 10 animals were analyzed at every time point. B: Induction of P. falciparum 
sporozoite cross-reactive IgG upon immunization with UK-39. Shown are IFA 
endpoint titers of 10 individual mice. Sera have been taken pre-immune and two 
weeks after first, second and third immunization. C: Anti-UK-39 IgG response in 
ELISA of mice immunized with UK-39 presented either on liposomes or on 
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virosomes. Shown are the means ± SD of 5 animals per group. Sera have been 
taken 2 weeks after the third immunization. 
 
Figure 6. Inhibitory capacity of anti-UK-39 antibodies. Sporozoite invasion inhibition 
by purified IgG from rabbits immunized with UK-39. A: P. falciparum sporozoites 
have been cultured with primary human hepatocytes in the presence of purified 
polyclonal rabbit IgG at different concentrations. Shown is the mean percentage of 
inhibition compared to PBS control ± SD of 3 experiments for two animals immunized 
with IRIV-formulated UK-39 (D1 and D3) and one control animal immunized with 
empty IRIVs (IRIV). B: Fluorescence microscopy of CSP trails deposited by P. 
falciparum sporozoites upon gliding on a glass slide. Left panel: Trails of sporozoites 
incubated with purified IgG from a rabbit immunized with empty IRIVs. Middle panel: 
Reduced trails of sporozoites incubated with purified IgG from an UK-39-immunized 
animal. Right panel: Agglutination of sporozoites incubated with purified IgG from a 
rabbit immunized with UK-39.  
 
Table 1. Cross-reactivity of anti-NPNA mAbs. 
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Supplementary material 
Figure S1. BP-125 a shortened version of BP-65. ELISA with anti-BP-65 mAbs EP3 
and EP9 on CSP mimetics BP-65 and the shortened version BP-125. Shown are 
serial dilutions of the mAbs on constant concentrations of the two peptides. 
 
Figure S2. Sections from 2D DQF-COSY spectra in aqueous solution for: A, UK-40; 
and B, the linear peptide Ac-(NPNA)3-NH2. Cross-peaks for HN-C(α)H 3J couplings 
are indicated. 
 
Figure S3. Results from 2D COESY spectra of UK-40. NOE connectivities from 
NOESY spectra, and temperature coefficients (− Δδ/ΔT ppb/K) of peptide amide NH 
resonances from 2D TOCSY spectra of UK-40 measured in the range 279 -314 K. 
The thickness of the lines for the sequential distances dNN (i,i+1), dαN (i,i+1) and dβN 
(i,i+1) is inversely proportional to the squared upper distance restraint. 
 
Figure S4. Backbone amide HN-HN cross peaks in a NOESY spectrum of UK-40 in 
aqueous solution. The residue assignments are shown for each cross peak. 
 
Figure S5. Immunogenicity of UK-39 in rabbits. A: Anti-UK-39 IgG levels measured in 
ELISA. Shown are the means ± SD of 3 rabbits. Sera have been taken pre-immune 
and two weeks after first, second and third immunization. B: Cross-reactivity of UK-39 
induced IgG with P. falciparum sporozoites. Shown are IFA endpoint titers of 3 
individual animals pre-immune and two weeks after first, second and third 
immunization. Arrows indicate immunizations with IRIV-formulated UK-39. 
 
Table S1. 1H Chemical shift assignments for UK-40 in 90% H2O/10% D2O, pH 5, 293 
K. 
 
Table S2.  Experimental distance restraints and statistics for the final 20 NMR 
structures calculated for UK-40. 
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Figure 1. Structures of peptidomimetics discussed in the text. 
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Figure 2. Hepatocyte invasion inhibition by anti-BP-65 mAbs. A: Inhibition of parasite 
invasion into primary human hepatocytes by mAb EP3 and mAb EP9. Shown is the 
mean percentage of inhibition compared to PBS control ± SD deviation for duplicates. 
B: Competition of invasion inhibition by increasing concentrations of BP-66 peptide 
(BP-65 without PE). Inhibitory mAbs were used at a constant concentration of 20 
µg/ml. 
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Figure 3. A: An NPNA motif is depicted in a helical turn conformation (see text). N-
atoms dark blue, O-atoms red, C-atoms grey, amide H-atoms light white, H-bonds 
pale blue broken line. Here the first Asn has φ/ψ angles in the ß-region, and the 
following Pro, Asn and Ala in the α-region. A green ribbon traces the backbone. B: 
Superimposition of the final 20 DYANA structures for UK-40. The backbone only is 
represented, superimposed using all heavy atoms from Apro6 to Glu16 (region in 
blue). 
 
A 
 
B 
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Figure 4. Backbone superimposition of the 20 DYANA structures of UK-40 with a 
helical turn conformation (red, A - C), and with the ANPNA crystal structure (green, D 
- F). In A and D only residues 5-8 in UK-40 were used for the superimposition, for B 
and E only residues 9-12, and for C and F only residues 13-16. 
 
A   (res. 5-8)    B  (res. 9-12)   C  (res. 13-16) 
 
D   (res. 5-8)    E  (res. 9-12)   F  (res. 13-16) 
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Figure 5. Immunogenicity of virosomal and liposomal formulations of UK-39 in mice. 
A: Anti-UK-39 IgG response in ELISA after immunization with IRIV-formulated UK-39. 
Shown are mean serial dilutions ± SD of mouse sera taken pre-immune and two 
weeks after first, second and third immunization. Sera from 10 animals were 
analyzed at every time point. B: Induction of P. falciparum sporozoite cross-reactive 
IgG upon immunization with UK-39. Shown are IFA endpoint titers of 10 individual 
mice. Sera have been taken pre-immune and two weeks after first, second and third 
immunization. Arrows indicate immunizations with IRIV-formulated UK-39. C: Anti-
UK-39 IgG response in ELISA of mice immunized with UK-39 presented either on 
liposomes or on virosomes. Shown are the means ± SD of 5 animals per group. Sera 
have been taken 2 weeks after the third immunization. 
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Figure 6. Inhibitory capacity of anti-UK-39 antibodies. Sporozoite invasion inhibition 
by purified IgG from rabbits immunized with UK-39. A: P. falciparum sporozoites 
have been cultured with primary human hepatocytes in the presence of purified 
polyclonal rabbit IgG at different concentrations. Shown is the mean percentage of 
inhibition compared to PBS control ± SD of 3 experiments for two animals immunized 
with IRIV-formulated UK-39 (D1 and D3) and one control animal immunized with 
empty IRIVs (IRIV). B: Fluorescence microscopy of CSP trails deposited by P. 
falciparum sporozoites upon gliding on a glass slide. Left panel: Trails of sporozoites 
incubated with purified IgG from a rabbit immunized with empty IRIVs. Middle panel: 
Reduced trails of sporozoites incubated with purified IgG from an UK-39-immunized 
animal. Right panel: Agglutination of sporozoites incubated with purified IgG from a 
rabbit immunized with UK-39.  
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Table 1. Cross-reactivity of anti-NPNA mAbs. 
Cross-reactivity with mab Immunogen 
JL934c JL1036c BP-65c UK-39c Sporozoitesd 
1.26e + - - ND + 
1.7e + - ND ND - 
1.15e 
JL934a 
+ - ND ND - 
2.1e - + + + + 
3.1e - + + + + 
3.2e  - + - - + 
3.3e - + + + + 
3.4e - + ND ND -  
3.5e 
JL1036a 
- + ND ND - 
EP3 - - + + + 
EP9 
BP-65a 
- + + + + 
Sp4-5F2 (+) + + + + 
Sp4-2H1 (+) + + + + 
Sp3-E6 - + + + + 
Sp3-C6 - (+) + + + 
Sp3-E9 - (+) + + + 
Sp4-4B6 - - + + + 
Sp4-7C2 - - + + + 
Sp4-7E4 - - + + + 
Sp4-7H1 - - (+) + + 
Sp4-4D7 - - + + + 
Sp3-B4-C12 - - + + + 
Sp4-1B4 
sporozoitesb 
- - (+) + + 
 
amice were immunized with IRIVs loaded with the respective peptide 
bmice were immunized with P. falciparum sporozoites from A. stephensi salivary 
glands in Freund’s adjuvant  
cELISA reactivity to the peptides 
dIFA reactivity to P. falciparum sporozoites 
eDescribed by Moreno et al (Moreno et al. 2001) 
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Supplementary material 
Figure S1. BP-125 a shortened version of BP-65. ELISA with anti-BP-65 mAbs EP3 
and EP9 on CSP mimetics BP-65 and the shortened version BP-125. Shown are 
serial dilutions of the mAbs on constant concentrations of the two peptides. 
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Figure S2. Sections from 2D DQF-COSY spectra in aqueous solution for: A, UK-40; 
and B, the linear peptide Ac-(NPNA)3-NH2. Cross-peaks for HN-C(α)H 3J couplings 
are indicated. 
 
A      B 
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Figure S3. NOE connectivities from NOESY spectra, and temperature coefficients 
(− Δδ/ΔT ppb/K) of peptide amide NH resonances from 2D TOCSY spectra of UK-40 
measured in the range 279 -314 K. The thickness of the lines for the sequential 
distances dNN (i,i+1), dαN (i,i+1) and dβN (i,i+1) is inversely proportional to the squared 
upper distance restraint. 
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Figure S4. Backbone amide HN-HN cross peaks in a NOESY spectrum of UK-40 in 
aqueous solution. The residue assignments are shown for each cross peak. 
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Figure S5. Immunogenicity of UK-39 in rabbits. A: Anti-UK-39 IgG levels measured in 
ELISA. Shown are the means ± SD of 3 rabbits. Sera have been taken pre-immune 
and two weeks after first, second and third immunization. B: Cross-reactivity of UK-39 
induced IgG with P. falciparum sporozoites. Shown are IFA endpoint titers of 3 
individual animals pre-immune and two weeks after first, second and third 
immunization. Arrows indicate immunizations with IRIV-formulated UK-39. 
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Table S1.  1H Chemical shift assignments for UK-40 in 90% H2O/10% D2O, pH 5, 293 
K. 
 
Residue NH H-C(α) H-C(β) Others 
UK-40 
     
Asn1 8.43 4.97 2.86, 2.71 NH(δ)a 
Pro2 - 4.43 2.31, 1.98 CH(γ) 2.04 – 1.98; CH2(δ) 3.81, 3.81 
Asn3 8.38 4.67 2.85, 2.74 NH(δ)αa 
Ala4 8.02 4.28 1.39  
Asn5 8.41 4.91 2.87, 2.74 NH(δ)a 
Apro6 8.21b 4.51 2.66, 2.00 CH(γ) 4.45; CH2(δ) 4.24, 3.62 
Asn7 8.44 4.54 2.80, 2.80 NH(δ) 7.63, 6.95 
Ala8 8.07 4.29 1.40  
Asn9 7.95 5.009 2.92, 2.74 NH(δ) 7.71, 7.08 
Pro10 - 4.40 2.33, 1.96 CH2(γ) 2.04 – 1.98; CH2(δ) 3.81, 3.81 
Asn11 8.33 4.68 2.88, 2.76 NH(δ)a 
Ala12 7.76 4.31 1.40  
Asn13 8.42 4.92 2.87, 2.76 NH(δ)a 
Pro14 - 4.43 2.31, 1.99 CH2(γ) 2.04 – 1.98; CH2(δ) 3.80, 3.80 
Asn15 8.34 4.68 2.84, 2.74 NH(δ) 7.66, 6.98 
Glu16 8.13 4.27 2.12, 1.99 CH2(γ) 2.34, 2.34 
Asn17 8.47 4.97 2.88, 2.74 a(δ)a 
Pro18 - 4.43 2.30, 1.99 CH2(γ) 2.04 – 1.98; CH2(δ) 3.80, 3.80 
Asn19 8.42 4.69 2.87, 2.75 NH(δ)a 
Ala20 8.04 4.25 1.41  
     
a Overlapping resonances. Range H(δ) (Z) 7.75-7.65 and H(δ)E 7.11-6.96 
b The C(γ)-NH proton, Apro6 = (2S,4S)-4-aminoproline 
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Table S2.  Experimental distance restraints and statistics for the final 20 NMR 
structures calculated for UK-40. 
  
  UK-40 
NOE upper-distance 
limits 
Intraresidue 
Sequential 
Medium- and longe-
range 
99 
 
27 
60 
12 
Residual target function 
value (Å2) 
0.16 ± 0.05 
 
Mean rmsd values (Å) 
All backbone atoms 
Backbone atoms of 
residue 6-16 
 
3.74 ± 1.02 
 
1.59 ± 0.54 
Residual NOE violation 
Number > 0.2  Å  
Maximum (Å) 
 
13 
 
0.34 
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ABSTRACT 
Presentation of synthetic peptides on immunopotentiating reconstituted influenza 
virosomes is a promising technology for subunit vaccine development. An optimized 
virosomally delivered peptide representing 4 NPNA repeats of P. falciparum CSP is 
highly immunogenic in mice. Antibodies against this peptide, designated UK-39, 
inhibit sporozoite invasion of primary human hepatocytes. A second peptide, AMA49-
CPE, is based on domain III of apical membrane antigen 1 and induces high titers of 
parasite-binding antibodies in mice. Monoclonal antibodies against AMA49-CPE 
inhibit blood-stage parasite growth in vitro. The present study shows a detailed pre-
clinical profiling of these two virosomally-formulated peptides alone and in 
combination in mice and rabbits. Two immunizations with virosomally formulated UK-
39 or AMA49-CPE were enough to elicit high titers of parasite cross-reactive 
antibodies in mice and rabbits. No dose-dependency was observed for UK-39 in 
rabbits, where a low dose of 10µg was enough to induce maximal titers. AMA49-CPE 
induced higher titers at 25 and 50µg peptide. Combination of UK-39 and AM49CPE 
did not have any negative effect on anti-peptide antibody titers elicited in mice nor 
rabbits. No MHC restriction was observed in the development of humoral responses 
in outbred rabbits with different immunogenetic backgrounds. Taken together these 
results show that low amounts of synthetic peptides delivered on IRIVs induce high 
antibody titers. Different peptides on separate virosomes can be combined without 
interfering with individual anti-peptide responses, augmenting the value of the IRIV 
system for the development of a multi-component subunit malaria vaccine. 
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Introduction 
With emerging resistance of parasites against drugs and mosquitoes against 
insecticides the development of a malaria vaccine remains an urgent need. Despite 
worldwide efforts no successful vaccine has come to market to date. It has been 
shown more than 30 years ago that sterile protection in humans can be achieved by 
immunization with x-irradiated sporozoites (Clyde et al., 1973). The mechanisms of 
this protection are still not fully understood but include humoral as well as cellular 
components of the immune system (Schofield et al., 1987; Doolan and Martinez-
Alier, 2006; Hafalla et al., 2006). Circumsporozoite protein (CSP) is the major surface 
protein on sporozoites and one of the best studies antigens of P. falciparum (Kappe 
et al., 2004). Anti-sporozoite antibodies are mainly directed against the 
immunodominant central NANP-repeat region (Zavala et al., 1983; Dame et al., 
1984). Different vaccine candidates are based on this protein and have shown partial 
or total protection from disease in artificial challenge experiments (reviewed in 
(Targett, 2005; Hill, 2006). A recent field trial with the recombinant CSP vaccine 
RTS,S/AS02A in children in Mozambique has shown promising results in terms of 
protection from severe disease (Alonso et al., 2004; Alonso et al., 2005). One of the 
leading vaccine candidates in blood-stage parasites is apical membrane antigen 1 
(AMA-1), an 83-kDa protein. During the course of merozoite release, an additional N-
terminally processed 66-kDa form of AMA-1 appears on the merozoite surface 
(Peterson et al., 1989; Narum and Thomas, 1994). Several passive and active 
immunization studies have indicated that AMA-1 is involved in eliciting protective 
immune responses (Deans et al., 1982; Deans et al., 1988; Collins et al., 1994; 
Crewther et al., 1996; Anders et al., 1998; Kocken et al., 2000; Narum et al., 2000; 
Xu et al., 2000; Burns et al., 2004) and serves as a target for invasion-blocking 
antibodies (Deans et al., 1982; Deans et al., 1988; Kocken et al., 1998; Kocken et al., 
2000; Hodder et al., 2001). Loop 1 of domain III binds to the erythrocyte membrane 
protein Kx, and invasion of Kxnull erythrocytes is reduced, indicating a significant role 
of AMA-1 and Kx in parasite invasion of erythrocytes (Kato et al., 2005).  
We have previously shown the development of two synthetic peptides based on 
these two proteins for inclusion into a multivalent subunit malaria vaccine (Bisang et 
al., 1998; Moreno et al., 2001; Mueller et al., 2003; Pfeiffer et al., 2003) (Okitsu et al. 
submitted). Peptide UK-39 is based on the NANP repeats of CSP (Okitsu et al. 
submitted) and peptide AMA49-CPE on the erythrocyte-binding loop 1 of domain III 
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from AMA-1 (Mueller et al., 2003). Both peptides, designated UK-39 (CSP) and 
AMA49-CPE (AMA-1), were developed in a stepwise optimization process and the 
optimized peptides were able to induce high antibody titers in mice. Purified IgG from 
UK-39-immunized rabbits and anti-AMA-1 monoclonal antibodies (mAbs) inhibited in 
vitro growth of sporozoites and blood-stage parasites respectively. Both peptides 
were delivered on immunopotentiating reconstituted influenza virosomes (IRIVs) for 
animal immunizations. Virosomes are immunogenic liposomes incorporating the 
influenza virus derived surface proteins neuraminidase and hemagglutinin, facilitating 
antigen uptake and presentation by antigen presenting cells. Peptides from other 
sources, such as P. falciparum antigens, can be incorporated by adding 
phosphatidylethanolamine (PE) tails, anchoring the peptide in the phospholipid 
bilayer. Antigens presented on the IRIV surface induce an MHC II restricted antibody-
oriented immune response, whereas incorporation of antigens into the virosome, 
leads to induction of a MHC I restricted CD8 T cell responses. Experience with two 
licensed vaccines based on virosomes has shown that the technology is very safe 
and immunogenic (Westerfeld and Zurbriggen, 2005). 
In this report we show a detailed dose-finding analysis of UK-39 and AMA49-CPE 
alone and in combination in mice and rabbits. UK-39 and AMA49-CPE both induced 
high titers of peptide-specific IgG in mice and rabbits irrespective of MHC restriction. 
Both peptides induced parasite cross-reactive antibodies alone and in combination 
and at all doses tested. Depending on the animal species one or two immunizations 
were enough to induce maximal IgG titers. 
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Results 
Development of anti-peptide IgG responses in mice.  
Mice were immunized three times with 10µg of virosomally formulated AMA49-CPE 
or UK-39 alone and in combination. Blood samples were taken pre-immune, 2 weeks 
after the first and second, and three weeks after the third immunization. High anti-
peptide IgG titers could be detected after the second immunization with both vaccine 
components (Figure 1). After two immunizations titers were slightly lower in animals 
vaccinated with a combination of the two virosomally formulated peptides, but were 
boosted by the third immunization to levels comparable to titers in the single 
component immunization groups. No titer increase after the third vaccination was 
observed in the single immunization groups. 
 
Induction of parasite-binding antibodies in mice.  
Sera from UK-39 immunized mice were tested for cross-reactivity with P. falciparum 
salivary gland sporozoites in IFA. One immunization was enough to induce parasite-
binding antibodies in 19 out of 20 animals from the UK-39 single and double 
immunization group (Figure 2A). After the second immunization all UK-39 immunized 
animals had high parasite-binding IgG titers. Maximal titers were reached after three 
vaccinations for both groups, though the increase after the third vaccination in the 
single immunization group was small and statistically not significant (P=0.2500). 
Parasite-binding properties of anti-AMA49-CPE IgG were tested in IFA with in vitro 
cultivated P. falciparum blood-stage parasites. 5 out of 20 animals developed a 
parasite cross-reactive IgG response already after the first immunization (Figure 2B). 
This number gradually increased to 16 out of 20 after the third immunization. The 
highest anti-peptide IgG titers were found for both peptides in the group receiving a 
combination of virosomally formulated UK-39 and AMA49-CPE. 
After three immunizations with UK-39 all animals had IgG recognizing a double band 
typical for CSP in Western blot with lysate from P. falciparum salivary gland 
sporozoites. IgG endpoint titers were above 100 in Western blotting experiments 
(data not shown).  
 
Development of anti-peptide IgG responses in rabbits.  
Rabbits were immunized with virosomally formulated UK-39 or AMA49-CPE at three 
different doses (10, 25 and 50µg peptide-PE conjugate) alone and in combination. 
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Already after one immunization all rabbits receiving UK-39 developed an anti-UK-39 
IgG response. Maximal anti-UK-39 IgG titers were reached already after one 
immunization in all groups and no significant increase in titers was observed after 
subsequent immunizations. Vaccine formulation, e.g. dose and combination of 
peptides, had no marked effect on anti-UK-39 IgG titer development. Also all animals 
immunized with AMA49-CPE alone or in combination with UK-39 developed an anti-
AMA49-CPE IgG response already after the first immunization regardless of the dose 
of peptide. A booster effect after the second immunization was observed in the low 
dose AMA49-CPE single and double immunization groups. A booster effect after the 
third immunization was not observed in any of the AMA49-CPE immunized animals. 
The highest anti-AMA49-CPE titers were measured after one vaccination with 50µg 
of AMA49-CPE in combination with UK-39. No peptide-specific IgG responses were 
found in control animals immunized with IRIVs alone. 
 
Rabbit anti-UK-39 IgG cross-reactivity with sporozoites.  
Sera from all UK-39 immunized rabbits were cross-reactive with P. falciparum 
sporozoites isolated from mosquito salivary glands (Figure 4). IFA IgG titer 
development was closely following the observations made in ELISA, i.e. one 
immunization was enough to induce high parasite cross-reactive IgG titers, 
regardless of vaccine formulation. Booster immunizations did not lead to an increase 
in parasite-binding IgG. No induction of sporozoite cross-reactive antibodies was 
seen in rabbits immunized with AMA49-CPE alone (data not shown) or empty IRIVs 
(Figure 4). One animal in the IRIV control group had a titer of 100 after the first 
immunization. No boost of this response was seen after subsequent immunizations. 
Parasite-binding properties of anti-AMA49-CPE responses could not be assessed 
due to high unspecific cross-reactivity of rabbit sera with blood-stage parasites 
masking possible AMA-1 specific antibody stainings. 
All sera from rabbits immunized with UK-39 recognized a characteristic double band 
corresponding to P. falciparum CSP in Western blot after two immunizations (Figure 
5). All animals had Western blot titers above 500 and no dose-dependency or 
interference by combined delivery with AMA49-CPE was observed. No staining of 
CSP was seen with pre-immune sera and sera from animals immunized with AMA49-
CPE alone or empty IRIVs (data not shown). 
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17 out of 18 AMA49-CPE immunized rabbits recognized an AMA-1 specific double 
band in Western blot after the third immunization (Figure 6). No dose-dependency 
was observed and combination with UK-39 did not interfere with the development of 
an AMA-1 cross-reactive response. Pre-immune sera and control sera from animals 
immunized with UK-39-IRIVs or IRIVs alone (data not shown) showed unspecific 
background staining but no reactivity with parasite derived AMA-1. 
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Discussion 
The immunogenicity of peptide vaccines is a matter of debate since many years. The 
main problems are poor immunogenicity and the lack of cross-reactivity of elicited 
antibodies with native target antigens. We circumvent these problem by using IRIVs, 
a safe and highly immunostimulatory adjuvant/delivery system, and by optimizing 
synthetic peptide antigens based on their potential to elicit parasite cross-reactive 
antibodies (Poltl-Frank et al., 1999; Moreno et al., 2001; Mueller et al., 2003; Pfeiffer 
et al., 2003) (Okitsu et al. submitted). The goal of this study in mice and rabbits was 
to analyze the dependence of the immune response elicited by different doses of 
virosomally formulated UK-39 and AMA49-CPE. Additionally the influence of 
combined delivery of the two candidate antigens for a multivalent vaccine on 
immunogenicity was tested. 
ELISA results showed that virosomally formulated UK-39 and AMA49-CPE are highly 
immunogenic in both animal species. A low dose of 10µg was enough to induce high 
titers of anti-UK-39 IgG after two immunizations in mice and after one immunization 
in rabbits. Higher doses of UK-39 tested in rabbits did not increase anti-UK-39 IgG 
titers. With AMA49-CPE a dose of 50µg was superior to lower doses of peptide in 
terms of antibody titers elicited. AMA49-CPE-specific IgG was detected after two 
immunizations in mice and after one immunization in rabbits. Combined delivery of 
separate IRIV preparations carrying the two peptides did not interfere with the 
immune response against one of the components. There was even a tendency for 
higher titers after combined delivery, which may be due to the doubling of the dose of 
IRIVs. The induction of high antibody titers upon two immunizations with relatively 
low doses of synthetic peptides demonstrates that the IRIV system is highly suitable 
for peptide antigen delivery in vaccine development. The possibility to combine 
different antigens makes it an ideal system for the development of a multivalent 
malaria vaccine, targeting antigens from different life-stages of P. falciparum. 
The fact that all outbred rabbits immunized with UK-39 and AMA49-CPE mounted a 
strong peptide-specific immune response, including a T cell dependent 
immunoglobulin class-switch, shows the possibility to use the IRIV system in 
individuals with different immunogenetic backgrounds.  
UK-39 induced IgG was cross-reactive with P. falciparum sporozoites in IFA and 
stained a band corresponding to CSP in Western blot analyses in mice and rabbits. 
IFA titers closely followed ELISA titers, indicating a close relationship between UK-39 
Chapter 4: Preclinical Profiling of a Virosomal Vaccine Candidate 
 
 76 
and the natural conformation of the CSP repeats. This observation is supported by a 
comparison of NMR studies of UK-39 with the crystal structure of an NPNA repeat 
showing that both adopt a type-I b-turn (Ghasparian et al., 2006) (Okitsu et al. 
submitted). AMA49-CPE elicited IgG cross-reacting with P. falciparum blood-stage 
parasites. 95% of all AMA49-CPE immunized mice produced parasite-binding IgG, 
recognizing P. falciparum in IFA. Despite problems with high unspecific cross-
reactivity of rabbit sera with blood-stage parasites in IFA we were able to show the 
induction of AMA-1-binding antibodies in Western blot. 
Purified IgG preparations of UK-39 immunized rabbits have shown inhibitory activity 
in in vitro parasite inhibition assays (Okitsu et al. submitted). Reduced gliding motility 
and agglutination of sporozoites in the presence of anti-UK-39 antibodies indicate an 
interference with gliding motility of the parasite by disrupting the molecular machinery 
itself, sterical hindrance and/or cross-linking of CSP of neighboring parasites. It has 
been reported before that anti-CSP antibodies can immobilize sporozoites in the skin 
after injection by a mosquito (Vanderberg and Frevert, 2004). 
The results presented in this report are confirmed by results from a phase I clinical 
trial in Caucasians (Genton et al. submitted), where the same vaccine proved to be 
safe and immunogenic. At an appropriate dose UK-39 and AMA49-CPE led to 100% 
seroconversion alone and in combination. The detailed immunogenicity results 
(Genton et al. submitted, Okitsu et al. manuscript in preparation) closely followed the 
animal results presented in this report, validating the mouse and rabbit model for 
immunogenicity studies of virosomally formulated vaccine candidates.  
Taken together easy to synthesize peptides together with IRIVs, already registered 
for use in humans, are a very promising system for the swift development of a 
multivalent subunit malaria vaccine.  
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Materials and Methods 
 
Mouse immunogenicity studies. Peptide synthesis and vaccine formulation was 
done as described before (Mueller et al., 2003) (Okitsu et al. submitted). BALB/c 
mice were pre-immunized intramuscularly with 0.1 ml of the commercial whole virus 
influenza vaccine Inflexal BernaTM (Berna Biotech, Bern, Switzerland). Three weeks 
later they were immunized with 10µg peptide delivered on IRIVs in intervals of at 
least two weeks. Blood was collected before each immunization and three weeks 
after the final injection. 
 
Rabbit immunogenicity studies. New Zealand rabbits were pre-immunized 
intramuscularly with 0.5 ml of the commercial whole virus influenza vaccine Inflexal 
BernaTM (Berna Biotech, Bern, Switzerland). Three weeks later they were immunized 
with peptide-loaded IRIVs (10, 25, and 50µg UK-39 or AMA49-CPE) in intervals of at 
least two weeks. For combined delivery of UK-39 and AMA49-CPE peptides were 
formulated separately and mixed before immunization. Blood was collected before 
each immunization and two weeks after the final injection. 
 
ELISA. ELISA analyses with peptide-PE conjugates were performed essentially as 
described before (28). Briefly, PolysorpTM plates (Nunc, Fisher Scientific, Wohlen, 
Switzerland) were coated overnight at 4°C with 100 µl of a 10 µg/ml solution of UK-39 
or AMA49-CPE in PBS (pH 7.2). After three washings, wells were blocked with 5% 
milk powder in PBS for 30 min at 37°C and washed three times again. Plates were 
then incubated with serial dilutions of anti-peptide mouse or rabbit sera in PBS 
containing 0.05% Tween-20 and 0.5% milk powder for 2 h at 37°C. After washing, 
plates were incubated with alkaline phosphatase-conjugated goat anti-mouse 
γ−heavy chain antibodies (Sigma, St. Louis, Mo) for 1 h at 37°C. After washing again, 
phosphatase substrate solution containing 1 mg/ml p-nitrophenyl phosphate (Sigma, 
St. Louis, Mo) was added and the plates were incubated until the colorimetric 
reaction had progressed sufficiently. The optical density was measured at 405 nm on 
a Titertek Multiscan MCC/340 reader (Labsystems, Helsinki, Finland).  
For experiments with rabbit sera, horseradish peroxidase-conjugated goat anti-rabbit 
IgG heavy and light chain antibodies (Bio-Rad Laboratories, Hercules, CA) were 
used as secondary antibody. For experiments with horseradish peroxidase-
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conjugated antibodies TMB microwell peroxidase substrate system (KPL, 
Gaithersburg, MD) was used according to the manufacturer and optical density was 
measured at 650 nm. After stopping the reaction by addition of 50 µl 1N HCl per well 
OD was measured at 450nm.  
 
Indirect immunofluorescence assay (IFA) with P. falciparum sporozoites. IFAs 
were essentially done as described before (Okitsu et al. submitted). Air-dried unfixed 
P. falciparum salivary gland sporozoites (strain NF54) attached to microscope glass 
slides were kindly provided by Hugues Matile (F. Hoffmann La Roche, Basel). After 
thawing, wells were incubated for 15 min at room temperature with 25 µl blocking 
solution containing 1% fatty acid-free bovine serum albumin (BSA) in PBS. 
Immunostaining was performed by incubating the wells with 25 µl of an appropriate 
serum dilution in blocking solution in a humid chamber for 1 h at room temperature. 
After five washes with blocking solution 25 µl of 5 µg/ml cyanine dye (Cy3)-
conjugated affinity-pure F(ab´)2 fragment goat anti-mouse Ig γ-heavy chain antibodies 
(Jackson Immuno Research Laboratories, West Grove, Pa.), diluted in blocking 
solution containing 0.01 mg/ml Hoechst dye no. 33256 (Sigma, St. Louis, Mo) were 
added to the wells and incubated for 1 h at room temperature. Finally, wells were 
washed five times with PBS, mounted with mounting solution (90% [vol/vol] glycerol 
containing 0.1 M Tris-Cl, pH 8.0 and 2 mg/ml o-phenylenediamine) and covered with 
a coverslip. Antibody binding and DNA staining were assessed by fluorescence 
microscopy on a Leitz Dialux 20 fluorescence microscope and documented with a 
Leica DC200 digital camera system.  
For IFAs with blood-stage parasites multiwell immunofluorescence microscopy slides 
(Flow Laboratories, Baar, Switzerland) were treated with 0.01% poly-L-lysine (Sigma) 
at room temperature for 30 min and washed five times with RPMI basal salts medium 
(Gibco-BRL, Basel, Switzerland). Erythrocytes from in vitro cultures (Matile and 
B.Pernis, 1990) of P. falciparum strain K1 with a parasitemia between 5 and 10% 
were washed twice in RPMI and resuspended in RPMI and 2 volumes of a solution 
containing 4% formaldehyde and 0.1% Triton X-100. From this cell suspension, 30 µl 
was added to each well, incubated at room temperature for 30 min, and washed five 
times with PBS. Blocking and incubation with sera or mabs was done as described 
above for IFA with sporozoites. 
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For experiments with rabbit sera a Cy3-conjugated donkey anti-rabbit IgG heavy and 
light chain antibody (Jackson Immuno Research Laboratories, West Grove, PA) was 
used. 
 
SDS-PAGE and immunoblotting. 100 µl of Anopheles stephensi salivary gland 
lysate kindly provided by Hugues Matile (F. Hoffmann La Roche, Basel) containing 
about 100’000 P. falciparum sporozoites were thawed, diluted with an equal volume 
of 2x loading buffer (1.7ml, 0.5M Tris-HCl pH 6.8, 2 ml glycerol, 4.5 ml 10% SDS, 1 
ml β-mercaptoethanol, 0.8 ml bromophenol blue (0.3% w/v)) and heated to 95°C for 
10 minutes. Proteins were separated on a 10% SDS PAGE mini-gel. Separated 
proteins were electrophoretically transferred to a nitrocellulose filter (Protran® 
Nitrocellulose, BA85, Schleicher & Schuell) by semi-dry blotting. Blots were blocked 
with PBS containing 5% milk powder and 0.1% Tween-20 over night at 4°C. The filter 
was cut into strips and incubated with appropriate dilutions of immune sera in 
blocking buffer for 2 h at room temperature. Filter strips were then washed three 
times for 10 minutes in blocking buffer and incubated at room temperature for 1 h 
with alkaline peroxidase-conjugated goat anti-mouse γ-heavy chain antibodies 
(Sigma, St. Louis, Mo) diluted 1:30’000 in blocking buffer. After washing again, blots 
were finally developed using ECLTM Western blotting detection (Amersham 
Biosciences, Buckinghamshire, England) reagents to visualize bands. Blood stage 
parasite lysates were prepared essentially as described previously (Matile and 
B.Pernis, 1990) by saponin lysis of P. falciparum K1-infected erythrocytes. In brief, 
cultured parasites were washed once with PBS. Pelleted infected red blood cells 
were lysed by mixing with a large volume (adjusted to 5% hematocrit) of 0.015% 
(wt/vol) saponin in 150 mM NaCl and 15 mM sodium citrate (pH 7.0) and incubated 
on ice for 20 min. Finally, the pelleted parasites were resuspended in 3 volumes of 
PBS and stored at -80°C until further use. A total of 50 µl of parasite lysate was 
solubilized in an equal volume of 2x loading buffer (1.7 ml of 0.5 M Tris-HCl [pH 6.8], 
2 ml of glycerol, 4.5 ml of 10% sodium dodecyl sulfate, 1 ml of  -mercaptoethanol, 0.8 
ml of bromophenol blue [0.3%, wt/vol]) and heated to 95°C for 10 min. Proteins were 
separated on an SDS–10% PAGE minigel and transferred to a nitrocellulose 
membrane as described above. 
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Experiments with rabbit sera were performed with horseradish peroxidase-
conjugated goat anti-rabbit IgG heavy and light chain antibodies (Bio-Rad 
Laboratories, Hercules, CA) diluted 1:6’000 in blocking buffer. 
 
Parasite culture 
P. falciparum strain K1 was cultured essentially as described previously (Matile and 
B.Pernis, 1990). The culture medium was supplemented with 0.5% AlbuMAX (Gibco, 
Paisley, Scotland) as a substitute for human serum (Dorn et al., 1995). 
Synchronization of cultures was achieved by sorbitol treatment as described before 
(Lambros and Vanderberg, 1979). 
 
Statistical analysis 
All statistical analyses and graphs were made using GraphPad Prism version 4.03 for 
Windows, GraphPad Software, San Diego California USA, www.graphpad.com. Sera 
showing no reactivity in immunogenicity tests were assigned a titer of 1 instead of 0 
to calculate geometric means. Statistical significance of boost effects in ELISA and 
IFA was tested using a Wilcoxon test to compare the geometric mean titers between 
different immunizations.  
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Figure legends 
 
Figure 1. Development of anti-UK-39 IgG responses in mice. Mice were immunized 
three times with virosomally formulated UK-39 alone or in combination with AMA49-
CPE. Sera were taken pre-immune (pI) and two weeks after the first, second, and 
three weeks after the third immunization. Shown are serial dilutions of sera in ELISA 
(means +/-SD of 10 mice per group and immunization). 
 
Figure 2. Mouse anti-UK-39 IgG cross-reactivity with P. falciparum sporozoites. Sera 
of immunized mice (pre-immune and two weeks after the first, second, and three 
weeks after the third immunization) were tested for parasite binding in IFA with P. 
falciparum sporozoites from mosquito salivary glands. Shown are 10 animals, lines 
representing the geometric mean. 
 
Figure 3. Anti-UK-39 IgG titer development in ELISA. Rabbits were immunized three 
times with different amounts of virosomally formulated UK-39 alone or in combination 
with AMA49-CPE. Blood samples were taken pre-immune and two weeks after the 
first, second and third immunization. Shown are serial dilutions of sera in ELISA 
(means +/- SD 3 rabbits per group and immunization). 
 
Figure 4. Anti-UK-39 IgG cross-reactivity with sporozoite derived CSP. Shown are 
sera from three rabbits immunized with 10µg virosomally formulated UK-39. Sera 
were taken pre-immune and two weeks after the second immunization. Dilution for 
pre-immune sera is 1:100, for immune sera 1:2500, 1:5000, 1:10,000, and 1:20,000. 
 
Table 1. Rabbit anti-UK-39 IgG cross-reactivity with P. falciparum sporozoites. 
Shown are the geometric mean IFA endpoint titers and 95% CI of three animals per 
group. 
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Figures and Tables 
 
 
 
 
Figure 1. Development of anti-peptide IgG responses in mice. Mice were immunized 
three times with virosomally formulated UK-39 or AMA49-CPE alone and in 
combination. Sera were taken pre-immune (pI) and two weeks after the first, second, 
and three weeks after the third immunization. Shown are serial dilutions of sera in 
peptide-ELISA (means +/-SD of ten mice per group and immunization). A: Anti-UK-39 
IgG response of animals immunized with UK-39 alone and in combination with 
AMA49-CPE. B: Anti-AMA49-CPE response of animals immunized with AMA49-CPE 
alone and in combination with UK-39. 
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Figure 2. Induction of P. falciparum cross-reactive IgG after immunization of mice 
with UK-39 or AMA49-CPE alone and in combination. Sera of immunized mice were 
taken pre-immune (pI) and two weeks after the first, second, and three weeks after 
the third immunization. Shown are ten animals per group, lines representing the 
geometric mean. A: Parasite-binding properties of anti-UK-39 responses as 
measured in IFA with P. falciparum sporozoites isolated from mosquito salivary 
glands. B: Cross-reactivity of anti-AMA49-CPE IgG responses with cultured P. 
falciparum blood-stage parasites.  
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Fig 3. Anti-peptide IgG titer development in ELISA. Rabbits were immunized three 
times with virosomally formulated UK-39 or AMA49-CPE at three different doses of 
peptide (10, 25 and 50µg) alone and in combination. Blood samples were taken pre-
immune (pI) and two weeks after the first, second and third immunization. Shown are 
serial dilutions of sera in ELISA (means +/- SD) of three rabbits per group and 
immunization). A: Development of anti-UK-39 IgG responses measured in UK-39 
peptide ELISA. B: Development of anti AMA49-CPE IgG responses measured in 
AMA49-CPE peptide ELISA. 
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Figure 4. Cross-reactivity of anti-UK-39 responses measured in IFA with P. 
falciparum sporozoites from mosquito salivary glands. Sera of immunized rabbits 
were taken pre-immune (pI) and two weeks after the first, second and third 
immunization. Shown are three animals per group, lines represent the geometric 
mean.  
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Figure 5. Anti-UK-39 IgG cross-reactivity with sporozoite derived CSP in Western blot 
analysis. Shown are results obtained with sera from rabbits immunized with 
virosomally formulated UK-39 alone (A) and in combination with AMA49-CPE (B). 
Sera were taken two weeks after the second immunization and used at a dilution of 
1:500. 
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Figure 6. Western-Blot analysis of rabbit serum samples with P. falciparum blood 
stage parasite saponin lysate. Each lane represents a serum sample derived from 
one individual rabbit immunized either with AMA49 alone (A), a combination of 
AMA49 and UK-39 (B), or IRIVs alone (C). Upper rows represent serum samples 
taken two weeks after the third immunization (3), lower rows samples taken before 
the first immunization (pI). All serum samples were tested at a dilution of 1:1000. 
Arrows indicate full-length AMA-1 (83kDa) and its major processing product (66 kDa). 
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Abstract 
 
Background and objectives 
Influenza virosomes represent an innovative human-compatible antigen delivery 
system that has already proven its suitability for subunit vaccine design. The aim of 
the study was to proof the concept that virosomes can also be used to elicit high 
titers of antibodies against synthetic peptides. The specific objective was to 
demonstrate the safety and immunogenicity of two virosome-formulated P. 
falciparum protein derived synthetic peptide antigens given in two different doses 
alone or in combination. 
 
Methodology/Principal findings  
The design was a single blind, randomized, placebo controlled, dose-escalating 
study involving 46 healthy Caucasian volunteers aged 18-45 years. Five groups of 8 
subjects received virosomal formulations containing 10 µg or 50 µg of AMA49-CPE, 
an apical membrane antigen-1 (AMA-1) derived synthetic phosphatidylethanolamine 
(PE)-peptide conjugate or 10 µg or 50 µg of UK-39, a circumsporozoite protein (CSP) 
derived synthetic PE-peptide conjugate or 50 µg of both antigens each. A control 
group of 6 subjects received unmodified virosomes. Virosomal formulations of the 
antigens (designated PEV301 and PEV302 for the AMA-1 and the CSP virosomal 
vaccine, respectively) or unmodified virosomes were injected i. m. on days 0, 60 and 
180.  
In terms of safety, no serious or severe adverse events (AEs) related to the vaccine 
was observed. 11/46 study participants reported 16 vaccine related local AEs.  Of 
these 16 events, all being pain, 4 occurred after the 1st, 7 after the 2nd and 5 after the 
3rd vaccination.  6 systemic AEs probably related to the study vaccine were reported 
after the 1st injection, 10 after the 2nd and 6 after the 3rd. Generally, no difference in 
the distribution of the systemic AEs between either the doses applied (10 
respectively 50 µg) or the synthetic antigen vaccines (PEV301 and PEV302) used for 
immunization was found. In terms of immunogenicity, both PEV301 and PEV302 
elicited already after two injections a synthetic peptide-specific antibody response in 
all volunteers immunized with the appropriate dose. In the case of PEV301 the 50 µg 
antigen dose was associated with a higher mean antibody titer and seroconversion 
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rate than the 10 µg dose. In contrast, for PEV302 mean titer and seroconversion rate 
were higher with the lower dose. Combined delivery of PEV301 and PEV302 did not 
interfere with the development of an antibody response to either of the two antigens. 
No relevant antibody responses against the two malaria antigens were observed in 
the control group receiving unmodified virosomes. 
 
Conclusions 
The present study demonstrates that three immunizations with the virosomal malaria 
vaccine components PEV301 or/and PEV302 (containing 10 µg or 50 µg of antigen) 
are safe and well tolerated. At appropriate antigen doses seroconversion rates of 
100% were achieved. Two injections may be sufficient for eliciting an appropriate 
immune response, at least in individuals with pre-existing anti-malarial immunity. 
These results justify further development of a final multi-stage virosomal vaccine 
formulation incorporating additional malaria antigens. 
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Introduction 
Apart from plans to develop a radiation-attenuated sporozoite vaccine [1], vaccine 
development against Plasmodium falciparum malaria is focusing largely on subunit 
vaccine technologies [2]. It is thought that an effective malaria subunit vaccine will 
have to incorporate antigens against several development stages of the parasite. A 
combination of effects against sporozoites, infected liver cells, merozoites and 
infected red blood cells may be required to achieve substantial protective activity [2]. 
Attempts to produce such a multi-stage subunit vaccine against malaria have so far 
met with limited success, indicating that new strategies both for the targeting of the 
immune response to suitable antigenic determinants of the parasite and for the safe 
and appropriate delivery of antigens are required. We are addressing these problems 
by developing synthetic peptide structures that elicit antibodies against the native 
conformation of the malaria antigens [3-5], and by displaying them as PE-peptide 
conjugates on the surface of immunopotentiating reconstituted influenza virosomes 
(IRIV) as carrier and adjuvant system [3;6]. 
 
IRIVs are spherical, unilammelar vesicles, prepared by detergent removal from a 
mixture of natural and synthetic phospholipids and influenza surface glycoproteins. 
The hemagglutinin of the influenza virus is a fusion-inducing membrane glycoprotein, 
which facilitates antigen delivery to immunocompetent cells. IRIVs represent a 
universal antigen-delivery system for multi-component subunit vaccines, since 
antigens can be either attached to their surface to elicit CD4 T cell and antibody 
responses or encapsulated in their lumen to elicit CD8 T cell responses. They have 
an excellent safety profile and are already registered for human use, as two 
virosomal vaccines, the influenza vaccine Inflexal V® and the hepatitis A vaccine 
Epaxal® are commercialized [7]. 
 
We have shown, that synthetic peptide vaccine antigens bypassing many of the 
problems associated with the production of stable recombinant protein-based 
formulations can be developed by iterative cycles of compound design, synthesis and 
immunological profiling [3-6]. Sequential rounds of optimization may lead to 
candidate antigens which elicit primarily antibodies that contribute to immune 
protection when displayed as PE-conjugates on the surface of IRIVs. Here we 
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describe the first clinical profiling of virosomal formulations of two optimized synthetic 
antigens, the CSP repeat region derived PE-peptide conjugate UK-39 and the AMA-1 
derived PE-peptide conjugate AMA49-CPE [4]. CSP of P. falciparum is a leading 
sporozoite candidate antigen for inclusion in a malaria subunit vaccine. In a stepwise 
medicinal chemistry lead optimization process [3,8-10], we have developed the 
conformationally constrained synthetic compound UK-39, which has optimal 
structural and antigenic similarity to the immunodominant NPNA-repeat region of 
native CSP. PEV302, the virosomal formulation of UK-39, elicits high titers of 
sporozoite cross-reactive antibodies in mice and rabbits and these antibodies inhibit 
invasion of liver cells by P. falciparum sporozoites. AMA-1 of P. falciparum is a 
leading merozoite candidate antigen. Its ectodomain can be divided into three 
subdomains each with disulfide bond-stabilized structures. Since the majority of 
antibodies raised against the ectodomain appear to recognize epitopes in domain I 
that are strain-specific, we have developed a synthetic antigen based on the more 
conserved loop-I of domain III, which interacts with the erythrocyte membrane protein 
Kx [11]. PEV301, the virosomal formulation of the optimized loop-I derived cyclized 
peptide antigen AMA49-CPE, elicits high titers of blood stage parasite cross-reactive 
antibodies in mice and rabbits and these antibodies recognize primarily 
discontinuous epitopes comprising conserved sequence stretches of AMA-1 [4]. 
Monoclonal antibodies generated from PEV301 immunized mice have shown P. 
falciparum blood stage growth inhibitory activity in vitro [4].  
The specific objectives of the Phase l trial were to demonstrate the safety, tolerability 
and immunogenicity of PEV301 and PEV302 incorporating two different amounts of 
PE-peptide conjugate (10 µg or 50 µg per dose) given alone or in combination (50 µg 
of each conjugate). 
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Methods 
Overall Study Design and Plan 
This prospective phase I, single blind, randomized, placebo controlled, dose-
escalating study was conducted in 46 healthy adult volunteers at the Clinical 
Research Center, University Hospital, Basel, Switzerland. Eligible study participants 
were randomized into six groups: PEV301 10 µg (n = 8; group 1), PEV302 10 µg (n = 
8; group 2), PEV301 50 µg (n = 8; group 3), PEV302 50 µg (n = 8; group 4), PEV301 
50 µg + PEV302 50 µg (n = 8; group 5) or unmodified virosomes (IRIVs) serving as 
controls (n = 6; group 6). Vaccine formulations contained different amounts of PE-
peptide conjugate, but throughout the same amounts of IRIV per dose. 
 
Subject Selection Criteria 
Healthy volunteers of both sexes, aged between 18 and 45 years, with a BMI > 18.5 
and <30 were included if they gave written informed consent. Outside usual criteria 
(chronic disease, pregnancy etc.), volunteers were excluded if they lived in the past 
in a malaria endemic area, had visited such an area in the last 12 months, or had a 
history of clinical malaria.  
 
Vaccine 
Two virosome-formulated P. falciparum malaria vaccines PEV301 (incorporating the 
AMA-1 derived PE-peptide conjugate AMA49-CPE) and PEV302 (incorporating the 
CSP derived PE-peptide conjugate UK-39) were produced according to the rules of 
GMP. Tests for sterility, pyrogenicity, immunogenicity in animals, stability and 
chemical composition were performed on the vaccine lots used in this trial. Each 
dose was composed of 10 or 50 µg AMA49-CPE or UK-39, 10 µg Influenza 
hemagglutinin, 100 µg phospholipids and PBS ad 0.500 ml. Volunteers immunized 
with a combination of AMA49-CPE and UK-39 received a double dose of virosomes 
i.e. hemagglutinin and phospholipids. 
During the course of the study, stability tests were performed. We identified an 
unusual curve profile of PEV301 analyzed by HPLC.  Potency tests were not 
performed at this stage. This potential stability problem may have slightly impacted 
on the immunogenicity of this component, but has been solved since then, thanks to 
lyophilization of the vaccine candidate. 
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Randomization, assignments to treatment groups and trial procedures  
Sequence generation for the randomization was computer performed (SAS 
software). The first 18 volunteers were stratified into males and females and then 
randomized by two blocks of 9 (1 block = females, 1 block = males) in 3 groups: 
PEV301 10 µg  (n= 8), PEV302 10 µg  (n = 8), and IRIVs alone (control; n = 2). Five 
weeks later, another 18 volunteers followed the same procedure: PEV301 50 µg (n = 
8), PEV302 50 µg  (n = 8), and IRIVs (n = 2). Five weeks after the 2nd vaccination of 
previous groups, 10 volunteers were randomized in blocks of 5 to either the 
combination of PEV301 & PEV302 50 µg  (n = 8) or IRIVs (n = 2).  
Randomization concealment was done using sealed envelopes with numbers (1 to 
46) corresponding to the sequence of assignment to the study. For implementation, 
the physician in charge of the screening and inclusion opened the envelopes 
sequentially, using one block for each sex. 
The study was single blind (participant unaware of product applied).The trial vaccines 
were administered i.m. in the left arm on day 0, in the right one on day 56-65, and the 
left one on day 175-186. 
 
Safety parameters  
Occurrence of local and systemic adverse events was assessed by the physician in 
charge for 30 minutes, and on days 2 (+1) and 7 (+2) after each vaccination, and by 
the subject him/herself on a diary card for 4 days. Intensity of local adverse events 
was graded as follows: for pain, 1= painful on touch, 2 painful when moved, 3 
spontaneously painful; for redness and swelling, 1 = >5 mm, 2 = > 20mm, 3 = >50 
mm. For all other adverse events, grading and reporting was done according to 
Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Hematological and 
biochemical analysis was carried out at screening visit (baseline), 7 (+2) and 21 (+5) 
days after each vaccination. 
 
Immunogenicity parameters 
Blood samples for antibody titer measurement by ELISA against AMA49-CPE and 
UK-39 were taken during the screening visit, at the days of the 2nd and 3rd 
vaccination, 21 days after each vaccination and one year after the third vaccination 
(groups 2, 3 and 5 only).   
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Laboratory methods  
ELISA polysorp microtiter plates (Nunc, Dr. Grogg, Stetten-Deiswill, Switzerland) 
were coated at 4°C overnight with 10 µg/ml AMA49-CPE (for PEV301) or UK-39 (for 
PEV302) in PBS, pH 7.2. Wells were then blocked with 5% milk powder in PBS for 2 
h at 37°C followed by three washings with PBS containing 0.05% Tween-20. Plates 
were then incubated with two-fold serial dilutions of human serum starting with 1:50 
in PBS containing 0.05% Tween-20 and 0.5% milk powder for 2 h at 37°C. After 
washing, the plates were incubated with horseradish-peroxidase-conjugated goat 
anti-human IgG antibodies (KPL, Socochim, Lausanne, Switzerland) (1:2000 in PBS 
containing 0.05% Tween-20) for 1 h at 37°C and then washed. Citrat-buffer 
containing 4 mg/ml 1,2-diaminobezene substrate (OPD; Fluka, Sigma, Buchs, 
Switzerland) and 0.01% H2O2 was added and incubated at room temperature. After 
10 minutes the reaction was stopped by addition of sulphuric acid (Merck, Darmstadt, 
Germany) to reach a final concentration of 0.5M. The optical density (OD) of the 
reaction product was recorded at 492 nm using a microplate reader (SpectraMax 
plus, Bucher Biotech, Basel, Switzerland). Titration curves were registered using 
Softmax PRO software.  Endpoint titers were calculated by comparing the ELISA OD 
of the test serum with the ELISA OD of a negative serum pool. Endpoint titer is last 
serum dilution where the ODtest  sera ≥ 2 x ODnegativ serum. 
 
Data Quality Management 
The study was monitored by the Pharmaceutical Medicine Unit (PMU) of the Swiss 
Tropical Institute (STI) according to a monitoring plan.  
 
Statistical Methods  
The safety analysis population included all subjects who received at least one 
injection, independently from protocol deviations. Data collected from drop-outs were 
used for the statistical analysis until the date of discontinuation. Safety of the injected 
study materials was determined as the incidence of adverse events and the 
occurrence of significant clinical, hematological and biochemical abnormalities during 
the procedure and at the intervals indicated in the schedule of assessments. The 
safety analysis population listings were made of the safety data collected at each 
time point.  
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The Per Protocol (PP) immunogenicity analysis population included all subjects, who 
received the three doses of the allocated product in the allowed intervals and timely 
attended all the scheduled blood sampling visits. The Intention-to-treat (ITT) 
immunogenicity analysis population included all subjects and all time points, 
independently from protocol deviations (which mainly consisted in a 1-2 day deviation 
from the allowed time interval). Data collected from drop-outs were included for ITT 
analysis until the date of discontinuation.  
The criteria for the evaluation of immunogenicity of PEV301 and PEV302 were the 
results of antibody titers by Elisa against AMA49-CPE and UK-39. ELISA responders 
were defined as subjects with a minimum titer ≥ 1: 500 and a >2 fold increase after 
immunization. 
The geometric means and 95% confidence intervals of the antibody titers determined 
by ELISA (total IgG) for PEV 301 and PEV 302 in the four different groups were 
calculated separately for each time point and study group. The statistical significance 
of the vaccine component effects was tested using a Wilcoxon test to compare the 
median of the antibody titers between group 1 (PEV301 10 µg) and 3 (PEV301 50 
µg), group 1 (PEV301 10 µg) and 5 (PEV301&302 50 µg) and group 3 (PEV301 50 
µg) and 5 (PEV301&302 50 µg) at each study week assessment. Same was done for 
the respective groups of PEV302. The Fishers exact test was applied to compare the 
proportion of respondents between the groups above and at each time point with the 
exception weeks 9/10 and 26/27 where the titre could not be determined. 
Indices of antibody response were expressed as the ratio of the antibody 
concentration obtained by Elisa at the 4, 12/14 and 29/30 weeks with reference the 
baseline measurement point. The geometric mean and 95% confidence limits were 
calculated and the Wilcoxon test was used to compare between groups and between 
the follow-up times at the 4, 12/14 and 29/30 week and the baseline.  
 
Determination of Sample Size 
The sample size of this pilot study was determined by the requirement to determine 
safety of each formulation and dose. A sample size of 8 in each group constituted a 
reasonable sample size to estimate the incidence rate of frequent AEs with an 
acceptable accuracy, allowing for dropouts. The study was not powered to ensure 
that differences in safety or immunogenicity between regimens would be statistically 
significant.  
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Ethics  
The protocol was approved by the Ethikkommission beider Basel (EKBB) and the 
study conducted in full compliance with the international ethical guidelines for 
biomedical research involving human subjects. 
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RESULTS 
The study was conducted from November 2003 to October 2005. 46 Caucasian 
subjects (half female, see study procedures) were enrolled as planned. All 46 
received the 1st injection, 44 the 2nd and 43 the 3rd. Demographic and other baseline 
characteristics of the population enrolled in the study are listed in Table 1. Three 
subjects discontinued participation in the trial, all of them due to a systemic AE (one 
of them possibly related to the study vaccine) (see below and study flowchart on 
figure 1). 
 
Safety evaluation 
No subject was excluded from the safety analysis. No serious or severe AE occurred 
after the 1st, 2nd or 3rd vaccination. Exclusively pain was reported as local AE, i.e. no 
subject experienced at any time redness and/or swelling at the injection site. In total, 
16 local AEs were reported by 11 study participants (3 from PEV301 10 µg , 2 from 
PEV301 50 µg , 2 from PEV302 50 µg , 2 from PEV301 & 302 50 µg and 2 from 
IRIV) during the period of the trial. Of these 16 events, 4 occurred after the 1st, 7 after 
the 2nd and 5 after the 3rd vaccination. No volunteer from PEV302 10 µg suffered 
from local AEs. Ten events (62.5%) were of mild and 6 (37.5%) of moderate 
intensity. All listed local vaccine related AEs completely resolved without sequelae 
within maximal 3 days after injection and no intervention was required to treat any of 
the local AEs. 
In total 69 systemic AEs (6 possibly related and 63 either unrelated, or unlikely 
related to the study vaccine) were reported by 31 subjects after the 1st vaccination, 
44 systemic AEs (10 possibly related and 34 unrelated/unlikely related) by 22 
subjects after the 2nd immunization, and 18 systemic AEs (6 possibly related and 12 
unrelated/unlikely related) by 13 subjects after the 3rd injection. One serious, vaccine 
unrelated, adverse event was reported in the PEV302 10 µg group after the 1st 
immunization (hospitalisation for tooth abscess). This subject and two others 
voluntarily discontinued participation in the trial, the first two prior to the 2nd and the 
last prior to the 3rd vaccination. Only one was graded as possibly related by the 
investigator (dishydrosis). 
The type and distribution of vaccine related systemic AEs is shown in Table 2. 
Generally, no difference in the distribution of the systemic AEs between either the 
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doses applied (10 respectively 50 µg) or the synthetic antigens (PEV301 and 
PEV302) was found. No possibly related systemic AE was experienced by volunteers 
from the IRIV group and less flu-like symptoms were reported in the IRIV group when 
compared to the verum groups. 
Only one subject was measured with a body temperature >38.0ºC (38.0ºC one day 
after the 3rd vaccination in the PEV301 50 µg group). Most of the AEs (related or 
unrelated), either observed by the physician in charge, or mentioned in the diary card 
were of mild (39%) or moderate (59%) intensity. Only 2% experienced severe AEs. 
Several laboratory values were reported to be outside the normal ranges during the 
trial. However, none of them was judged as clinically significant by the investigator. 
After pooling groups and doses, the parameters most often outside the normal 
ranges were: red blood cells count (45 values), ALAT (29 values), CRP (19 values), 
white blood cells count (15 values) and hemoglobin (14 values).  
 
Immunogenicity evaluation 
The per protocol analysis population for the ELISA evaluation included 37 subjects 
(see study flowchart on figure 1 for details). ELISA was performed with blood 
samples taken during the screening visit, at the days of the 2nd and 3rd vaccination 
21 days after each vaccination and one year after the third vaccination. Mean ELISA 
endpoint titers are given in Table 3 and the antibody titers of the optimal doses are 
shown in figure 2. 
Indices of responses of the two PEV301 50 µg groups were significantly higher than 
those of the 10 µg group at all time points (p always <0.004), demonstrating that the 
dose of 50 µg AMA49-CPE was superior to that of 10 µg. While all volunteers in the 
50 µg groups reached a titer >1:500 after the second and third immunization, none of 
the PEV301 10 µg group reached this titer (Table 3). Nevertheless, there was a 
significant difference between the response indices (shown in figure 3a) of PEV301 
10 µg after the second and third immunization versus that of the IRIV (control group) 
(both p=0.004). Differences in response indices between groups PEV301 50 µg and 
PEV301 & 302 50 µg were not statistically significant at weeks 4, 9/10, and 29/30 (p 
always >0.1), indicating that the combination with PEV302 did not interfere with the 
response to PEV301. These differences were borderline significant at weeks 12/14 
(p=0.055) and 26/27 (0.067). When comparing response indices after the first to the 
ones after the second immunization in the PEV301 50 µg groups, the difference was 
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borderline significant (p=0.09) indicating that the initial response was boosted by the 
second administration. There was no additional benefit of having a third immunization 
(p=0.7). All volunteers in the two 50 µg groups had developed an IgG response after 
the second immunization, whereas 62.5% (5/8) of the volunteers in the 10 µg group 
seroconverted. Importantly, antibody titers evaluated one year after the third 
immunization had remained high (Fig. 2 and Tab. 3).  
With PEV302 the highest mean ELISA titers were observed after three injections, 
versus two for both PEV301 50 µg groups (Table 3 and figure 2). In contrast to the 
results with PEV301, mean ELISA endpoint titers of the group receiving 10 µg of the 
antigen were higher than those receiving 50 µg. Furthermore, all volunteers in the 
PEV302 10 µg group, but only 11/14 in the two PEV302 50 µg groups had 
seroconverted after two injections. After the third immunization, all volunteers in the 
PEV302 10 µg group, but only 11/14 in the two PEV302 50 µg groups reached an 
ELISA titer >1:500. The percentage of volunteers reaching this titer increased with 
each immunization (Table 3). Response indices of the three groups receiving 
PEV302 were not significantly different (see figure 3b) (p always >0.2), 
demonstrating that the combination of PEV302 with PEV301 did not interfere with the 
response to PEV302. However, the index of response obtained in the PEV301 & 302 
50 µg group was higher than that of PEV302 50 µg group at all time points (although 
not statistically significant), suggesting that the combination with PEV301 may 
improve the response to PEV302. When comparing response indices after the first to 
the ones after the second immunization in the 10 µg group, the difference was 
borderline significant (p=0.056) indicating that the initial response was boosted by the 
second administration. There was no significant additional benefit of having a third 
immunization (p=0.2). As for PEV301, antibody titers tested one year after the last 
immunization had remained high (Fig. 2 and Tab. 3). 
In contrast to PEV301 and PEV302, no significant ELISA endpoint titers and 
response indices were observed against the malaria antigens in the control subjects 
receiving IRIVs only. The results after ITT analysis are perfectly superposable to 
those obtained after PP analysis (data not shown). 
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Discussion  
This is the first clinical trial that tested two new technology platforms in malaria 
vaccinology: synthetic peptides were optimized for eliciting parasite binding and 
inhibitory antibodies in iterative cycles of compound design, synthesis and 
immunological profiling and IRIV were tested as an immunopotentiating delivery 
system for PE-peptide conjugates. The results presented in this paper prove the 
relevance and the feasibility of the concept: i) GMP formulated material can be easily 
and quickly manufactured, ii) the vaccine formulation is extremely safe, and iii) the 
vaccine formulation is immunogenic leading to seroconversion of all volunteers after 
two injections with an appropriate antigen dose. 
In terms of safety, the antigen delivery platform (IRIVs) used for the tested vaccines 
is already commercialized and has been given to ~20 million people, including 
children and infants [12-13]. This safety record is a major advance, since, the two 
malaria vaccines that have shown some efficacy in Phase IIb trials in endemic areas 
are formulated in adjuvants that have been given at best to only a few thousands of 
subjects so far [14-15]. Also, although probably safe, these new adjuvants are quite 
reactogenic [16-17]. As with other vaccine types, rare serious adverse events have 
been reported following immunizations with synthetic malaria peptides [18], but these 
may have occurred, because the doses of antigen were too high for the potent 
adjuvant used. Since the two synthetic antigens used in the present study were 
applied in lower doses and combined with the human approved IRIVs we expected 
an excellent safety profile. This was confirmed by our results that showed that the 
virosome-formulated PE-peptide conjugates AMA49-CPE and UK-39 as well as the 
combination of both are very safe. The local reactogenicity was minimal with only 
mild or moderate pain, and no redness or swelling. This contrasts with results 
obtained in Phase I trials with recombinant malaria proteins formulated with ASO2A 
or Montanide ISA 720, or DNA vaccines in viral vectors [28]. There was no difference 
in the incidence rate and intensity of AEs between the subjects given one or the other 
synthetic antigen, or both, and between the two doses, which proves the safety of the 
formulation.  
In terms of immunogenicity, the ELISA results demonstrate that the formulation of 
synthetic peptides with virosomes elicited a response in all volunteers immunized 
with an appropriate dose. These results represent a proof of principle, i.e. they 
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demonstrate that virosomes are a suitable antigen delivery system for peptide 
antigens in humans and that immunogenetic restriction of the response does not 
represent a serious limitation for this approach. In the majority of volunteers 
immunized with PEV302, we observed cross-reactivity with the target proteins on the 
cell surface of P. falciparum sporozoites (data not shown). Also in the case of a 
minority of PEV301 immunized volunteers development of an AMA-1 specific staining 
pattern of malaria blood stage parasites was found in spite of variable background 
staining. These results demonstrate that the two synthetic antigens display the native 
structure of antigenic domains of the target antigens AMA-1 and CSP.  
In the case of PEV301, the higher antigen dose (50 µg) was significantly superior to 
the lower dose (10 µg) with respect to mean antibody titers and seroconversion rate. 
For PEV302, the trend was reverse. These results may imply that additional antigens 
included in a multivalent vaccine will need a proper dose-finding assessment. In the 
case of PEV301 and PEV302 trends observed in animal immunogenicity studies and 
the clinical trial were comparable (Mueller et al. unpublished). Since the combined 
delivery of PEV301 and PEV302 did not interfere with the development of an immune 
response to either of the two components, it is hoped that the inclusion of additional 
antigens should not be detrimental to the overall immunogenicity. In addition, a 
persistent antibody titer was measured after one year. In the present trial a 100% 
seroconversion rate was achieved in malaria non-immune volunteers already after 
two injections with the appropriate dose of antigen. This is highly promising, since it 
is expected that the immunogenicity will be even higher in populations with a certain 
degree of pre-existing immunity. The present findings justify the ongoing efforts to 
develop a virosomal multi-valent multi-stage malaria vaccine. Our approach of 
developing optimized IRIV-formulated synthetic peptide vaccines should be generally 
applicable and amenable for other infectious and non-infectious diseases.  
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Figure legends: 
 
Figure 1: Study flowchart 
 
Figure 2: Geometric mean anti-AMA49-CPE and anti-UK-39 IgG endpoint titers in 
ELISA of groups immunized with optimal doses of PEV301 (50µg)  or PEV302 
(10µg), or with 50µg each of both antigens. Sera analyzed were collected during the 
screening visit, at the days of the 2nd and 3rd vaccination, 21 days after each 
vaccination and one year after the third vaccination 
 
Figure 3: Geometric means of the ratios of geometric mean antibody endpoint titers 
(log scale) for samples taken three weeks after each immunization with reference to 
pre-vaccination titers in sera taken at the screening visit (week -1). 
 
a) anti-AMA49-CPE IgG titers (Group 1= PEV301 10 µg; Group 3= PEV301 50 µg; 
Group 5= PEV301&302 50 µg, Group 6=IRIV)  
b) anti-UK-39 IgG titers (Group 2= PEV302 10 µg; Group 4= PEV302 50 µg; 
Group 5= PEV301&302 50 µg, Group 6=IRIV) 
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Figure 1: Study flowchart 
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Figure 2: Geometric mean anti-AMA49-CPE and anti-UK-39 IgG endpoint titers in 
ELISA of groups immunized with optimal  doses of PEV301 (50µg)  or PEV302 
(10µg), or with 50µg each of both antigens. Sera analysed were collected during 
the screening visit, at the days of the 2nd and 3rd vaccination, 21 days after each 
vaccination and one year after the third vaccination 
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Figure 3: Geometric means of the ratios of geometric mean antibody endpoint titers 
(log scale) for samples taken three weeks after each immunization with reference to 
pre-vaccination titers in sera taken at the screening visit (week -1). 
 
a) anti-AMA49-CPE IgG titres (Group 1= PEV301 10 µg; Group 3= PEV301 50 µg; 
Group 5= PEV301&302 50 µg, Group 6=IRIV) 
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b) anti-UK-39 IgG titres (Group 2= PEV302 10 µg; Group 4= PEV302 50 µg; 
Group 5= PEV301&302 50 µg, Group 6=IRIV) 
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Table 1: Demographic characteristics at baseline. 
 
 PEV301 PEV302 PEV301 + 302  
 10 µg 50 µg 10 µg 50 µg 50 µg of each IRIV 
 N= 8 N= 8 N= 8 N= 8 N= 8 N= 6 
Age (years)       
Mean 26 27 28 28 25 26 
Min-Max 22-37 22.-40 21-42 20-40 20-30 20-42 
Weight (kg)       
Mean 68.1 68.7 71.3 69.4 71.8 70.1 
Min-Max 50.9-82.5 60.8-84.0 56.5-106.3 49.7-96.4 55.0-86.5 57.0-80.6 
BMI       
Mean 22.6 22.9 23 22 23.8 23.7 
Min-Max 19.6-25.5 20.4-28.7 19.3-29.8 19.2-26.2 20.4-29.8 20.0-27.4 
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Table 2: Vaccine-related systemic adverse events 
Vaccine PEV301 PEV302 
PEV301 & 
302 IRIV 
 10 µg 50 µg 10 µg 50 µg 50 µg each   
Stdy group n = 8 n = 8 n = 8 n = 8 n = 8 n = 6 
       
After 1st immunization 
Headache –  1 12.5% 2 25.0% –  –  –  
Nasopharyngitis 1 12.5% –  –  –  –  –  
Rhinitis   1 12.5% –  –  –  –  
Dyshidrosis –  –  –  1 12.5% –  –  
Number of subjects 
with at least one AE  1/8 12.5% 2/8 25.0% 2/8 25.0% 1/8 12.5% 0/8 0% 0/6 0% 
After 2nd immunization 
Headache –  1 12.5% –  1 12.5% –  –  
Pharyngolarnyngeal pain –  2 25.0% –  –  –  –  
Ear pain –  1 12.5% –  –  –  –  
Rhinitis –  1 12.5% –  –  –  –  
Nausea –  –  –  1 12.5% –  –  
Vertigo –  –  –  1 12.5% –  –  
Fatigue –  –  –  1 12.5% –  –  
Malaise –  –  –  1 12.5% –  –  
Number of subjects 
with at least one AE 0/8 0% 2/8 25.0% 0/7 0% 2/8 25.0% 0/7 0% 0/6 0% 
After 3rd immunization 
Pyrexia –  1 14.3% –  –  –  –  
Rhinitis –  –  1 14.3% –  –  –  
Asthenia –  –  –  1 14.3% –  –  
Vertigo –  –  –  1 14.3% –  –  
Vaginal infection –  –  –  –  1 14.3% –  
Headache –  –  1 14.3% –  –  –  
Number of subjects 
with at least one AE 0/8 0.0% 1/8 12.5% 2/7 28.6% 1/7 14.3% 1/7 14.3% 0/6 0.0% 
Note: the values in bold indicate the number of AEs experienced.    
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Table 3. Geometric means of anti-AMA49 and anti-UK-39 IgG endpoint titers in 
ELISA and number of volunteers that seroconverted  
 
Vaccine PEV301 PEV302 PEV301 & PEV302 IRIV 
Dose 10 µg 50 µg 10 µg 50 µg 50 µg   
Study group Group 1 Group 3 Group 2 Group 4 Group 5 Group 6* 
Target antigen in 
ELISA AMA49 AMA49 UK-39 UK-39 AMA49 UK-39 AMA49 UK-39 
Titers  after 1st 
injection 77 6893 425 488 5593 392 25 77 
95% CI 21-289 2057-28893 40-4559 10-23019 1654-18911 24-6391 25-25  
Titers  after 2nd 
injection 360 45614 5658 1449 18813 11404 25 77 
95% CI 88-1479 20170-103156 1064-30083 61-34615 6849-51676 963-135025 25-25  
Titers  after 3rd 
injection 582 29117 19993 4307 16600 21945 25 77 
95% CI 248-1367 11850-71541 2734-146208 243-76258 6391-43112 2892-166548 25-25  
Titers 1 year after 3rd n.d. 3342 3200 n.d. 1213 696 n.d. n.d. 
Nb. responders after 
1st 2/8 6/8 4/7 3/7 7/7 3/7 0/6 1/6 
Nb. responders after 
2nd 5/8 8/8 7/7 5/7 7/7 6/7 0/6 1/6 
Nb. responders after 
3rd 5/8 8/8 7/7 6/7 7/7 7/7 0/6 1/6 
Nb. responders 1 year 
after 3rd n.d. 7/8 5/6 n.d. 5/5 3/5 n.d. n.d. 
* Controls included simultaneously to Group 1 and 3 (301) or 
2 and 4 (302)       
n.d.: not done 
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Abstract 
Background 
The development of a malaria vaccine is an urgent need in tropical countries. Here 
we report a detailed immunological and functional analysis of the antibody response 
elicited by a virosomal malaria vaccine candidate. 
 
Methods 
46 Healthy malaria-naïve adults were immunized with virosomal formulations of two 
peptides, derived from the NANP repeat region of P. falciparum circumsporozoite 
protein (designated UK-39), and from P. falciparum apical membrane antigen 1 
(designated AMA49-CPE). The two peptides were delivered in two different 
concentrations alone and in combination.  
 
Results 
Three vaccinations with a 10µg dose of UK-39 induced high titers of sporozoite-
binding antibodies in all volunteers. This IgG response was affinity maturated and 
long-lived. Co-administration of UK-39 and AMA49-CPE loaded virosomes did not 
interfere with the immunogenicity of UK-39. Purified total IgG from UK-39 immunized 
volunteers inhibited sporozoite migration and invasion of hepatocytes in vitro. 
Sporozoite inhibition closely correlated with titers measured in immunogenicity 
assays. 
 
Conclusions 
Virosomal delivery of a short, conformationally constrained peptide induced a long-
lived parasite-inhibitory antibody response in humans. Combination with a second 
virosomally-formulated peptide did not interfere with the immunogenicity of either 
peptide, demonstrating the suitability of the IRIV system for the development of 
multivalent subunit vaccines. 
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Introduction 
With more than 2 million deaths per year, malaria remains one of the most important 
infectious diseases in humans [1]. More than 30 years after the first successful 
protective vaccination of man with attenuated sporozoites, vaccine development 
against both Plasmodium falciparum and P. vivax is still ongoing [2, 3]. The most 
advanced experimental vaccine, RTS,S/AS02A gave 35% protection against the first 
episode of malaria and 49% protection against severe malaria for at least 18 months 
in a clinical trial in Mozambican children [4, 5]. Despite this success it is assumed that 
a malaria vaccine that is more effective and more cost effective than current malaria 
control tools, such as insecticide treated bed nets and drug treatment, will not be 
available in the next ten years [6-8]. It is thought that a successful malaria subunit 
vaccine will have to incorporate antigens against several developmental stages of the 
parasite. A combination of activities against sporozoites, infected liver cells, 
merozoites and infected red blood cells may be required to achieve substantial 
immune protection [9]. Vaccine development against malaria is focusing largely on 
subunit technologies [9], where the major obstacles include difficulties to retain the 
native conformation of key antibody epitopes and the need for an effective but safe 
human-compatible exogenous adjuvant [10]. A main advantage of the subunit 
approach is that the ideal vaccine will induce immune responses against only those 
determinants relevant to protection, thus minimizing the possibility of deleterious 
responses. 
We are addressing the problem of protein subunit vaccine design by developing 
synthetic peptide structures and coupling them to the surface of immunopotentiating 
reconstituted influenza virosomes (IRIV) as a liposomal carrier system [11-14] (Okitsu 
et al. submitted). IRIVs are spherical, unilamellar vesicles, prepared by detergent 
removal from a mixture of natural and synthetic phospholipids and influenza surface 
glycoproteins. Hemagglutinin, a membrane glycoprotein of the influenza virus 
mediates binding to sialic acid on target cells and is a fusion-inducing component, 
facilitating antigen delivery to immunocompetent cells. IRIVs represent a universal 
antigen-delivery system for multivalent subunit vaccines, since antigens can be either 
attached to their surface to elicit antibody responses or encapsulated in their lumen 
to elicit CD8 T cell responses. They have an excellent safety profile and are already 
registered for human use [15].  
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We are optimizing synthetic peptides in an iterative selection process to develop 
vaccine components with a native-like conformation that elicit high titers of parasite 
cross-reactive antibodies [11-14, 16, 17] (Okitsu et al. submitted). Peptides are 
synthesized from antigens that (i) have a documented and essential role in parasite 
development, (ii) have secondary structure motifs suggesting surface exposition, (iii) 
have conserved sequence stretches, and (iv) induce parasite-inhibitory antibodies. 
Based on these criteria we try to choose protein domains containing protection-
relevant epitopes, thus avoiding the induction of deleterious immune responses as 
observed during infection with P. falciparum. Lead peptides are optimized in a step-
wise process. The key readout is the parasite-binding properties of antibodies elicited 
in mice after immunization with the corresponding peptide coupled to the surface of 
IRIVs. After preclinical profiling in experimental animals, two candidate peptides, i.e. 
AMA49-CPE, a cyclic peptide derived from loop I of domain III of P. falciparum apical 
membrane antigen 1 (AMA-1) [13], and UK-39, a conformationally constrained cyclic 
peptide derived from the central repeat region of P. falciparum circumsporozoite 
protein (CSP) (Okitsu et al. submitted) have been tested in a phase I clinical trial. 
Virosomal formulations of AMA49-CPE (designated PEV301) and UK-39 (designated 
PEV302) were both safe and elicited anti-peptide IgG in all volunteers immunized 
with an appropriate peptide concentration (Genton et al. submitted). While ELISA titer 
development for the different vaccination groups has been described previously  
(Genton et al. submitted), we analyze and correlate here anti-peptide ELISA titers 
with titers of parasite cross-reactive antibodies and with parasite-inhibitory activities 
at the level of individual sera. Moreover, we show affinity maturation of UK-39-
specific antibodies induced by vaccination. 
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Materials and Methods 
Overall Study Design and Plan 
This prospective phase I, single blind, randomized, placebo controlled, dose-
escalating study was conducted in 46 healthy adult volunteers. Eligible study 
participants were randomized into six groups: 10 µg AMA49-CPE (group A, n = 8), 10 
µg UK-39 (group B, n = 8), 50 µg AMA49-CPE (group C, n = 8), 50 µg UK-39 (group 
D, n = 8), 50 µg AMA49-CPE + 50 µg UK-39 (group E, n = 8) or unmodified 
virosomes serving as controls (group F, IRIV, n = 6). Vaccine formulations contained 
different amounts of PE-peptide conjugate, but throughout the same amounts of 
influenza proteins per dose. Volunteers immunized with a combination of virosomally 
formulated AMA49-CPE and UK-39 thus received a double dose of influenza 
proteins. 
 
Vaccine 
Two virosome-formulated vaccines, PEV 301 (incorporating the AMA-1 derived PE-
peptide conjugate AMA49-CPE) and PEV 302 (incorporating the CSP derived PE-
peptide conjugate UK-39) were produced according to the rules of GMP. Tests for 
sterility, pyrogenicity, immunogenicity in animals, stability and chemical composition 
were performed on the vaccine lots used in this trial. Each dose was composed of 10 
or 50 µg AMA49-CPE or UK-39, 10 µg Influenza hemagglutinin, 100 µg 
phospholipids and PBS ad 0.500 ml. The trial vaccines were administered i.m. in the 
left arm on day 0, in the right one on day 56-65, and in the left again on day 175-186. 
 
Ethics  
The protocol was approved by the Ethikkommission beider Basel (EKBB) and the 
study conducted in full compliance with the international ethical guidelines for 
biomedical research involving human subjects. Informed consent was obtained from 
all volunteers. 
 
Immunogenicity 
Blood sampling for antibody titer measurement by ELISA, IFA and Western blot was 
done at screening visit (baseline and 1st vaccination), at the days of the 2nd and 3rd 
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vaccination, 21 days after each vaccination and one year after the third vaccination 
(groups B and E only). 
 
ELISA  
Standard ELISAs were performed as described before [13]. Briefly, PolysorpTM 
microtiter plates (Nunc, Dr. Grogg, Stetten-Deiswill, Switzerland) were coated with 10 
µg/ml AMA49-CPE or UK-39 in PBS. After blocking, plates were incubated with two-
fold serial dilutions of human serum. Horseradish-peroxidase-conjugated goat anti-
human IgG antibodies (KPL, Socochim, Lausanne Switzerland) were used as 
secondary antibodies and 1,2-Diaminobezene substrate (OPD) (Fluka, Sigma. 
Buchs, Switzerland) in citrat-buffer (4 mg/ml OPD) + 0.01% H2O2 for development.  
The endpoint titer is the last serum dilution where the ODtest sera ≥ 2 x ODnegativ serum 
pool. 
 
NH4SCN elution ELISA 
Avidity ELISA analyses with peptide-PE conjugates were performed essentially as 
described before [18]. After coating and blocking, as described for standard ELISA, 
serum samples were added in triplicates at constant dilutions (approx. halfmax titer). 
After a wash step, plates were incubated 15min with NH4SCN diluted in 0.1M 
NaH2PO4 buffer (pH 6) at the following molarities: 5 M, 4 M, 3 M, 2 M, 1 M, 0.5 M, 
0.25 M. Control wells were incubated with 0.1M NaH2PO4 buffer without NH4SCN. 
After washing, plates were incubated with alkaline phosphatase-conjugated affinity-
pure F(ab´)2 fragment goat anti-human IgG (Fc-specific) antibodies (Jackson Immuno 
Research Laboratories, West Grove, Pa.) and developed with phosphatase substrate 
solution.  
The avidity index corresponds to the NH4SCN concentration (M) eluting 50% of the 
bound antibodies. 
 
Indirect immunofluorescence assay (IFA) 
Air-dried unfixed P. falciparum (strain NF54) salivary gland sporozoites attached to 
microscope glass slides were incubated with serial dilutions of sera and detected with 
CyTM3-conjugated affinity-pure F(ab´)2 fragment goat anti-human IgG (Fc-specific) 
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antibodies (Jackson Immuno Research Laboratories, West Grove, Pa.) diluted in 
blocking solution containing 0.01 mg/ml Hoechst dye no. 33256 (Sigma, St. Louis, 
Mo).  
 
SDS-PAGE and immunoblotting 
Anopheles stephensi salivary gland lysate containing about 100’000 P. falciparum 
sporozoites was separated on a 10% SDS PAGE mini-gel and transferred to a 
nitrocellulose filter as described before [13]. Filter strips were incubated with serial 
dilutions of sera. Monoclonal antibody EP9 served as a positive control [14]. 
Antibodies were detected with alkaline peroxidase-conjugated affinity-pure F(ab’)2 
fragment goat anti-human IgG (Fc-specific) antibodies (Jackson Immuno Research 
Laboratories, West Grove, Pa.) Blots were developed using ECLTM Western blotting 
detection (Amersham Biosciences, Buckinghamshire, England) reagents.  
 
P. falciparum in vitro invasion inhibition assay 
Inhibition assays were performed as described before [19]. Briefly, triplicate primary 
human hepatocyte cultures were inoculated with P. falciparum sporozoites (1 x 
105/Lab-Tek well). After 3 h at 37 °C, cultures were washed, further incubated in 
fresh medium for 3 days, and fixed in methanol. Quantification of exoerythrocytic 
forms was done by immunofluorescence. To determine the effects of anti-UK-39 
antibodies on sporozoite infectivity, sporozoites were incubated with hepatocytes in 
the presence of affinity purified polyclonal human IgG from immunized volunteers. 
Inhibition was determined in comparison to PBS control. 
 
P. falciparum migration inhibition assay.  
Migration inhibition assays, were performed as described before [20]. Briefly, HepG2 
cells were incubated with sporozoites in the presence of cell-impermeant tracer 
fluorescein isothiocyanate (FITC)-dextran. After 2 hours at 37°C cells were washed 
to remove extracellular FITC-dextran and analyzed by FACS. Inhibition was 
determined in comparison to PBS control. 
 
Statistical analyses 
All statistical analyses and graphs were made using GraphPad Prism version 4.03 for 
Windows, GraphPad Software, San Diego California USA. Statistical significance of 
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boost effects by second and third immunization in IFA and Western blot was tested 
using a Wilcoxon test to compare geometric mean titers. Correlation of titers in 
immunogenicity assays was analyzed with nonparametric (Spearman) correlation. 
For correlation of invasion and migration inhibition a Pearson test for Gaussian 
distribution was used. 
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Results 
Development of IgG responses against the synthetic antigen UK-39 
Already after two immunizations, all volunteers receiving the virosomal formulation of 
10 µg UK-39 alone (group B) or 50 µg UK-39 in combination with 50 µg of AMA49-
CPE (group E) had developed an anti-UK-39 IgG response with an endpoint titer 
above 400 in ELISA (Figure 1), as shown before (Genton et al. submitted). In group 
D receiving 50 µg of UK-39 alone, 5 out of 7 volunteers had sero-converted after two 
immunizations with titers above 600. In all vaccination groups, a further increase in 
IgG titer after the third immunization was observed only in some volunteers. One 
year after the third immunization titers had dropped, but all volunteers of groups B 
and E remained positive (endpoint titer >102) in ELISA. No increase in anti-UK-39 
antibody titers after vaccination was observed in volunteers of the control group F 
receiving empty IRIVs (Figure 1). The overall highest endpoint titer (>106) was 
observed after the first immunization in a volunteer (35/D) from the 50 µg UK-39 
group, which had a pre-immunization ELISA endpoint titer of about 103 (Figure 1).  
Antibody affinity maturation is a key event during memory B cell development. 
Therefore we measured the avidity of anti-UK-39 IgG in elution ELISAs with 
chaotropic salt. The mean avidity of the vaccine-induced IgG responses gradually 
increased by two-fold in all groups over the course of immunization (Figure 2). 
Volunteer 35/D who had pre-existing UK-39 cross-reactive antibodies had high-
affinity anti-UK-39 IgG already after the first immunization. 
 
Sporozoite cross-reactivity of anti-UK-39 IgG responses 
After three immunizations all volunteers (14/14) immunized with 10µg UK-39 or 50µg 
UK-39 combined with 50µg AMA49-CPE and 5 of 7 volunteers immunized with 50µg 
UK-39 alone had developed IgG responses that were cross-reactive (endpoint titers 
≥102) with P. falciparum sporozoites in IFA and in Western blotting (Figure 3). Mean 
IFA and Western blotting endpoint titers increased with each of the three 
immunizations. One year after the third immunization 10 out of 11 volunteers in the 
10µg UK-39 and the combination group were still positive (endpoint titers ≥102). 
IRIVs alone (group F) did not elicit parasite cross-reactive IgG; volunteer 12/F that 
had exhibited a persistent anti-UK-39 ELISA titer already present before the first 
vaccination also had an IFA and Western blotting titer.  
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Statistical analysis of ELISA, IFA and Western blotting titers revealed a close 
correlation between all assays (Table 1). For the three vaccination groups r-values 
were >0.819 (P<0.0001) for the comparison of titers in ELISA and IFA, >0.561 
(P=0.0019) for the comparison of titers in ELISA and Western blot, and >0.550 
(P=0.0024) for the comparison of titers in IFA and Western blot. 
Volunteer 35/D, who had a pre-immune ELISA titer that strongly increased by just 
one immunization, also developed very high IFA and Western blotting titers (105) 
after the first immunization (Figure 4A). While this volunteer had a pre-existing 
Western blotting (Figure 4B) and ELISA titer of 103, no IFA staining was observed 
with the pre-immune serum (Figure 4C).  
 
Sporozoite inhibitory activity 
Anti-sporozoite antibodies can interfere with critical steps of sporozoite development 
like migration through tissue [20, 21] and invasion of hepatocytes [22]. To test the 
impact of anti-UK-39 antibodies on sporozoite infectivity we used two different in vitro 
assays measuring sporozoite migration through hepatocytes (HepG2 cell line) and 
sporozoite invasion of hepatocytes in the presence of purified IgG from immunized 
volunteers. 
Migration inhibition experiments were performed as described by Mota et al. [20]. 
Sporozoites were incubated with HepG2 cells in the presence of cell-impermeant 
FITC-dextran. Wounded cells take up FITC-dextran, which is trapped in the cell 
cytoplasm after wound resealing and can be detected by FACS analysis. Total IgG 
from nine volunteers from all immunization groups representing the whole range of 
observed immune responses (including controls) were purified. The presence of 
purified total IgG (final concentration 1mg/ml) from UK-39-immunized volunteers 
reduced sporozoite migration in a dose dependent manner. Vaccination-induced 
increases in migration inhibitory activity were observed in all UK-39-immunized 
volunteers (with the exception of volunteer 46/E) (Figure 5A). Dose of UK-39 and 
combination with AMA49-CPE had no influence on the inhibitory potential of the 
elicited antibodies. IgG preparations from control individuals, immunized with 
AMA49-CPE or IRIVs alone showed no vaccine-induced inhibition of sporozoite 
migration (data not shown). 
The impact of antibodies on sporozoite invasion can be determined in invasion 
inhibition assays where the development of liver stage parasites after incubation of 
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primary human hepatocyte cultures with P. falciparum sporozoites is quantified. 
Vaccine-induced inhibition of sporozoite invasion was seen with purified IgG (final 
concentration 1mg/ml) from all volunteers immunized with UK-39 (with the exception 
of volunteer 46/E) irrespective of dose and formulation of the vaccine (Figure 5B). 
IgG preparations from controls immunized with AMA49-CPE or IRIVs did not inhibit 
sporozoite invasion (data not shown). Boosting of a pre-existing UK-39 cross-reactive 
antibody response in volunteer 35/D (Figure 4) induced IgG with high migration and 
invasion inhibitory potential showing no difference to IgG preparations of other UK-
39-immunized volunteers (Figure 5A and B). 
We found a strong correlation (r = 0.8648, P<0.0001) between inhibition of invasion 
and inhibition of migration by IgG preparations (Figure 6). To determine a relation 
between this functional activity and the immunogenicity results we also compared 
IgG titers measured in ELISA, IFA and Western blotting with inhibition results. IgG 
titers measured in all three immunogenicity assays closely correlated with the 
migration and invasion inhibitory activity of the antibodies (data not shown for 
invasion inhibition) (Figure 6). 
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Discussion 
In this report we describe immunological and functional properties of antibodies 
elicited by the virosomally formulated synthetic peptide UK-39 in a phase I clinical 
trial. Since virosomally formulated UK-39 molecules represent repeat structures on 
the surface of IRIVs, they have the potential to amplify the antigen-specific B cell pool 
enormously, allowing a very early and efficient switch to a long-lived IgG response 
(Bachmann and Zinkernagel 1997; Huckriede et al. 2003). Two immunizations with 
10µg UK-39 were indeed enough to induce high titers of peptide-specific IgG in all 
volunteers (Genton et al. submitted). A higher dose of 50µg peptide delivered with 
the same amount of IRIVs was not superior in terms of sero-conversion and mean 
antibody titers elicited. However, when co-administered with a second virosomal 
vaccine component, the 50µg dose of UK-39 was as immunogenic as the 10µg dose 
alone. This may be related to the doubling of the amount of influenza antigens 
administered with the combination vaccine and the adjuvant-effect associated with 
the viral components. One volunteer (35/D) of the 50µg UK-39 group needs special 
attention. Pre-immune serum of this volunteer already contained antibodies that were 
reactive with UK-39 in ELISA and with CSP in Western blotting. This cross-reactivity, 
which was not related to a known history of malaria exposure, was exceptionally 
boosted already by the first immunization, yielding the highest titers observed in the 
entire trial. Even though the observed pre-existing humoral response was not 
malaria-related, this suggests that IRIV-based vaccines have the potential to boost 
natural immunity. It is therefore highly likely, that two or even one vaccine dose may 
be sufficient to boost pre-existing immunity in vaccine recipients from endemic areas. 
We found a close correlation between IgG titers against the peptide UK-39 in ELISA 
and IgG titers in IFA and Western blotting with whole parasites and parasite-derived 
antigens, respectively. Moreover titers in these immunogenicity assays were closely 
correlating with in vitro inhibition of sporozoite migration and invasion of hepatocytes. 
This confirms the observation that the conformationally restrained peptide UK-39 is 
very close to the natural conformation of the NANP repeats, as already indicated by 
NMR analysis of UK-39 and the crystal structure of an NPNA repeat [23] (Okitsu et 
al. submitted).  
Vaccine induced immunity has to include formation of immunological memory, the 
key to successful immune protection [24]. One crucial step of memory formation is 
antibody affinity maturation in germinal centers where high-affinity variants of 
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antigen-specific B cells are selected for entry into the long-lived memory B cell 
compartment [25]. We found an increase in anti-UK-39 antibody avidity over the 
course of immunization in all three vaccine groups indicating memory B cell 
formation. Due to particularly high avidity indices in two individuals (35/D and 36/D), 
the mean avidity was highest in group D receiving 50µg of UK-39. One year after the 
third immunization all volunteers receiving the 10µg dose of UK-39 had remained 
positive in ELISA, Western blotting analysis and IFA supporting the hypothesis that 
vaccination with virosomally formulated UK-39 has induced long-term IgG production 
by memory B cells. 
One of the major problems associated with malaria vaccine development are missing 
in vitro and in vivo correlates of protection. Various in vitro assays and experimental 
animal models are available to test functional activity of induced responses, but the 
predictive value of these systems cannot be determined until the results are 
correlated with clinical efficacy of vaccine candidates [26]. No in-depth study 
comparing in vitro results, animal studies, artificial human challenge and vaccine 
efficacy in endemic areas has been reported to date.  
Induction of antibodies inhibiting in vitro sporozoite migration, growth, and 
development was observed in a majority of UK-39-immunized volunteers tested, 
regardless of vaccine formulation. Inhibition was IgG concentration-dependent and 
confirmed data obtained with animal sera (Okitsu et al. submitted). Inhibition of 
sporozoite migration and invasion was observed at concentrations of total purified 
IgG from immunized volunteers that were more than ten times lower than the 
physiological IgG concentration of about 13mg/ml. Even though this inhibition might 
only be partial and would not prevent the development of blood-stage infection, 
previous experience with sporozoite vaccines and insecticide treated bednets has 
shown that reduction of merozoites released from the liver can reduce the 
occurrence of severe forms of disease [5, 27]. It will be crucial to follow-up these 
inhibition results in phase 2a challenge trials and efficacy studies in field trials to 
validate these in vitro inhibition assays as correlates for protection.  
Invasion inhibition was positively correlated with migration inhibition, suggesting that 
anti-UK-39 antibodies interfered with parasite gliding motility, which is based on the 
same mechanism of redistribution of proteins along the sporozoite surface as host 
cell invasion [28]. Whether inhibition is due to a specific block of a component of the 
machinery necessary for gliding or by steric hindrance is difficult to elucidate. In vitro 
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sporozoite invasion inhibition with primary human hepatocytes is a very labor 
intensive and demanding test system. Based on the observed close correlation of 
results in invasion inhibition experiments and the far easier migration inhibition 
assays, the migration inhibition system might be a valuable second line method to 
measure the biological activity of anti-CSP antibodies. Further advantages of the 
migration inhibition assays are the reduced time needed, the option for quantitative 
analysis by flow cytometry and the possibility to perform the experiments with 
hepatocyte cell lines. Altogether, these properties make the migration inhibition assay 
an interesting tool for screening large numbers of serum samples in clinical trials. 
Taken together these results demonstrate the suitability of IRIVs as a carrier/adjuvant 
system for the induction of potent humoral immune responses against synthetic 
peptide antigens. The humoral immune responses characterized in this report were 
very uniform, cross-reactive with P. falciparum, affinity maturated, long-lived and 
parasite-inhibitory. Combination of two components had no negative effect on the 
elicited immune response against the single components, showing the potential of 
this universal antigen delivery platform for multivalent vaccine development. 
Chapter 6: Phase 1 Immunogenicity of a CSP-derived peptide 
 
 140 
Acknowledgements 
We thank D. Vogel, M. Tamborrini, G.J. van Gemert, J.F. Franetich, and L. Hannoun 
for their contribution to this study.  
Chapter 6: Phase 1 Immunogenicity of a CSP-derived peptide 
 
 141 
References 
 
1. Snow RW, Guerra CA, Noor AM, Myint HY and Hay SI. The global distribution of 
clinical episodes of Plasmodium falciparum malaria. Nature 2005;434:214-7 
2. Clyde DF, Most H, McCarthy VC and Vanderberg JP. Immunization of man against 
sporozite-induced falciparum malaria. Am J Med Sci 1973;266:169-77 
3. Targett GA. Malaria vaccines 1985-2005: a full circle? Trends Parasitol 
2005;21:499-503 
4. Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS,S/AS02A 
malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican 
children: single-blind extended follow-up of a randomised controlled trial. Lancet 
2005;366:2012-8 
5. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine 
against Plasmodium falciparum infection and disease in young African children: 
randomised controlled trial. Lancet 2004;364:1411 
6. Greenwood B. Malaria vaccines. Evaluation and implementation. Acta Trop 
2005;95:298-304 
7. Greenwood BM, Bojang K, Whitty CJ and Targett GA. Malaria. Lancet 
2005;365:1487-98 
8. Waters A. Malaria: new vaccines for old? Cell 2006;124:689-93 
9. Good MF. Vaccine-induced immunity to malaria parasites and the need for novel 
strategies. Trends Parasitol 2005;21:29-34 
10. Tongren JE, Zavala F, Roos DS and Riley EM. Malaria vaccines: if at first you 
don't succeed. Trends Parasitol. 2004;20:604 
11. Poltl-Frank F, Zurbriggen R, Helg A, et al. Use of reconstituted influenza virus 
virosomes as an immunopotentiating delivery system for a peptide-based vaccine. 
Clin.Exp.Immunol. 1999;117:496 
12. Moreno R, Jiang L, Moehle K, et al. Exploiting conformationally constrained 
peptidomimetics and an efficient human-compatible delivery system in synthetic 
vaccine design. Chembiochem. 2001;2:838 
13. Mueller MS, Renard A, Boato F, et al. Induction of parasite growth-inhibitory 
antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of 
Plasmodium falciparum apical membrane antigen 1. Infect.Immun. 2003;71:4749 
Chapter 6: Phase 1 Immunogenicity of a CSP-derived peptide 
 
 142 
14. Pfeiffer B, Peduzzi E, Moehle K, et al. A Virosome-Mimotope Approach to 
Synthetic Vaccine Design and Optimization: Synthesis, Conformation, and Immune 
Recognition of a Potential Malaria-Vaccine Candidate. Angew.Chem.Int.Ed Engl. 
2003;42:2368 
15. Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine 
2003;21:921 
16. Bisang C, Jiang L, Freund E, et al. Synthesis, Conformational Properties, and 
Immunogenicity of a Cyclic Template-Bound Peptide Mimetic Containing an NPNA 
Motif from the Circumsporozoite Protein of Plasmodium falciparum. J. Am. Chem. 
Soc. 1998;120:7439-7449 
17. James S, Moehle K, Renard A, et al. Synthesis, solution structure and immune 
recognition of an epidermal growth factor-like domain from Plasmodiun falciparum 
merozoite surface protein-1. ChemBioChem 2006;In press 
18. Ferreira MU, Katzin AM. The assessment of antibody affinity distribution by 
thiocyanate elution: a simple dose-response approach. J.Immunol.Methods 
1995;187:297 
19. Silvie O, Rubinstein E, Franetich JF, et al. Hepatocyte CD81 is required for 
Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat.Med. 
2003;9:93 
20. Mota MM, Pradel G, Vanderberg JP, et al. Migration of Plasmodium Sporozoites 
Through Cells Before Infection. Science 2001;291:141 
21. Vanderberg JP, Frevert U. Intravital microscopy demonstrating antibody-
mediated immobilisation of Plasmodium berghei sporozoites injected into skin by 
mosquitoes. Int.J.Parasitol. 2004;34:991 
22. Mazier D, Mellouk S, Beaudoin RL, et al. Effect of antibodies to recombinant and 
synthetic peptides on P. falciparum sporozoites in vitro. Science 1986;231:156-9 
23. Ghasparian A, Moehle K, Linden A and Robinson JA. Crystal structure of an 
NPNA-repeat motif from the circumsporozoite protein of the malaria parasite 
Plasmodium falciparum. Chem Commun (Camb) 2006:174-6 
24. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: 
implications for vaccine development. Cell 2006;124:849-63 
25. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell 
development. Annual Review of Immunology 2005;23:487-513 
Chapter 6: Phase 1 Immunogenicity of a CSP-derived peptide 
 
 143 
26. Moorthy VS, Dubovsky F. Progress in development of a vaccine to aid malaria 
control. Washington, D.C.: ASM Press, 2005 (Sherman IW, ed. Molecular 
approaches to malaria) 
27. Nevill CG, Some ES, Mung'ala VO, et al. Insecticide-treated bednets reduce 
mortality and severe morbidity from malaria among children on the Kenyan coast. 
Trop Med Int Health 1996;1:139-46 
28. Kappe SH, Buscaglia CA, Bergman LW, Coppens I and Nussenzweig V. 
Apicomplexan gliding motility and host cell invasion: overhauling the motor model. 
Trends Parasitol. 2004;20:13 
 
 
 
 
Chapter 6: Phase 1 Immunogenicity of a CSP-derived peptide 
 
 144 
Figure legends 
Figure 1. ELISA endpoint titers. Shown are anti-UK-39 IgG ELISA endpoint titers for 
individual volunteers at baseline (0), 21 days after each vaccination and one year 
after the third vaccination. Arrows indicate days of immunization. Only the groups 
immunized with 10µg UK-39 or 50µg UK-39+50µg AMA49-CPE were followed up for 
one year. 
 
Figure 2. Avidity indices. Mean avidity indices for the anti-UK-39 IgG responses in all 
vaccination groups receiving UK-39 three weeks after the first, second and third 
immunization. The avidity index is the NH4SCN concentration (M) where 50% of the 
bound antibodies are eluted. Shown are results obtained with individual sera and the 
geometric mean (line) for each time point. Wilcoxon t-test was used to calculate the 
statistical significance of the avidity increase after the third immunization compared to 
the first vaccination. 
 
Figure 3. IFA and Western blotting endpoint titers. IFA (left panel) and Western 
blotting (right panel) endpoint titers and number of volunteers showing an increase in 
titer compared to pre-immune (pI) serum. Blood samples were taken pre-immune, 
three weeks after the first, second and third immunization and one year after the third 
immunization. Lines represent geometric means of all volunteers in the respective 
group. Arrows indicate volunteer 35/D that had a pre-existing anti-UK39 IgG ELISA 
titer of 103. Only the groups immunized with 10µg UK-39 or 50µg UK-39+50µg 
AMA49-CPE were followed up for one year. 
 
Figure 4. Boost of a pre-existing anti-UK-39 cross-reactive antibody response in 
volunteer 35/D. A: Comparison of ELISA, IFA and Western blot titers of pre-immune 
serum and sera taken three weeks after each immunization. B: Western blotting 
results obtained with serum taken before and three weeks after the first 
immunization. Dilutions are: 1, 1:200; 2, 1:400; 3, 1:800; 4, 1:3,000; 5, 1:9,000; 6, 
1:27,000; 7, 1:81,000; 8, 1:243,000; 9, 1:729,000; 10, 1:2,187,000; 11, 1:6,561,000; 
12, Positive control anti-NANP mAb EP9. C: IFA on P. falciparum sporozoites with 
serum taken before and three weeks after the first immunization. An overlay of DNA 
staining with Hoechst dye no. 33256 (blue) and Cy3-immunofluorescence staining 
(red) is shown. 
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Fig 5. Functional activity of anti-UK39 IgG responses. Sporozoite migration and 
invasion inhibition by IgG preparations (final concentration 1mg/ml) purified from sera 
taken before the first (pI) and three weeks after the third immunization (3.imm). Three 
volunteers (xy/B) immunized with 10µg UK-39, one volunteer (35/D) immunized with 
50µg UK-39, and three volunteers (xy/E) immunized with 50µg UK-39+50µg AMA49-
CPE were chosen. Shown are the means and SDs from at least two independent 
experiments. A: In vitro inhibition of sporozoite migration through human HepG2 
cells. B: In vitro Inhibition of sporozoite invasion of primary human hepatocytes. 
 
Figure 6. Correlation (r) of functional activity with antibody titers. Sera taken before 
the first and 21 days after the third immunization from nine volunteers analyzed in 
inhibition assays were included in the analysis. Correlation coefficients were 
calculated with a Pearson test (Gaussian distribution) for correlation of invasion and 
migration inhibition; nonparametric (Spearman) correlation was used for analysis with 
immunogenicity assays. 
 
Table 1. Correlation (Spearman r) of IgG endpoint titers in immunogenicity assays. 
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Figure 1 
 
 
Chapter 6: Phase 1 Immunogenicity of a CSP-derived peptide 
 
 147 
Figure 2 
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Figure 3 
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Figure 4 
 
Chapter 6: Phase 1 Immunogenicity of a CSP-derived peptide 
 
 150 
Figure 5 
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Figure 6 
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Table 1. Correlation (Spearman r) of IgG endpoint titers in immunogenicity assays. 
Comparison 10µg UK-39 50µg UK-39 50µg combination 
ELISA-IFA 0.9233 (P<0.0001) 0.8192 (P<0.0001) 0.8401 (P<0.0001) 
ELISA-Western blot 0.8563 (P<0.0001) 0.5609 (P=0.0019) 0.7505 (P<0.0001) 
IFA-Western blot 0.7928 (P<0.0001) 0.5499 (P=0.0024) 0.6691 (P<0.0001) 
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Abstract 
Plasmodium falciparum apical membrane antigen 1 (AMA-1) is one of the leading 
blood stage candidate antigens for inclusion in a malaria subunit vaccine. The 83kDa 
protein consists of three domains. Loop 1 of domain III binds to the erythrocyte 
protein Kx, underlining an important role of AMA-1 during invasion of host cells. We 
have previously described the development and characterization of a virosomally 
formulated synthetic peptide vaccine component (designated PEV301) which is 
based on the sequence of loop 1. Monoclonal antibodies against this peptide 
inhibited parasite growth in vitro. PEV301 was safe and immunogenic in a phase 1 
clinical trial in malaria-naïve adult volunteers. Two vaccinations were sufficient to 
induce high titers of peptide-specific IgG in all volunteers immunized with 50µg of 
virosomally formulated AMA-1 peptide-phospholipid conjugate. Co-administration 
with a second peptide-based vaccine component did not interfere with the 
development of an AMA-1 peptide specific response. In this report cross-reactivity of 
the IgG response elicited by PEV301 with parasite derived AMA-1 is described. After 
the third immunization half of the volunteers were positiv for P. falciparum blood 
stage parasite-expressed AMA-1 in IFA and/or Western blotting analysis. With one 
exception, all peptide induced IgG responses increased in affinity over the course of 
the immunizations and AMA-1 peptide-reactive IgG was still detectable one year after 
the third immunization, indicating formation of long-lived memory B cells. Taken 
together results demonstrate, that the virosome-based universal antigen delivery 
platform is suitable to elicit long-lived and parasite cross-reactive IgG responses 
against suitable synthetic peptide-phospholipid conjugates anchored on the surface 
of the virosomes. 
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Introduction 
With more than 2 million deaths per year (23) malaria remains one of the most 
threatening human diseases. Current methods of control include the use of 
antimalarial drugs to treat the disease, as well as preventive tools like insecticide 
treated bednets (ITN), indoor spraying with residual insecticides (IRS), and 
environmental changes. As emerging resistance of parasites against drugs and 
mosquitoes against insecticides pose a problem to these control measures, vaccine 
development is as urgent as never before. A lot of progress has been done in the 
development of a malaria vaccine and RTS,S/AS02A was the first malaria vaccine to 
show efficacy against severe disease in an endemic area (1). Despite this success a 
cheap and effective vaccine might still be years away and faces many problems like 
production of recombinant material and missing human compatible adjuvant and 
delivery systems (15). 
We try to circumvent these problems by delivering easy to synthesize peptides 
corresponding to sequence stretches of P. falciparum antigens on the surface of 
immunopotentiating reconstituted influenza virosomes (IRIVs). IRIVs are a liposomal 
carrier system characterized as spherical, unilaminar vesicles with a mean diameter 
of approximately 150 nm. They consist of coat proteins of H1N1 influenza virus 
(A/Singapore/6/86) and phospholipids. Like fusion-inducing viruses, virosomes enter 
cells by receptor-mediated endocytosis and subsequently fuse with the endosomal 
membrane. The strong immune response induced by antigens presented on the 
surface of virosomes is predominantly humoral, whereas a supplementary T-helper 
immune response is evoked by virosomal influenza-derived glycoproteins. Antigens 
encapsulated in the virosome are delivered to the host cell cytosol and enter the 
MHC I pathway, inducing cytotoxic T cell responses. Two virosome-based vaccines 
are registered for human use in more than 38 countries, and have been administered 
to more than 20 million individuals (24). 
One of the leading candidate antigens for inclusion in a malaria vaccine is apical 
membrane antigen 1 (AMA-1), a blood-stage protein of P. falciparum. This 83kDa 
protein is synthesized in mature stages of the parasite and is first localized in the 
neck of the rhoptries (5, 20). It is rapidly processed after synthesis giving rise to a 83- 
and a 66-kDa fragment initially localized at the merozoite apex. While the full-length 
83-kDa molecule remains in the apical region following merozoite release, the 
processed 66-kDa form spreads around the merozoite surface (19, 20). Several 
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passive and active immunization studies have indicated that AMA-1 is involved in 
eliciting protective immune responses (2-7, 12, 18, 25) and serves as a target for 
invasion-blocking antibodies (6, 7, 9, 12, 13). The ectodomain of AMA-1 is divided 
into three subdomains, each with disulfide bond-stabilized structures. Domain III of 
AMA-1 binds to the erythrocyte membrane protein, Kx, and the invasion rate of Kxnull 
erythrocytes is reduced, indicating a significant role of AMA-1 and Kx in parasite 
invasion of erythrocytes (11). We have developed a synthetic peptide designated 
AMA49-CPE, which is mimicking the semi-conserved loop I of domain III (residues 
446 to 490) and elicits parasite growth-inhibitory antibodies in mice. A virosomal 
formulation of this peptide was tested in a phase I clinical trial in combination with a 
peptide derived from P. falciparum circumsporozoite protein (CSP) and proved to be 
safe and immunogenic in malaria naïve Caucasians (Genton et al. submitted). Here 
we describe the individual anti-peptide IgG responses and compare anti-peptide IgG 
responses with the generation of parasite cross-reactive antibodies. 
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Results 
Development of IgG responses against the synthetic antigen AMA49-CPE 
One immunization with 50µg of virosomally formulated AMA49-CPE alone (group C) 
or in combination with 50µg UK-39 (group E) was enough to induce anti-AMA49-CPE 
IgG titers above 250 in all volunteers (Figure 1). A second immunization with the 
same vaccine formulations increased the titers to more than 10,000 with the 
exception of one volunteer (37/E) who had a titer of 4525. A third immunization did 
not lead to a further titer increase in most of the volunteers. Combined delivery of 
AMA49-CPE together with UK-39 did not interfere with the development of anti-
AMA49-CPE antibody responses. One year after the third immunization 12 out of 13 
volunteers immunized with the 50µg dose still had anti-AMA49-CPE IgG titers above 
800. No volunteer of the control group (group F) receiving IRIVs alone developed an 
anti-AMA49-CPE IgG response. One volunteer in this group (34/F) had a pre-existing 
anti-AMA49-CPE IgG titer of 200, which decreased over the course of the 
immunizations. 
In volunteers receiving 10µg of virosomally formulated AMA49-CPE (group A), 
humoral immune responses were weaker. Only 3/8 volunteers had developed anti-
AMA49-CPE IgG titers after one immunization (Figure 1) and  100% sero-conversion 
in ELISA was only observed after the third immunization with a relatively low mean 
anti-peptide titer of 582. 
An AMA49-CPE-specific IgM titer of ~1000 was found after the first immunization in 
the two groups receiving 50µg AMA49-CPE (Figure 2). An increase in titer to 10,000 
after the second immunization was only observed in the combination group. Virtually 
no antiAMA49-CPE IgM was found in the 10µg AMA49-CPE group (max geomean 
titer ~65). No peptide-specific IgM was found in controls immunized with IRIVs. 
The mean avidity index, a measure for antibody affinity maturation, increased with 
one exception in all individuals of group C and E, receiving the 50µg AMA49-CPE 
dose (Figure 3). A three-fold increase was observed in the group receiving AMA49-
CPE alone after two immunizations, whereas a more gradual two-fold increase over 
all three immunizations was observed after combined immunization with AMA49-CPE 
and UK-39. Avidity indices were not assessed for group 1 immunized with 10µg 
virosomally formulated AMA49-CPE. 
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Cross-reactivity of anti-AMA49-CPE IgG responses with P. falciparum blood-
stage parasites 
None of the volunteers immunized with empty IRIVs or with 10µg AMA49-CPE 
developed a sufficiently high titer of AMA-1 cross-reactive IgG to be detectable in IFA 
or Western blotting analysis. In contrast, 50% (8/16) of volunteers receiving 50µg 
AMA49-CPE alone or in combination with UK-39 sero-converted in IFA and/or 
Western blotting analysis (Table 1) in spite of a considerable background staining 
observed with many of the pre-immune sera. 
In Western blotting analysis with complete P. falciparum blood stage parasite lysate, 
most of the pre-immune sera yielded some background staining, which was highly 
variable both with respect to intensity and the molecular mass of the stained proteins 
(Figure 4). Nevertheless, development of IgG, reactive with the characteristic AMA-1 
66/83kDa double bands (Figure 4), was clearly detectable with immune sera from 
8/16 volunteers receiving 50µg AMA49-CPE. While none of the volunteers had sero-
converted after the first immunization, 7/8 Western blotting sero-converters were 
already positive after the second immunization (Table 1).  One year after the third 
immunization 2/13 volunteers still had an anti-AMA-1 Western blotting IgG titer of 
100.  
As expected from the Western blotting results, many of the pre-immune sera yielded 
variable background staining in IFA with P. falciparum blood stage parasites (Figure 
5). It is likely, that this often compromised detectability of a potential vaccine-induced 
AMA-1 cross-reactive IgG response. Nevertheless, development of a punctuate 
staining pattern characteristic for AMA-1 (Figure 5) was observed with immune sera 
from 5/15 volunteers receiving 50µg AMA49-CPE (endpoint titer ≥1000 after the third 
immunization). Parasite cross-reactive responses were first detected after the second 
immunization and both titers and the proportion of identified responders increased 
after the third immunization (Table 1). One year after the third immunization only one 
of the volunteers still had a titer of parasite cross-reactive IgG that was above the 
detection threshold of 100.  
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Discussion 
The difficulties of producing a vaccine with attenuated sporozoites and problems with 
recombinant expression of full-length parasite proteins make the subunit approach 
very interesting for the development of a malaria vaccine. We have shown before the 
development of synthetic peptides for inclusion in a multivalent virosomal subunit 
vaccine (10, 16, 17, 21, 22) (Okitsu et al. submitted). Two peptides derived from CSP 
and AMA-1 respectively were safe and immunogenic in a phase 1 clinical trial 
(Genton et al. submitted). This report presents a detailed immunological analysis of 
the humoral response in this phase 1 trial. We found that immunization with 50µg of 
virosomally formulated AMA49-CPE induced high anti-peptide titers in all volunteers 
already after one immunization. After the second immunization the induced titers 
were very homogeneous, highlighting the potential of IRIVs as a powerful delivery 
and adjuvant system for synthetic peptides. In group A receiving 10µg AMA49-CPE 
both sero-conversion rates and titers were low. Also in rabbit immunization studies 
the 50µg dose of AMA49-CPE was superior to the 10µg dose (manuscript in 
preparation).  
Measurement of IgG cross-reactivity in IFA with blood-stage parasites was difficult, 
due to high background staining already observed with pre-immune sera. Individual-
specific cross-reactivity with a range of protein bands was also found Western 
blotting analysis. In particular in IFA negative results may be the result of a masking 
of an AMA-1 specific staining by high background reactivity. Western blot staining 
patterns were easier to evaluate with respect to AMA-1 reactivity and confirmed the 
presence of a pre-existing anti-parasite response not related to vaccination. 
Taken together we have shown that it is possible to induce parasite-binding 
antibodies in malaria-naïve volunteers by immunization with an optimized peptide of 
AMA-1 in a virosomal formulation. The good immunogenicity, the possibility to 
combine various antigens, and the excellent safety profile make the IRIV approach 
highly suitable for the development of a multivalent malaria subunit vaccine. 
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10µg AMA49-
CPE IFA Western blotting 
 titer sero-conv titer sero-conv 
pI - 0/0 - 0/0 
1. Imm - 0/0 - 0/0 
2. Imm - 0/0 - 0/0 
3. Imm - 0/0 - 0/0 
1y after 3. Imm nd nd nd nd 
     
     
50µg AMA49-
CPE IFA Western blotting 
 titer sero-conv titer sero-conv 
pI - 0/0 - 0/0 
1. Imm - 0/0 - 0/0 
2. Imm 1000 1/8 8409 4/8 
3. Imm 1710 3/8 7071 4/8 
1y after 3. Imm - 0/0 25 2/8 
     
     
50µg combi IFA Western blotting 
 titer sero-conv titer sero-conv 
pI - 0/0 - 0/0 
1. Imm - 0/0 - 0/0 
2. Imm 707 2/7 4642 3/8 
3. Imm 1000 2/7 8409 4/8 
1y after 3. Imm 100 1/7 - 0/8 
     
     
IRIV IFA Western blotting 
 titer sero-conv titer sero-conv 
pI - 0/0 - 0/0 
1. Imm - 0/0 - 0/0 
2. Imm - 0/0 - 0/0 
3. Imm - 0/0 - 0/0 
1y after 3. Imm nd nd nd nd 
 
Table 1. Parasite cross-reactivity of anti-AMA49-CPE IgG responses.  Shown are 
geometric mean IgG titers of responders and rates of sero-conversion for IFA and 
Western blotting with sera from immunized volunteers taken pre-immune, three 
weeks after every immunization and one year after the third immunization.  
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Figure 1. Development of anti-AMA49-CPE IgG responses. Shown are anti-AMA49-
CPE IgG ELISA endpoint titers for individual volunteers at baseline (0), 21 days after 
each vaccination and one year after the third vaccination. Arrows indicate days of 
immunization. One year samples were only taken for groups immunized with 50µg 
AMA49-CPE. 
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Figure 2. Development of anti-AMA49-CPE IgM responses. Shown are anti-AMA49-
CPE IgM ELISA endpoint titers for individual volunteers at baseline (0), and 21 days 
after each vaccination. Arrows indicate days of immunization. 
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Figure 3. Affinity maturation of anti-AMA49-CPE IgG. Mean avidity indices for the 
anti-AMA49-CPE IgG responses in the 50µg AMA49-CPE (C), and the 50µg AMA49-
CPE+50µg UK-39 (E) groups three weeks after the first, second and third 
immunization. Shown are results obtained with individual sera and the geometric 
mean (line) for each time point. Wilcoxon t-test was used to calculate the statistical 
significance of the avidity increase after the third immunization compared to the first 
vaccination. 
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Figure 4. Development of AMA-1 cross-reactive IgG in Western blotting analysis with 
total lysate from P. falciparum schizonts. Serum samples taken pre-immune (pI) and 
three weeks after the second immunization (2) from volunteers immunized with either 
50µg of AMA49-CPE (group C), 50µg AMA49-CPE plus 50µg UK-39 (group E), or 
IRIVs alone (group F; negative control) were tested at a dilution of 1:100 (pI sera) or 
1:100, 1:500, 1:2500 and 1:5000 (2 sera), respectively. Full-length AMA-1 (83kDa) 
and its 66kDa processing fragment are indicated by arrows. AMA-1 fragments were 
identified by staining with an anti-AMA-1 monoclonal antibody (lane +). 
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Figure 5. Development of AMA-1 cross-reactive IgG in IFA with P. falciparum 
schizonts. Serum samples were taken from human volunteers immunized with 50µg 
AMA49-CPE (27/C and 30/C) or 50µg AMA49-CPE plus 50µg UK-39 (46/E) pre-
immune (pI), three weeks after the second (2. imm) or three weeks after the third 
immunization (3. imm). Sera were diluted 1:1000 (pre-immune and after the second 
immunization) or 1:2000 (after the third immunization). The upper panel shows DNA 
staining with Hoechst dye no. 33256 (blue), the lower panel Cy3-
immunofluorescence staining (red). Representative examples demonstrating the 
variation in background staining by pre-immune sera are shown. 
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Materials and Methods 
 
Overall Study Design and Plan 
This prospective phase I, single blind, randomized, placebo controlled, dose-
escalating study was conducted in 46 healthy adult volunteers. Eligible study 
participants were randomized into six groups: PEV 301 (virosomally formulated 
AMA49-CPE) 10 µg (group A, n = 8), PEV 302 (virosomally formulated UK-39) 10 µg 
(group B, n = 8), PEV 301 50 µg (group C, n = 8), PEV 302 50 µg (group D, n = 8), 
PEV 301 50 µg + PEV 302 50 µg (group E, n = 8) or unmodified virosomes serving 
as controls (group F, IRIV, n = 6). Vaccine formulations contained different amounts 
of PE-peptide conjugate, but throughout the same amounts of IRIV per dose. 
Volunteers immunized with a combination of virosomally-formulated AMA49-CPE 
and UK-39 received a double dose of IRIVs.  
 
Vaccine 
Two virosome-formulated vaccines, PEV 301 (incorporating the AMA-1 derived PE-
peptide conjugate AMA49-CPE) and PEV 302 (incorporating the CSP derived PE-
peptide conjugate UK-39) were produced according to the rules of GMP. Tests for 
sterility, pyrogenicity, immunogenicity in animals, stability and chemical composition 
were performed on the vaccine lots used in this trial. Each dose was composed of 10 
or 50 µg AMA49-CPE or UK-39, 10 µg Influenza hemagglutinin, 100 µg 
phospholipids and PBS ad 0.500 ml. The trial vaccines were administered i.m. in the 
left arm on day 0, in the right one on day 56-65, and in the left again on day 175-186. 
 
Ethics  
The protocol was approved by the Ethikkommission beider Basel (EKBB) and the 
study conducted in full compliance with the international ethical guidelines for 
biomedical research involving human subjects. 
 
Immunogenicity 
Blood sampling for antibody titer measurement by ELISA, IFA and Western blot was 
done at screening visit (baseline and 1st vaccination), at the days of the 2nd and 3rd 
vaccination, 21 days after each vaccination and one year after the third vaccination 
(groups B, C and E only). 
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ELISA  
ELISA PolysorpTM microtiter plates (Nunc, Dr. Grogg, Stetten-Deiswill, Switzerland) 
were coated at 4°C overnight with 10 µg/ml AMA49-CPE in PBS, pH 7.2. Wells were 
then blocked with 5% milk powder in PBS for 2 h at 37°C followed by three washings 
with PBS containing 0.05% Tween-20. Plates were then incubated with two-fold 
serial dilutions of human serum starting with 1:50 in PBS containing 0.05% Tween-20 
and 0.5% milk powder for 2 h at 37°C. After washing, the plates were incubated with 
horseradish-peroxidase-conjugated goat anti-human IgG antibodies (KPL, Socochim, 
Lausanne Switzerland) (1:2000 in PBS containing 0.05% Tween-20) for 1 h at 37°C 
and then washed. 1,2-Diaminobezene substrate (OPD) (20 mg/tablet (Fluka, Sigma. 
Buchs, Switzerland)) in citrat-buffer (4 mg/ml OPD) + 0.01% H2O2 was added and 
incubated at room temperature. After 10 minutes the reaction was stopped by 
addition of sulphuric acid (final concentration 0.5M (Merck, Darmstadt, Germany). 
The optical density (OD) of the reaction product was measured at 492 nm using a 
microplate reader (SpectraMax plus, Bucher Biotech, Basel, Switzerland). Titration 
curves were registered using Softmax PRO software. 
Antibody titer measurement by ELISA against AMA49-CPE was done at screening 
visit (baseline), 7 (±2) days and 21 (±5) days after first, second and third vaccination. 
An additional sample was taken one year after the third immunization for the 10µg 
UK-39, the 50µgAMA49-CPE, and the 50µg AMA49-CPE+UK-39 groups. Endpoint 
titers were calculated by comparing the ELISA OD of the test serum with the ELISA 
OD of a negative serum pool. The endpoint titer is the last serum dilution where the 
ODtest sera ≥ 2 x ODnegativ serum. 
 
NH4SCN elution ELISA 
Avidity ELISA analyses with peptide-PE conjugates were performed essentially as 
described before (8). Briefly, PolysorpTM plates (Nunc, Fisher Scientific, Wohlen, 
Switzerland) were coated overnight at RT with 50 µl of a 10µg/ml solution of AMA49-
CPE in PBS (pH 7.2). After three washings with PBS containing 0.05% Tween-20 
wells were blocked with 5% milk powder in PBS for 30 min at RT and washed two 
times. Serum samples were added in triplicates at constant dilutions (approx. 
halfmax titer) in PBS containing 0.05% Tween-20 and 0.5% milk powder for 2 h at 
RT. After antibody incubation and an additional wash step, NH4SCN (Sigma, St. 
Louis, MO) diluted in 0.1M NaH2PO4 buffer (pH 6) was incubated for 15 min at room 
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temperature (100 µl/well) at the following molarities: 5 M, 4 M, 3 M, 2 M, 1 M, 0.5 M, 
0.25 M. Control wells were incubated with 0.1M NaH2PO4 buffer without NH4SCN. 
After a standard washing procedure with PBS-Tween-20, plates were incubated with 
alkaline phosphatase-conjugated affinity-pure F(ab´)2 fragment goat anti-human IgG 
(Fc-specific) antibodies (Jackson Immuno Research Laboratories, West Grove, Pa.) 
for 1 h at RT. After washing, phosphatase substrate solution (1 mg/ml p-nitrophenyl 
phosphate (Sigma, St. Louis, Mo) in a pH 9.8 buffer solution containing 10% [vol/vol] 
diethanolamine and 0.02% MgCl2) was added and the plates were incubated in the 
dark at RT until the colorimetric reaction had progressed sufficiently. The optical 
density was measured at 405 nm on a Titertek Multiscan MCC/340 reader 
(Labsystems, Helsinki, Finland). 
 
Indirect immunofluorescence assay (IFA) 
Erythrocytes from in vitro cultures (14) of P. falciparum strain K1 with a parasitemia 
between 5 and 10% were washed twice in RPMI and resuspended in RPMI and 2 
volumes of a solution containing 4% formaldehyde and 0.1% Triton X-100. From this 
cell suspension, 30 µl were added to each well of a multiwell diagnostic microscope 
slide (Erie Scientific Company, Portsmouth, NH), incubated at room temperature for 
30 min, and washed five times with PBS. Slides were then incubated for 15 min at 
room temperature with 25 µl blocking solution containing 1% fatty acid-free bovine 
serum albumin (BSA) in PBS. Immunostaining was performed by incubating the wells 
with 25 µl of an appropriate serum dilution in blocking solution in a humid chamber 
for 1 h at room temperature. After five washes with blocking solution 25 µl of 5 µg/ml 
CyTM3-conjugated affinity-pure F(ab´)2 fragment goat anti-human IgG (Fc-specific) 
antibodies (Jackson Immuno Research Laboratories, West Grove, Pa.) diluted in 
blocking solution containing 0.01 mg/ml Hoechst dye no. 33256 (Sigma, St. Louis, 
Mo) were added to the wells and incubated for 1 h at room temperature. Finally, wells 
were washed five times with PBS, mounted with mounting solution (90% [vol/vol] 
glycerol containing 0.1 M Tris-Cl, pH 8.0 and 2 mg/ml o-phenylenediamine) and 
covered with a coverslip. Antibody binding and DNA staining were assessed by 
fluorescence microscopy on a Leitz Dialux 20 fluorescence microscope and 
documented with a Leica DC200 digital camera system. 
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SDS-PAGE and immunoblotting 
Blood stage parasite lysates were prepared essentially as described previously (14) 
by saponin lysis of P. falciparum K1-infected erythrocytes. In brief, cultured parasites 
were washed once with PBS. Pelleted infected red blood cells were lysed by mixing 
with a large volume (adjusted to 5% hematocrit) of 0.015% (wt/vol) saponin in 150 
mM NaCl and 15 mM sodium citrate (pH 7.0) and incubated on ice for 20 min. 
Finally, the pelleted parasites were resuspended in 3 volumes of PBS and stored at -
80°C until further use. A total of 50 µl of parasite lysate was solubilized in an equal 
volume of 2x loading buffer (1.7 ml of 0.5 M Tris-HCl [pH 6.8], 2 ml of glycerol, 4.5 ml 
of 10% sodium dodecyl sulfate, 1 ml of β-mercaptoethanol, 0.8 ml of bromophenol 
blue [0.3%, wt/vol]) and heated to 95°C for 10 min. Proteins were separated on a 
10% SDS PAGE mini-gel. Separated proteins were electrophoretically transferred to 
a nitrocellulose filter (Protran® Nitrocellulose, BA85, Schleicher & Schuell) by semi-
dry blotting. Blots were blocked with PBS containing 5% milk powder and 0.1% 
Tween-20 over night at 4°C. The filter was cut into strips and incubated with 
appropriate dilutions of immune sera in blocking buffer for 2 h at room temperature. 
An anti-AMA49-CPE monoclonal antibody served as a positive control (17). Filter 
strips were then washed three times for 10 minutes in blocking buffer and incubated 
at room temperature for 1 h with alkaline peroxidase-conjugated affinity-pure F(ab’)2 
fragment goat anti-human IgG (Fc-specific) antibodies (Jackson Immuno Research 
Laboratories, West Grove, Pa.) diluted 1:10’000 in blocking buffer. After washing 
again with PBS/0.1% Tween-20, blots were finally developed using ECLTM Western 
blotting detection (Amersham Biosciences, Buckinghamshire, England) reagents to 
visualize bands.  
 
Statistical analysis 
All statistical analyses and graphs were made using GraphPad Prism version 4.03 for 
Windows, GraphPad Software, San Diego California USA, www.graphpad.com. 
Statistical significance of increase in antibody avidity was tested using a Wilcoxon 
test to compare the geometric mean avidity indices of different immunizations.  
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Abstract 
Serine repeat antigen 5 (SERA5) is a candidate antigen for inclusion into a malaria 
subunit vaccine. During merozoite release and reinvasion the 120 KDa SERA5 
precursor protein (P120) is processed and a complex consisting of a N-terminal 47 
KDa (P47) and a C-terminal 18 KDa (P18) processing product associates with the 
surface of merozoites. This complex is thought to be involved in merozoite invasion 
of and/or egress from host erythrocytes. Here we describe the synthesis and 
immunogenic properties of virosomally formulated synthetic 
phosphatidylethanolamine (PE)-peptide conjugates incorporating amino acid 
sequence stretches from the N-terminus of Plasmodium falciparum SERA5. Choice 
of an appropriate sequence was crucial for the development of a peptide that elicited 
high titers of parasite cross-reactive antibodies in mice. Monoclonal antibodies 
(mAbs) raised against the optimized peptide FB-23 incorporating amino acids 57 to 
94 of SERA5 bound both to P120 and to P47. Western blotting analysis 
demonstrated the presence of P120 in erythrocytic forms and of P47 both in 
merozoites and in sporozoites. These analyses formally prove for the first time the 
presence of P47 SERA5 in sporozoites. In immunofluorescence assays the mAbs 
stained the parasitophorous vacuole in trophozoites and the parasite cell membrane 
in merozoites. The virosomal formulation of the peptide FB-23 is suitable for use in 
humans and represents a candidate component for a multi-valent malaria subunit 
vaccine that is targeting both sporozoites and blood stage parasites.  
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Introduction 
Vaccine development in the past two hundred years since Jenner has been for a long 
time an empirical approach. However, it appears that development of vaccines 
against chronic infectious diseases, such as malaria, tuberculosis and HIV/AIDS will 
only be possible, if more rational approaches based on the growing body of 
knowledge in immunology and parasite biology are applied. In particular for the 
design of subunit vaccines new antigen production and delivery technologies are 
required. Although a broad spectrum of approaches is being evaluated for subunit 
vaccine development against P. falciparum malaria (34), progress towards 
development of an effective vaccine is still limited (14). To circumvent problems 
associated with the large scale production of correctly folded recombinant proteins 
and of highly immunogenic and stable formulations, we are developing a universal 
technology platform for multi-valent subunit vaccine design (25, 27, 31) Okitsu et al. 
submitted, James et al. accepted), which is based on synthetic peptides delivered on 
the surface of immunopotentiating reconstituted influenza virosomes (IRIVs). IRIVs 
are spherical, unilammelar vesicles, prepared by detergent removal from a mixture of 
natural and synthetic phospholipids and influenza surface glycoproteins. The 
influenza membrane glycoprotein hemagglutinin is a fusion-inducing component, 
inducing antigen uptake by immunocompetent cells via receptor-mediated 
endocytosis. IRIVs are a universal antigen-delivery system for multi-valent subunit 
vaccines, since antigens can be either attached to their surface to elicit CD4 T cell 
and antibody responses or encapsulated in their lumen to elicit CD8 T cell 
responses. They have an excellent safety profile and are already registered for 
human use (36). 
One of the target antigens for inclusion into a malaria vaccine is the serine repeat 
antigen 5 (SERA5). SERA5 belongs to a gene family comprising eight members 
(SERA1 to 8) on chromosome 2 and one (SERA9) on chromosome 9 in P. falciparum 
(13, 15). SERA5 expression is abundant and found in the trophozoite and schizont 
stages of parasite blood stage development, as well as in salivary gland sporozoites 
(1, 10, 21). Accompanied by the removal of a 22-amino acid signal sequence, the 
SERA5 precursor protein (120 kDa) is secreted into the parasitophorous vacuole 
(PV) space (4). SERA5 is the major PV protein during the schizont stage and is also 
found on the surface of the developing merozoites (2, 6, 10, 19, 22, 29). During 
merozoite release and reinvasion a fraction of SERA5 is proteolytically processed 
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into a 47 kDa N-terminal (P47), a 56 kDa central (P56), and an 18 kDa C-terminal 
domain (P18) (3-5, 7). P56 is further processed into two fragments with a size of 50 
kDa and 6 kDa (P50 and P6) (4). A complex of P47 and P18 formed through disulfide 
bonds associates with the surface of merozoites, whereas P50 is released into the 
culture medium after merozoite release (22). The central domain of recombinantly 
expressed SERA5 (P50) has been shown to possess proteolytic activity, which may 
represent a functional activity of SERA5 involved in merozoites invasion of and/or 
egress from host erythrocytes (16). Antibodies against P47 have been associated 
with protection against severe malaria in children under five years (28) and a 
recombinantly expressed fragment of the same sequence has been shown to induce 
protective immune responses in Aotus monkeys (9, 17, 18).  
In this report we describe the immunological characterization of synthetic peptides 
derived from the P47 sequence of SERA5. Mice were immunized with virosomal 
formulations of the peptides to determine their immunogenicity and in particular their 
capacity to elicit P. falciparum parasite cross-reactive antibodies. Comparative 
immunological analysis led to the design of the optimized peptide FB-23, which 
induces high titers of parasite-binding antibodies in a virosomal vaccine formulation.  
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Results 
Design and synthesis of peptides 
Previous studies by Fox et al. (11) indicated that a parasite inhibitory epitope exists 
between residues 17-73 of SERA5, possibly in the region 57-73. Based on these 
results, we first prepared the lipopeptide FB-15 (Figure 1), which contains residues 
17-73 linked through its N-terminus and a succinate linker to an isomer of 
phosphatidylethanolamine (PE). The shorter mimetic DB-12 contains only the 
residues 48-73, again linked to the phospholipid. 
This region of SERA5 contains several proline residues within motifs that appear to 
have a significant propensity to form turn-like conformations. At present no 3D 
structural information is available for the protein. Nevertheless, a small library of 
constrained peptidomimetics was synthesized, in an attempt to stabilize turn 
structures and so improve the ability of the mimetics to elicit antibodies that cross-
react with the native protein. These constrained mimetics (DB-11, -14, -16 and -20 
(Figure-1)) contain an amide link between the C-terminus and the 4-amino group of 
(2S,4S)-4-aminoproline, which was introduced into the sequence in place of Pro. 
Other studies by Fox et al., (12) also suggested that inhibitory epitopes might be 
located in the fragment 17-165. In order to extend the mimetics in the C-terminal 
direction, we first prepared the mimetic FB-19. Since, however, this molecule was 
poorly water soluble, we also prepared mimetic FB-23, which showed much 
improved solubility. 
 
Immunogenicity of SERA5-derived peptides  
BALB/c mice were immunized with 10µg doses of virosomally formulated synthetic 
peptides comprising aa 48-73, aa 17-73 or aa 57-94 of P. falciparum SERA5 (Figure 
1). 
Sera taken prior to the first and two weeks after the third immunization were analyzed 
for the development of (i) peptide specific IgG in peptide ELISA, (ii) SERA5-binding 
IgG in Western blotting with P. falciparum blood stage lysate and (iii) parasite cross-
reactive IgG in IFA with in vitro cultivated blood stage parasites. All peptides tested 
were immunogenic, but most of them elicited only in part of the animals low titers of 
IgG that cross-reacted with schizonts in IFA or Western blotting (Table 1). Only the 
C-terminally extended peptide FB-19 (aa 57-94) elicited IFA and Western blotting 
titers ≥100 in all immunized mice. Since solubility of FB-19 was low, it was modified 
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by addition of four lysine residues to yield a better soluble derivative. This easier to 
produce and to formulate optimized peptide, designated FB-23, had immunological 
properties comparable to those of FB-19. Sera from all ten FB-23 immunized mice 
were parasite cross-reactive both in IFA and Western blotting analysis (Table 1). The 
mean IFA titer (2512±4846) was 10 to 100 fold higher than titers elicited by 
immunization with the peptides incorporating aa 47-73 or aa 17-73 of SERA5.  
 
Generation and characterization of anti-FB-23 mAbs  
MAbs against the optimized peptide FB-23 were generated for a more detailed 
analysis of the specificity of the elicited antibody response. Five cell lines producing 
mAbs (designated SO10.1 to SO10.5) binding to FB-23 in ELISA were obtained from 
a FB-23 immunized BALB/c mouse. While all five mAbs were of the IgG1 isotype and 
bound to the two peptides (FB-19 and FB-23) that comprised aa 57-94, they differed 
in cross-reactivity with FB-15 (aa 17-73) in ELISA (Table 2). mAb SO10.3 showed 
strong, mAbs SO10.1 and SO10.4 weak and mAbs SO10.2 and SO10.5 no cross-
reactivity with peptide FB-15. None of the mAbs was positive in ELISA with the 
peptides comprising aa 48-73 of SERA5.  
 
Detection of SERA5 in P. falciparum parasites 
To test whether the mAbs recognized full length (120 KDa) SERA5, as well as its N-
terminal 47KDa processing product, we performed Western blotting analyses with 
lysates of synchronized in vitro cultivated P. falciparum blood stage parasites. 
Samples were taken at different time-points from the synchronized cultures, thus 
representing ring, trophozoite or schizont stages. In addition, free merozoites isolated 
by MACS sorting were analysed. Full length SERA5 was stained by four of the five 
mAbs in Western blotting (Table 2). While ring stages were negative, first traces of 
full length SERA5 became detectable in the lysates corresponding to the late 
ring/early trophozoite stages taken from the cultures at 18 and 24 hours (Figure 2). 
Only in the merozoite lysate both the full length 120KDa and the processed 47kDa 
fragment were detectable by all four Western blotting positive mAbs (Figure 2).  
In Western blotting analysis with a sporozoite lysate only the processed P47 domain, 
but no full-length SERA5 was detected with SO10.1 and SO10.4 (Figure 3). The 
other three mAbs did not detect any of the SERA5 associated bands. 
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Changes in sub-cellular localisation of SERA5 during parasite blood stage 
development was analysed by IFA with the same synchronized parasite cultures as 
used for preparation of lysates for the Western blotting experiments. All five mAbs, 
including the Western blotting negative mAb SO10.2, yielded comparable results. In 
trophozoites a ring around the parasites was stained, providing further evidence for 
the proposed localization of SERA5 in the PV during this developmental stage 
(Figure 4A) (7). In contrast, a staining pattern characteristic for antigens associated 
with the cell membrane of the parasite was observed with segmented schizonts 
(Figure 4B) and free merozoites (Figure 4C). No SERA5-specific staining of 
sporozoites was obtained in IFA. 
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Discussion 
For our approach to develop a synthetic peptide-based multi-valent malaria vaccine 
(25, 27, 30), we employ an iterative selection process to design peptide structures 
with optimal immunogenic properties. Virosomally formulated candidate antigens are 
used to immunize mice and a biologically relevant test system, semi-quantitative 
detection of parasite-binding antibodies by IFA, is used to guide step-wise selection 
of suitable structures (Ref). As described here for all SERA 5 derived peptides 
tested, virosomally formulated peptide formulations are practically always 
immunogenic and elicit peptide-reactive IgG responses in ELISA. However, only a 
minority of parasite antigen derived peptides are able to consistently induce parasite 
cross-reactive antibodies. In some cases conformational stabilisation of peptide 
chains by intramolecular cross-linking is required for the design of compounds that 
structurally resemble surface loops of the native target protein response (25, 27, 30). 
In other cases, as demonstrated here for SERA 5 derived peptides, choice of an 
appropriate sequence stretch may be sufficient. Evidence that virosomally formulated 
linear peptides can elicit antibodies against conformational epitopes (25, 27, 30) 
indicates, that linear peptides may be able to acquire a native-like conformation, in 
particular, when they are delivered structurally undisturbed on the surface of 
virosomes in the context of a phospholipid bilayer. In contrast, delivery of peptide 
antigens adsorbed to alum or other adjuvants, may disturb the structure even of 
conformationally restricted peptides profoundly (25).   
Generation of sets of mAbs against a peptide antigen is a valuable tool to evaluate 
the quality of vaccine candidate components (Mueller, Moreno, Okitsu). One 
important quality criterion is the proportion of parasite binding mAbs within the 
population of peptide reactive antibodies elicited. In the case of the SERA 5 derived 
peptide FB-23 all five mAbs analysed bound to blood stage parasites in IFA with 
staining patterns expected for this antigen, i.e. staining of the PV in trophozoites and 
surface staining in schizonts and merozoites. While both the full-length SERA 5 
(P120) and its processed fragment P47 were recognized by four of the five mAbs, 
one mAb was generally negative in Western blot analysis. Further evidence for 
diversity of the fine specificity of the mAbs came from the analysis of their cross-
reactivity with the set of peptides evaluated for immunogenicity. Three of the mAbs 
reacted to a variable degree with the peptide comprising aa 17-73. This indicates that 
the sequence stretch aa 57-73, that overlaps with the FB23 sequence (aa 57-94) 
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comprises at least part of their epitope. Conformational aspects may be responsible 
for lack of binding to the C-terminally truncated peptide comprising only aa 48-73. 
Attempts to improve the anti-parsite cross-reactivity of responses against the 
sequence stretch aa 48-73 by introduction of intramolecular disulfide bonds failed 
and also none of the anti- FB-23 mAbs bound to the disulfide bond containing 
variants.  
Western blotting results reconfirmed that processing in the blood-stage parasites is a 
late event as P47 was only found in merozoites and not in schizonts. For the first 
time we could formally prove the expression of SERA 5 at the protein level in salivary 
gland sporozoites. In these the protein was completely processed and only P47 was 
detectable. The function of SERA5 in sporozoites remains to be elucidated, but it is 
tempting to speculate that that this protein is involved in invasion and/or egress not 
only in the blood stage, but also in other life stages of the parasite.  While the N-
terminus of SERA5 is highly polymorphic, the sequence stretch represented by FB-
23 (aa 57-94) is highly conserved (12). An alignment of 62 SERA5 sequences from 
African, Asian and South American P. falciparum isolates (10, 23, 26, 32) revealed 
only four isolates with polymorphisms (one or two amino acid exchanges at the N-
terminal end) in the FB-23 sequence. 
Taken together we were able to induce parasite cross-reactive antibodies with a 
human compatible formulation of a synthetic SERA5 peptide in mice. In a similar way 
we have developed virosomal formulations of peptides derived from P. falciparum 
circumsporozoite protein (CSP), apical membrane antigen 1 (AMA-1) and merozoite 
surface protein 1 (MSP-1) for inclusion into an IRIV-based multi-component malaria 
vaccine (27) (Okitsu et al, submitted, James et al. accepted). After successful testing 
of the CSP and the AMA-1 components in a  phase I clinical trial (Genton et al., 
submitted), the SERA5 peptide is now considered as candidate for clinical profiling. 
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Materials and methods 
Synthesis of peptides 
Mimetic FB-15. The peptide was synthesized on Rink Amide MBHA resin (0.66 
mmol/g, Novabiochem, Switzerland) using an ABI 433A peptide synthesizer and 
Fmoc chemistry. Couplings were performed using 4-fold excess (1 mmol) of each 
standard protected amino acid with extended coupling cycles. The synthesis was 
started with 380 mg (0.25 mmol) of resin. Following chain assembly on the resin, PE-
Succ (see below) was coupled to the free N-teminus of the peptide on the resin, 
using a solution of PE-Succ-OH (3 eq.), HATU (3 eq.), HOAt (3 eq.) and iPr2EtN (8 
eq.) in DMF, with agitation overnight at rt. The resin was then filtered and washed 
with DMF (3 x 5 ml), CH2Cl2 (3 x 5 ml), and MeOH (3 x 5 ml). The mimetic was then 
cleaved from the resin and deprotected by treatment with CF3COOH/i-Pr3SiH/H2O 
(95:2.5:2.5) for 3 h at rt. After filtration and concentration in vacuo, the peptide was 
precipitated with cold Et2O, and washed 3 times with cold Et2O. Purification of the 
crude product by semi-preparative reverse phase-HPLC (C4 column: Vydac 
214TP1010; 10µm, 300 Å, 10 x 250 mm; gradient from 20-100% EtOH + 0.1% TFA 
in 15 min.) gave FB-15. MALDI-TOF-MS (m/z ± 0.1%): 6048 [M+H]+, 3028 [M+2H]2+ 
(calc. MW: 6045.5 g/mol). 
Mimetic FB-19. This was synthesized in the same way as for FB-15, except that two 
pseudoproline (ΨPro) building blocks were used (Novabiochem, Switzerland), Fmoc-
ValSer(ΨMe,MePro)-OH at positions Val(19)-Ser(20) and Val(24)-Ser(25). ESI-MS (m/z 
± 0.01%): 1526.8 [M+3H]3+, 1145.4 [M+4H]4+ (calc. MW: 4578.0 g/mol). 
Mimetic FB-23. This was synthesized in the same way as for FB-15, except that five 
pseudoproline (ΨPro) building blocks were used (Novabiochem, Switzerland); Fmoc-
ValSer(ΨMe,MePro)-OH at positions Val(17)-Ser(18), Val(23)-Ser(24) and Val(28)-
Ser(29), and Fmoc-SerSer(YMe,MePro)-OH at Ser(10)-Ser(11) and Ser(34)-Ser(35). 
MALDI-TOF-MS (m/z ± 0.1%): 5089.4 [M+H]+ (calc. MW: 5090.7 g/mol). 
Mimetic DB-12. This was synthesized in the same way as for FB-15. ESI-MS (m/z ± 
0.01%): 1563.8 [M+2H]2+, 3126.7 [M+H]+ (calc. MW: 3125.4 g/mol). 
Cyclic mimetics DB-11, -14, -16 and -20. These mimetics were synthesized in the 
following 7 step procedure: 
Step-1. The linear peptide sequence was assembled by solid phase peptide 
synthesis, using Fmoc chemistry and chlorotrityl chloride resin, with an inital loading 
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of 0.2-0.3 mmol/g. N(α)-Fmoc(2S,4S)-4-(Alloc)aminoproline ((2S,4S)-
allyloxycarbonyl-4-amino-1-Fmoc-pyrrolidine-2-carboxylic acid) was incorporated in 
place of the desired proline. At the end of the chain assembly, the N-terminal Fmoc 
protecting group was not removed. 
Step-2. The Alloc protecting group was removed by stirring the resin-bound peptide 
with Pd(PPh3)4 and PhSiH3 in CH2Cl2 for 3 h at rt under Ar. The resin was then 
filtered and washed four times with DMF and 3 times with CH2Cl2. 
Step-3.  The peptide chain was cleaved from the resin by stirring in a solution of 
0.6% CF3COOH in CH2Cl2 for 1 h at rt. The solution was washed with brine and then 
evaporated to dryness. 
Step-4. For cyclization, the peptide chain from above was treated with HATU and 
HOAt (each 6 eq.) and iPr2EtN (12 eq.) in dry DMF (peptide concentration 1 mg/ml) 
for 72 h at rt.  The DMF was then removed under vacuo, and the residue was 
redissolved in CH2Cl2 and washed twice with brine. The solution was then dried over 
Na2SO4 and dried under vacuo. 
Step-5. To remove the Fmoc-group, the peptide from above was dissolved in a 
solution of piperidine (20%) in DMF and stirred for 1 h at rt. The solution was then 
dried under vacuo and the desired product was purified by preparative reverse phase 
HPLC. 
Step-6. For coupling to the phosholipid, PE-Succ-OH was made be reacting 1,3-
dipalmitoyl-glycero-2-phospho-ethanolamine (Bachem, Switzerland) (1 g, 1.45 mmol) 
in CHCl3 / MeOH (9:1, 100 ml) with succinic anhydride (203 mg, 2.03 mmol, 1.4 eq.) 
in CH2Cl2 (100 ml) and Et3N (600 ml, 4.31 mmol, 3 eq.). The solution was stirred for 5 
h at rt. Then CHCl3 (100 ml) and 0.02 M citric acid/sodium phosphate buffer (100 ml, 
pH 5.5) were added and the aqueous phase was extracted with CHCl3. The 
combined organic phases were separated, dried over Na2SO4 and solvent 
evaporated to give the product PE-Succ-OH (1.12 g, 98% yield). ESI-MS (m/z ± 
0.01%): 790.5[M+H]+, 394.7[M+2H]2+. The cyclic peptide was then coupled to PE-
Succ-OH in DMF with HATU (3 eq.) HOAt (3 eq.) and Et3N (6 eq.). After stirring at rt 
for 72 h, the DMF was removed under vacuo, the residue was dissolved in CH2Cl2 
and washed with brine, dried over Na2SO4 and evaporatd to dryness. 
Step-7. For deprotection, the product from above was dissolved in CF3COOH 
containing H2O (2.5 v/v%) and iPr3SiH (2.5%) and stirred at rt for 1 h.  The solution 
was then evaporated to dryness under vacuo, and the product was purifed by 
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preparative reverse phase HPLC. The product was obtained in >95% purity and was 
characterized by mass spectrometry. DB-11, ESI-MS (m/z ± 0.01%): 1562.7 
[M+2H]2+, 1042.3 [M+3H]3+ (calc. MW: 3123.4 g/mol); DB-14, ESI-ES (m/z ± 0.01%): 
3125.1 [M+H]+, 1563 [M+2H]2+, 1042 [M+3H]3+ (calc. MW: 3123.4 g/mol); DB-16, 
ESI-ES (m/z ± 0.01%): 3124.4 [M+H]+, 1563 [M+2H]2+, 1042 [M+3H]3+ (calc. MW: 
3123.4 g/mol); DB-20, ESI-ES (m/z ± 0.01%): 3124.6 [M+H]+, 1562.8 [M+2H]2+, 
1042.2 [M+3H]3+ (calc. MW: 3123.4 g/mol). 
Sequence from P. falciparum isolate UF-5 (Indonesia); accession BAA78509; (23) 
 
Preparation of peptide-loaded virosomes 
For the preparation of IRIV loaded with phosphatidylethanolamine (PE)-peptide 
conjugates, a solution of purified Influenza A/Singapore hemagglutinin (4 mg) in 
phosphate buffered saline (PBS) was centrifuged for 30 min at 100 000 g and the 
pellet was dissolved in PBS (1.33 ml) containing 100 mM 
octaethyleneglycolmonodecylether (PBS-OEG). Peptide-PE conjugates (4 mg), 
phosphatidylcholine (32 mg; Lipoid, Ludwigshafen, Germany) and PE (6 mg) were 
dissolved in a total volume of 2.66 ml of PBS-OEG. The phospholipid and the 
hemagglutinin solutions were mixed and sonicated for 1 min. This solution was then 
centrifuged for 1 hour at 100 000 g and the supernatant was filtered (0.22 µm) under 
sterile conditions. Virosomes were then formed by detergent removal using BioRad 
SM BioBeads (BioRad, Glattbrugg, Switzerland). 
 
Animal studies 
All procedures involving living animals were performed in accordance with the Rules 
and Regulations for the Protection of Animal Rights (Tierschutzverordnung) of the 
Swiss Bundesamt für Veterinärwesen. 
Mouse immunogenicity studies 
BALB/c mice were pre-immunized intramuscularly with 0.1 ml of the commercial 
whole virus influenza vaccine Inflexal BernaTM (Berna Biotech, Bern, Switzerland). At 
least three weeks later they were immunized with PE-peptide conjugate-loaded IRIVs 
(containing 10µg PE-peptide) in intervals of at least two weeks. Blood was collected 
before each immunization and two weeks after the final injection. 
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Generation of hybridomas and production of mAbs 
Hybridomas were generated from spleen cells of mice three days after an 
intravenous booster immunization with FB-23 loaded IRIVs using PAI mouse 
myeloma cells as a fusion partner. Hybrids were selected in HAT medium and cells 
that secreted anti-BP65 mAbs were identified by ELISA. For large-scale mAb 
production, hybridoma cell lines were cultured in 175 cm2 flasks and mAbs were 
purified by protein A or G affinity chromatography (Protein A SepharoseTM CL4B or 
HiTrapTM Protein G HP, Piscataway, NJ). Purified mAbs were dialyzed against PBS, 
aliquoted and stored at -80°C. Generation of anti-P. falciparum sporozoite mAbs has 
been described previously (33). 
 
ELISA 
ELISA analyses with peptide-PE conjugates were performed essentially as described 
before (27). Briefly, PolysorpTM plates (Nunc, Fisher Scientific, Wohlen, Switzerland) 
were coated overnight at 4°C with 100 µl of a 10 µg/ml solution of UK39 in PBS (pH 
7.2). After three washings with PBS containing 0.05% Tween-20 wells were blocked 
with 5% milk powder in PBS for 30 min at 37°C and washed three times again. Plates 
were then incubated with serial dilutions of anti-peptide mouse or anti-peptide mAbs 
in PBS containing 0.05% Tween-20 and 0.5% milk powder for 2 h at 37°C. After 
washing, plates were incubated with alkaline phosphatase-conjugated goat anti-
mouse IgG (Fc-specific) antibodies (Sigma, St. Louis, Mo) for 1 h at 37°C. After 
washing again, phosphatase substrate solution (1 mg/ml p-nitrophenyl phosphate 
(Sigma, St. Louis, Mo) in a pH 9.8 buffer solution containing 10% [vol/vol] 
diethanolamine and 0.02% MgCl2) was added and the plates were incubated in the 
dark at room temperature until the colorimetric reaction had progressed sufficiently. 
The optical density was measured at 405 nm on a Titertek Multiscan MCC/340 
reader (LAbsystems, Helsinki, Finland).  
 
Indirect immunofluorescence assay (IFA) 
Air-dried unfixed P. falciparum (strain NF54) salivary gland sporozoites attached to 
microscope glass slides were incubated for 15 min at room temperature with 25 µl 
blocking solution containing 1% fatty acid-free bovine serum albumin (BSA) in PBS. 
Immunostaining was performed by incubating the wells with 25 µl of an appropriate 
serum dilution in blocking solution in a humid chamber for 1 h at room temperature. 
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After five washes with blocking solution 25 µl of 5 µg/ml cyanine dye (Cy3)-
conjugated affinity-pure F(ab´)2 fragment goat anti-mouse IgG (Fc-specific) 
antibodies (Jackson Immuno Research Laboratories, West Grove, Pa.) or Cy3-
conjugated donkey anti-rabbit IgG heavy and light chain antibody (Jackson Immuno 
Research Laboratories, West Grove, PA), diluted in blocking solution containing 0.01 
mg/ml Hoechst dye no. 33256 (Sigma, St. Louis, Mo) were added to the wells and 
incubated for 1 h at room temperature. Finally, wells were washed five times with 
PBS, mounted with mounting solution (90% [vol/vol] glycerol containing 0.1 M Tris-
Cl, pH 8.0 and 2 mg/ml o-phenylenediamine) and covered with a coverslip. Antibody 
binding and DNA staining were assessed by fluorescence microscopy on a Leitz 
Dialux 20 or a Leica DM5000 fluorescence microscope and documented with a Leica 
DC200 digital camera system. For IFAs with blood stage parasites 5ul infected 
erythrocytes from an in vitro culture (24) were used to prepare thin smears. These 
were fixed in 50/50 acetone/methanol (vol/vol) for 2min at -20°C. Alternatively, 
multiwell immunofluorescence microscopy slides (Flow Laboratories, Baar, 
Switzerland) were treated with 0.01% poly-L-lysine (Sigma) at room temperature for 
30 min and washed five times with RPMI basal salts medium (Gibco-BRL, Basel, 
Switzerland). Erythrocytes from in vitro cultures (24) of P. falciparum strain K1 with a 
parasitemia between 5 and 10% were washed twice in RPMI and resuspended in 
RPMI and 2 volumes of a solution containing 4% formaldehyde and 0.1% Triton X-
100. From this cell suspension, 30 µl was added to each well, incubated at room 
temperature for 30 min, and washed five times with PBS. Blocking and incubation 
with sera or mAbs was done as described above. 
 
SDS-PAGE and immunoblotting 
100 µl of an Anopheles stephensi salivary gland lysate containing about 60000 P. 
falciparum sporozoites were diluted with an equal volume of 2x loading buffer (1.7ml, 
0.5M Tris-HCl pH 6.8, 2 ml glycerol, 4.5 ml 10% SDS, 1 ml β-mercaptoethanol, 0.8 ml 
0.3% w/v bromophenol blue) and heated to 95°C for 10 minutes. Proteins were 
separated on a 10% SDS PAGE mini-gel. Separated proteins were 
electrophoretically transferred to a nitrocellulose filter (Protran® Nitrocellulose, BA85, 
Schleicher & Schuell) by semi-dry blotting. Blots were blocked with PBS containing 
5% milk powder and 0.1% Tween-20 over night at 4°C. The filter was cut into strips 
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and incubated with appropriate dilutions of immune sera in blocking buffer for 2 h at 
room temperature. Filter strips were then washed three times for 10 minutes in 
blocking buffer and incubated at room temperature for 1 h with alkaline peroxidase-
conjugated goat anti-mouse IgG (Fc-specific) antibodies (Sigma, St. Louis, Mo) 
diluted 1:30’000 in blocking buffer or horseradish peroxidase-conjugated goat anti-
rabbit IgG heavy and light chain antibodies (Bio-Rad Laboratories, Hercules, CA) 
diluted 1:6’000 in blocking buffer. After washing again, blots were finally developed 
using ECLTM Western blotting detection (Amersham Biosciences, Buckinghamshire, 
England) reagents to visualize bands. 
Blood stage parasite lysates were prepared essentially as described previously (24) 
by saponin lysis of P. falciparum K1-infected erythrocytes. In brief, cultured parasites 
were washed once with PBS. Pelleted infected red blood cells were lysed by mixing 
with a large volume (adjusted to 5% hematocrit) of 0.015% (wt/vol) saponin in 150 
mM NaCl and 15 mM sodium citrate (pH 7.0) and incubated on ice for 20 min. 
Finally, the pelleted parasites were resuspended in 3 volumes of PBS and stored at -
80°C until further use. A total of 50 µl of parasite lysate was solubilized in an equal 
volume of 2x loading buffer (1.7 ml of 0.5 M Tris-HCl [pH 6.8], 2 ml of glycerol, 4.5 ml 
of 10% sodium dodecyl sulfate, 1 ml of  -mercaptoethanol, 0.8 ml of bromophenol 
blue [0.3%, wt/vol]) and heated to 95°C for 10 min. Proteins were separated on an 
SDS–10% PAGE minigel and transferred to a nitrocellulose membrane as described 
above. 
 
Parasite culture 
P. falciparum strain K1 was cultured essentially as described previously (24). The 
culture medium was supplemented with 0.5% AlbuMAX (Gibco, Paisley, Scotland) as 
a substitute for human serum (8). Synchronization of cultures was achieved by 
sorbitol treatment as described previously (20). Merozoites were isolated after 
parasite synchronization using MACS sorting (35) and continued parasite culture until 
schizont rupture. After rupture parasites were again passed through a MACS column 
and the flow through containing merozoites was collected. Serogroup A erythrocytes 
for passages were obtained from the Swiss Red Cross (Basel, Switzerland). 
Blood-stage parasite synchronization. 
Parasites were synchronized using D-sorbitol, as described before (20). Merozoites 
were isolated after parasite synchronization using MACS sorting (35) and continued 
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parasite culture until schizont rupture. After rupture parasites were again passed 
through a MACS column and the flow through containing merozoites collected.  
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Figure legends 
 
Figure 1. SERA5 processing products and SERA5-derived synthetic peptides. A: 
Proteolytic processing of SERA5. The shaded box indicates the sequence stretch 
(amino acids 17-94) comprising the synthetic peptides evaluated in this study and the 
filled box the signal peptide. Ser = serine repeat region. B: Structures of the 
peptidomimetics prepared in this work. The cyclic peptides contain a covalent amide 
link between the C-terminus (His73) and the 4-amino group in (2S,4S)-4-aminoproline 
(denoted X in the sequence). 
 
Figure 2. Western blotting analysis with anti-FB-23 mAb SO10.3 using parasite 
lysates taken every 6 hours from synchronized P. falciparum blood stage cultures (0-
42 hours). Merozoites (M) were purified using a MACS column. The anti-GAPDH 
mAb 1.10d served as a loading control. Comparable results were obtained with the 
other three Western blotting positive mAbs (Table 2). 
 
Figure 3. Western blotting with a lysate of salivary glands of infected mosquitoes 
(lane 1: mAb SO10.1; 2: mAb SO10.2; 3: mAb SO10.3; 4: mAb SO10.4; 5: mAb 
SO10.5) or with a blood stage merozoite lysate (lane 6: mAb SO10.3). 
 
Figure 4. Parasites were stained with anti-FB-23 mAb SO10.3 and a secondary 
antibody conjugated to Cy3. Nuclei were stained using Hoechst dye no. 33256. A: 
Localization of SERA5 in the parasitophorous vacuole in trophozoites. B: association 
of SERA5 with the parasite membrane of segmented schizonts. C: association of 
SERA5 with the membrane of free merozoites (mAb SO10.1). 
 
Table 1. Sera obtained prior to the first and after the third immunization were 
compared. Peptide ELISA: the mean halfmaximal IgG titer ±SD of immune sera and 
the proportion of animals that seroconverted are shown; IFA: the proportion of 
animals that had developed blood stage parasite cross-reactive IgG at a serum 
dilution of 1:50 is shown; Western blotting analysis: the proportion of immune sera 
that showed reactivity with a band of appropriate size (120 KDa) at a serum dilution 
of 1:100 is shown. None of the pre-immune sera was positive in IFA or Western 
blotting analysis. * see Fig. 1 for type of cyclization. 
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Table 2. Cross-reactivity of anti FB-23 mAbs with SERA5-derived peptides in ELISA 
and with P. falciparum sporozoites and blood-stage parasites in IFA and Western 
blotting analysis. *P120: detection of full length SERA5; P47: detection of processed 
SERA5 P47 fragment. 
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Figures and Tables 
 
 
 
Figure 1. SERA5 processing products and SERA5-derived synthetic peptides. A: 
Proteolytic processing of SERA5. The shaded box indicates the sequence stretch 
(amino acids 17-94) comprising the synthetic peptides evaluated in this study and the 
filled box the signal peptide. Ser = serine repeat region. B: Structures of the 
peptidomimetics prepared in this work. The cyclic peptides contain a covalent amide 
link between the C-terminus (His73) and the 4-amino group in (2S,4S)-4-aminoproline 
(denoted X in the sequence). 
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Peptide DB-012 DB-011 DB-014 DB-016 DB-020 FB-15 FB-19 FB-23 
SERA5 aa sequence 48-73 48-73 48-73 48-73 48-73 17-73 57-94 57-94 + 4 lysines 
Description linear cyclized* cyclized* cyclized* cyclized* linear linear linear 
Mean ELISA titer 100±147 141±155 1006±379 157±103 346±58 276±428 1056±438 633±599 
Responders in ELISA 5/5 4/4 4/4 4/4 4/4 5/5 5/5 10/10 
Responders in IFA 4/5 0/4 2/4 3/4 2/4 4/5 5/5 10/10 
Responders in 
Western blot analysis 1/5 1/4 0/4 0/4 0/4 3/5 5/5 10/10 
 
Table 1. Immune responses elicited by SERA5 derived peptides. Sera obtained prior 
to the first and after the third immunization were compared. Peptide ELISA: the mean 
halfmaximal IgG titer ±SD of immune sera and the proportion of animals that 
seroconverted are shown; IFA: the proportion of animals that had developed blood 
stage parasite cross-reactive IgG at a serum dilution of 1:50 is shown; Western 
blotting analysis: the proportion of immune sera that showed reactivity with a band of 
appropriate size (120 KDa) at a serum dilution of 1:100 is shown. None of the pre-
immune sera was positive in IFA or Western blotting analysis. * see Fig. 1 for type of 
cyclization. 
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         schizonts sporozoites 
peptide DB-011 DB-012 DB-014 DB-016 DB-020 FB-15 FB-19 FB-23 IFA Western blot IFA Western blot 
 48-73 48-73 48-73 48-73 48-73 17-73 57-94 57-94  P120* P47*  P120* P47* 
SO10.1 - - - - - (+) + + + + + - - + 
SO10.2 - - - - - - + + + - - - - - 
SO10.3 - - - - - + + + + + + - - - 
SO10.4 - - - - - (+) + + + + + - - + 
SO10.5 - - - - - - + + + + + - - - 
 
Table 2. Cross-reactivity of anti FB-23 mAbs with SERA5-derived peptides in ELISA 
and with P. falciparum sporozoites and blood-stage parasites in IFA and Western 
blotting analysis. *P120: detection of full length SERA5; P47: detection of processed 
SERA5 P47 fragment. 
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Figure 2. Western blotting analysis with anti-FB-23 mAb SO10.3 using parasite 
lysates taken every 6 hours from synchronized P. falciparum blood stage cultures (0-
42 hours). Merozoites (M) were purified using a MACS column. The anti-GAPDH 
mAb 1.10d served as a loading control. Comparable results were obtained with the 
other three Western blotting positive mAbs (Table 2). 
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Figure 3. SERA5 expression in sporozoites. Western blotting with a lysate of salivary 
glands of infected mosquitoes (lane 1: mAb SO10.1; 2: mAb SO10.2; 3: mAb 
SO10.3; 4: mAb SO10.4; 5: mAb SO10.5) or with a blood stage merozoite lysate 
(lane 6: mAb SO10.3). 
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Figure 4. IFA with P. falciparum blood stage parasites. Parasites were stained with 
anti-FB-23 mAb SO10.3 and a secondary antibody conjugated to Cy3. Nuclei were 
stained using Hoechst dye no. 33256. A: Localization of SERA5 in the 
parasitophorous vacuole in trophozoites. B: association of SERA5 with the parasite 
membrane of segmented schizonts. C: association of SERA5 with the membrane of 
free merozoites (mAb SO10.1). 
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9.1 General Discussion and Conclusions 
It is now over 30 years since it has been shown that man can be protected against 
malaria by vaccination1. In the meantime, many important advances in malaria 
vaccine development have taken place and a promising candidate, RTS,S/AS02A, is 
the first pre-erythrocytic vaccine to show clear protection against natural P. 
falciparum infection2-5. However, a safe, effective and affordable vaccine, that 
provides sustained protection to the residents of malaria endemic areas, is still many 
years away.  
History shows that vaccines are most easily developed for those organisms that 
induce natural immunity after a single infection. For malaria, partial anti-parasite 
immunity develops only after several years of endemic exposure6. This inefficient 
induction of immunity is partly a result of antigenic polymorphism, poor 
immunogenicity of individual antigens, the ability of the parasite to interfere with the 
development of immune responses and to cause apoptosis of effector and memory T 
and B cells, and the interaction of maternal and neonatal immunity (reviewed in 
Bolad and Berzins, 2000; Good et al., 2004)7,8. Vaccine development is widely 
recognized as one of the most cost-effective ways to improve public health and to 
protect humans against infectious diseases. According to the Jordan Report9 75% of 
all vaccine candidates in Phase 3 trials are attempting to induce full immunity using 
either recombinant or synthetic subunits. It is difficult to induce immunity with 
subunits and, of the vaccines currently in general use, only 25% are subunit-based. 
One appeal of subunit vaccine technology is that, for some pathogens, it is difficult or 
impossible to grow whole native organisms in vitro, leaving little alternative to a 
subunit approach. A further appeal is that the ideal subunit vaccine will induce 
immune responses against only those determinants relevant to protection, thus 
minimizing the possibility of deleterious responses. 
This thesis describes the detailed immunological characterization of synthetic peptide 
components for inclusion into a multivalent subunit malaria vaccine based on 
virosomal technology from preclinical development and profiling to a phase 1 safety 
and immunogenicity study in Caucasians.  
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9.1.1 A technology platform for the stepwise development and evaluation of 
synthetic peptide vaccine components 
P. falciparum candidate proteins were chosen on the basis of a known essential 
function in the host cell invasion process. Criteria for epitope selection include known 
induction of parasite inhibitory antibodies, sequence conservation and secondary 
structure motifs indicating surface exposition. Based on these criteria we started with 
the design of a series of peptides derived from P. falciparum antigens. The peptides 
were short in order to focus the immune response on protection-relevant epitopes. P. 
falciparum is known for various immune evasion mechanisms, like the presentation 
of irrelevant but immunodominant epitopes, inducing a non-protective immune 
response of the host. The epitope-focussed approach with short peptides should 
avoid such a useless response and induce only parasite-inhibitory antibodies. In this 
thesis we describe the development, evaluation and characterization process for 
CSP, AMA-1, and SERA5 derived peptides. All candidate peptides were hooked to 
virosomes via a phosphatidylethanolamine (PE) anchor for non-covalent linking to 
the membrane of virosomes. The key readout system for the evaluation of peptide 
quality and immunogenicity were parasite-binding properties of the elicited antibodies 
in IFA with either P. falciparum sporozoites or blood-stage parasites. The peptide 
sequences and/or conformations were optimized in cycles starting from a lead 
structure (Figure 1). Candidate peptides with satisfactory immunological properties 
were then ready to enter preclinical profiling and clinical testing. 
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Figure 1. IRIV-based malaria vaccine development: from peptide antigen 
development to clinical evaluation. 
 
In the case of CSP derived peptides we have shown that optimal conformational 
restriction of the peptide was crucial for the induction of parasite-binding antibodies in 
mice. First generation peptides with single or double loops of NANP repeats hooked 
to a rigid template were highly immunogenic but only low titers of parasite cross-
reactive IgG were induced10. Alum-adjuvanted formulations of the same peptides 
induced higher titers of IgG than IRIV formulations but were inferior in terms of cross-
reactivity of the induced antibodies with sporozoites, indicating interference of Alum 
with the peptide conformation10. Only internally cyclized and more flexible NANP 
peptides BP6511 and UK-39 were good at eliciting parasite-binding antibodies. This 
more flexible type of conformation is close to the natural conformation of the NANP 
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repeats found on the surface of sporozoites, as indicated by NMR and crystallization 
studies. Another example of a conformationally restricted peptide is based on P. 
falciparum merozoite surface protein 1 (MSP-1). The MSP-1 19 kDa fragment is a 
rare example of a P. falciparum protein where the detailed structure has been 
elucidated by crystallization studies12. We have shown recently that peptides of the 
N-terminal epidermal growth factor (EGF)-like domain can be chemically synthesized 
and efficiently refolded to a native-like state (James et al. manuscript accepted). Only 
correctly folded peptides with all three disulfide bonds in place induced parasite-
binding antibodies but not peptides with blocked cysteines. Moreover antibody 
binding to P. falciparum blood-stage parasites was abolished by competition with 
natively folded peptide but not with a linear one. Results with these two antigenic 
structures requiring conformational restriction of peptidomimetics are in contrast to 
results with peptides derived from the N-terminal region of SERA5 presented in this 
thesis. Optimal immunogenicity and induction of parasite-binding antibodies was 
depending on the right sequence stretch used for immunization. Cyclization of 
peptides via amide bonds had no positive influence on the parasite-binding 
properties of the antibodies induced after immunization of mice. SERA5 is a protein 
for which no structural information is available, therefore we cannot conclude whether 
the optimized peptide FB-23 has a conformation close to the natural N-terminal 
domain of the protein or not. Another example of a peptide where restriction of 
conformation was not needed is AMA49-CPE13. The optimized peptide AMA49-CPE 
seems to have enough internal driving force to adopt a conformation to elicit parasite 
cross-reactive antibodies, which recognize a discontinuous epitope. The cyclized 
form of this peptide had comparable immunogenic properties as the linear form13. 
AMA-1 is an example of an antigen, where induction of parasite inhibitory antibodies 
has been reported without a detailed characterization and localization of the epitope. 
In such cases peptide libraries covering the whole protein sequence can help 
selecting an epitope inducing inhibitory antibodies.  
Taken together these examples show the importance of a detailed preclinical profiling 
and optimization of every candidate antigen for inclusion into a malaria vaccine. 
Synthetic peptide chemistry strongly facilitates this approach, allowing rational 
stepwise peptide optimization based on structure-activity observations. Moreover 
peptide delivery with IRIVs does not interfere with peptide conformation as it was 
observed for Alum. Our technology and evaluation platform, which was established 
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during the last nine years, is now available for the swift design, evaluation and 
optimization of new candidate peptides for inclusion into a multi-component subunit 
malaria vaccine.  
 
9.1.2 Comparison of animal models and human studies 
In the phase 1 study conducted with UK-39 and AMA49-CPE the same 
immunological evaluations were performed as in the preclinical profiling studies in 
animals. Peptide-ELISA to show immunogenicity of virosomally formulated peptides 
and to study the development of an anti-peptide response, IFA with P. falciparum 
parasites as key readout system to estimate the proportion of responders producing 
parasite-binding antibodies, and Western blot to confirm specific recognition of the 
parasite-derived antigen. In an attempt to gain indirect evidence for the induction of 
long-lived antigen-specific memory B cells upon vaccination we performed 
competition ELISAs with chaotropic salt to measure avidity of peptide-specific IgG. 
Parasite inhibition assays were done to assess a biological function of the induced 
antibody response and additionally ELISPOT and T cell proliferation assays were 
used to investigate the cellular immune response to the candidate vaccine (data not 
shown). Virosomal formulations of both UK-39 and AMA49-CPE were safe and 
immunogenic. Vaccine-induced anti-UK-39 IgG was parasite-binding and growth-
inhibitory in a dose-dependent manner. Some of the AMA49-CPE positive sera were 
also parasite cross-reactive but not growth-inhibitory (data not shown). Antibody 
avidity was increasing over the course of immunization for both peptides, indicating 
formation of long-lived memory B cells. The presence of anti-peptide IgG titers one 
year after the third immunization supports this hypothesis.  
Generally, the humoral response induced in humans by vaccination with virosomally 
formulated UK-39 and AMA49-CPE was comparable to the one in animal models. 
Two immunizations with a 10µg dose of UK-39 and with a 50µg dose of AMA49-CPE 
were enough to induce high anti-peptide titers in mice, rabbits and humans. After 
immunization with an appropriate dose of UK-39, sera were always cross-reactive 
with P. falciparum sporozoites and inhibited sporozoite invasion and growth in a dose 
dependent manner. Partial cross-reactivity of the antibody response after 
immunization with AMA49-CPE and problems with pre-existing vaccine-unrelated 
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blood-stage parasite cross-reactive IgG in humans closely resembled the results 
obtained in the rabbit model. The main difference observed between animal models 
and humans was a higher variability of the induced immune responses in humans, 
which is probably due to more immunogenetic variability in human volunteers.  
Overall these findings confirm the suitability of the used animal models for 
immunogenicity, safety and dose-finding studies during design, optimization and pre-
clinical profiling of virosomally-formulated candidate peptides. 
 
9.1.3 Missing correlates of protection  
After preclinical profiling and a phase 1a safety and immunogenicity study the 
question remains open whether our vaccine candidate components show any 
efficacy in protection from malaria. Conventional immunological tests provide 
information on dose and vaccination schedule required but they cannot predict 
whether a vaccine will be successful in protecting against malaria. The only available 
in vitro tests to measure the biological activity of elicited antibodies are parasite 
growth inhibition assays (GIAs). GIAs compare invasion, growth and development of 
parasites in the absence and presence of sera or purified antibodies. GIAs can be 
performed with P. falciparum sporozoites isolated from mosquito salivary glands 
cultured in primary human hepatocytes or with blood-stage parasites cultured in 
human red blood cells. Inhibition assays are very fragile test systems and results 
have to be interpreted carefully. Reproducibility of results is often difficult, especially 
with low rates of inhibition. These are not necessarily mediated by antibodies but can 
also be seen with non-Ig components of human sera14. Correlations between GIA 
results, antibody titers and protection from disease were found after immunization 
with recombinant MSP-1 in the Aotus nancymai model but similar studies of in vitro 
correlates of protection in human trials are still missing15. Despite all these 
constraints parasite growth-inhibitory antibody responses can be identified with GIAs 
and give a first idea about a possible functional activity of a vaccine induced antibody 
response. As long as no other correlates of protection are available, GIAs will remain 
the gold standard for in vitro activity of anti-parasite antibody responses and are often 
used as selection criterion for competing vaccine candidates during preclinical 
development. 
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Small (rodent) animal models are not available for infection with P. falciparum. 
Plasmodium species infecting rodents are available. However since most laboratory 
strains of Plasmodium are not natural pathogens of the laboratory mouse, and since 
the different parasite-mouse strain combinations can differ in virulence of the 
pathogen and in mechanisms of elimination by the host, these models have to be 
used with care (summarized in Langhorne et al., 2004)16. Another complication is the 
fact that many of the P. falciparum antigen candidates are either not present or 
antigenically different in those Plasmodium species. Transgenic P. berghei strains 
carrying hybrid P. falciparum proteins of CSP17 and MSP-118 have been generated 
for murine studies but been of limited use in vaccine development up to now. Mice 
and rabbits are in many cases good models to study the safety and immunogenicity 
of candidate vaccines but fail to answer questions about protective efficacy of a 
vaccine. Non-human primates like Pan troglodytes and several Aotus species can be 
infected with P. falciparum as well as P. vivax for challenge studies, but parasites 
have to be adapted to these artificial hosts for successful infection. Besides that 
these primate animal models are difficult to access and detailed studies on the 
comparability of these models with natural infection of humans are still missing. 
Nevertheless non-human primate models can be useful in identifying optimal vaccine 
formulations and for conducting preclinical safety studies19. With DNA-based 
heterologous prime-boost immunization strategies, varying results were obtained in 
different animal models and humans20.  
Besides large-scale phase 3 clinical trials, experimental sporozoite challenge of 
human volunteers is another possibility to test vaccine efficacy. This well established 
method has been used extensively in the case of the sporozoite vaccine 
RTS,S/AS02A and the above mentioned DNA-based vaccines. Despite a high rate of 
sterile protection in laboratory challenge trials RTS,S/AS02A failed to confer sterile 
protection in field trials2,3,5,21. Even though detailed studies on the immune 
mechanisms have been done during artificial challenge trials no clear mechanism 
could be identified accounting for sterile protection by RTS,S/AS02A22. Comparable 
results have been reported with DNA-based prime-boost strategies developed at the 
University of Oxford: selected vaccine formulations have shown some protection after 
challenge of non-immune volunteers but failed to show efficacy in field trials23,24. 
Sporozoite challenge of human volunteers at an early clinical stage is thus a unique 
and intriguing possibility to test malaria vaccine efficacy with few volunteers in a short 
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time but the relevance of challenge results for predicting clinical efficacy has still to 
be demonstrated. Sporozoite challenge cannot be used to determine the efficacy of 
blood-stage vaccines, as challenged volunteers are treated as soon as they develop 
patent blood-stage parasitemia. Therefore phase 2b trials remain the generally 
accepted method of establishing proof of principle for blood-stage vaccines. Some 
early, promising work has been performed with blood-stage challenge by inoculation 
of ultra-low doses of infected erythrocytes25. If this is further developed, it may form 
the basis of a challenge trial framework for phase 2a trial to evaluate blood-stage 
candidates. 
While all these experimental human and animal challenge and in vitro model systems 
provide supporting evidence that an antigen was correctly chosen and presented to 
the immune system to induce a potent response, the predictive value for protective 
efficacy of these tools cannot be determined until the results are correlated with 
clinical efficacy of vaccine candidates. 
To improve our understanding of protection against malaria, various studies have 
been investigating immune responses underlying semi-immunity in endemic areas 
but mechanisms identified in the field have not helped in the development of a 
vaccine up to now. One well-studied example is Combination B, a vaccine combining 
MSP-1, MSP-2 and ring-infected erythrocyte surface antigen (RESA). Prospective 
field trials have identified a negative correlation between serum IgG levels against 
the vaccine components and incidence of clinical episodes in non-immunized 
residents of a malaria endemic region26,27. Nevertheless immunization with these 
components had no significant effect on the number of clinical episodes in a phase 
1/2b trial in children in the same malaria endemic region28.  
Overall it remains very difficult to choose the right antigens for inclusion into a 
vaccine and to estimate vaccine efficacy in animal models, and artificial challenge 
trials with malaria-naïve volunteers. Due to these missing correlates of protection, 
results on the efficacy of malaria vaccine candidates are obtained only very late in 
clinical development. And most worryingly, product development could be stopped 
based on failure to detect efficacy in current in vitro and in vivo models not known to 
be predictive of clinical efficacy. It will therefore be of crucial importance to 
understand the mechanism of action of partially effective vaccines. 
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9.1.4 Definition of an effective malaria vaccine and its contribution to current 
methods of control 
First attempts in malaria vaccine development aimed at sterile protection from 
infection, which can only be achieved with a pre-erythrocytic vaccine. So far only 
irradiated sporozoites1 and RTS,S/AS02A3 succeeded in conferring sterile protection 
to immunized volunteers. The feasibility of a sporozoite vaccine remains doubtful and 
RTS,S/AS02A failed to show sterile protection in the field5. Modern malaria vaccine 
development therefore focuses on an anti-disease vaccine and the endpoint in 
efficacy trials is now rather prevention of severe disease than infection. The first 
vaccine showing reduction of severe malaria in the field was RTS,S/AS02A although 
the mechanism of this reduction is not known5.  
An effective malaria vaccine will need to justify its place in the overall portfolio of 
tools for malaria control. A vaccine could add significant benefit to current methods of 
control like insecticide treated bednets (ITN), indoor spraying with residual 
insecticides (IRS), environmental changes, and drug treatment29. Some of the 
advantages of a malaria vaccine over other control methods are i.) existing tools (IRS 
or ITNs and drug therapy) alone are unlikely to provide complete protection against 
malaria in highly endemic areas, ii.) drug resistance and insecticide resistance will 
continue to pose threats to control strategies based on treatment and vector control 
with insecticides iii.) the expanded program of immunization (EPI) provides an 
effective delivery system that is in place, and already reaches a high proportion of 
children in malaria endemic countries, iv.) there is greater flexibility over the time 
interval during which a vaccine can be given than is the case for control strategies 
based on treatment, which must always be available immediately upon development 
of disease, v.) there is increasing political support from the international community to 
finance the costs of malaria vaccines for poor countries29. 
 
9.1.5 Application of an effective IRIV-based vaccine in malaria endemic areas 
and related problems 
The success of an IRIV-based malaria vaccine may depend at least in parts on pre-
existing anti-influenza immunity. Despite a lack of information anti-influenza IgG is 
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found in sera from residents of sub-Saharan Africa (Nicole Westerfeld personal 
communication) and widespread influenza outbreaks in malaria endemic regions 
have been reported30. IRIVs are highly immunogenic in infants, the target population 
for a malaria vaccine, as seen with virosomal influenza (Inflexal®)31 and hepatitis A 
(Epaxal®)32 vaccines. The IRIV-based malaria vaccine described in this thesis largely 
depends on CD4 T cell stimulation by influenza epitopes on the virosomes (Peduzzi, 
unpublished). T cell help in IRIV-immunized individuals during infection with P. 
falciparum has to come from T cells specific for parasite epitopes, which were not 
present in the vaccine. Several studies have shown that natural infection with P. 
falciparum indeed induces helper T cell responses27,33. Taking into account the 
presence of a variety of CD4 T cell epitopes on a parasite, chances are high that a 
helper T cell response against at least one of these antigens will develop and support 
a boost of the vaccine-induced immunity.  
A crucial property of a successful malaria vaccine is the induction of a good 
immunological memory response. A successful vaccine has to induce a protective 
and long-lasting immune response, which depends on immunological memory. For P. 
falciparum it is known that the parasite interferes with the development of a memory 
response by modulating both memory T and B cell responses (reviewed in Good et 
al., 2004; Wykes and Good, 2006)8,34. A malaria vaccine thus has to induce an 
immune response, which differs from a natural response in terms of memory 
induction. As the mechanisms underlying interference of the parasite with 
immunological memory are not well understood, it will be difficult to rationally design 
vaccines overcoming this problem. Another concern for the development of a malaria 
vaccine is the observation that the presence of maternally derived antibodies at the 
time of immunization may interfere with the development of the infant’s own active 
immune response (reviewed in Good et al., 2004)8. Immunization with Epaxal® 
induces an almost four-fold higher antibody response in infants without maternal anti-
hepatitis A virus antibodies than those with maternal antibodies at baseline32. One 
explanation for this observation is that the passively acquired antibodies most likely 
inhibit the development of an antibody response by blocking the access to critical B 
cell epitopes35. Maternal antibodies can also affect the fine specificity of the 
newborn’s immune response by inducing antibodies to alternate, unmasked B cell 
epitopes. Increasing the dose of vaccine can be sufficient to circumvent inhibition by 
maternal antibodies, presumably by providing additional antigenic epitopes, which 
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remain free and accessible to infant B cells36. Cellular responses are in general not 
affected by maternal antibodies and can be boosted by subsequent 
immunizations35,36. With an IRIV-based vaccine it would be interesting to investigate 
the influence of maternal anti-influenza antibodies, as these could enhance 
opsonization and thereby increase the immunogenicity of IRIVs in influenza-naïve 
infants. At the same time maternal antibodies to P. falciparum antigens could inhibit 
the development of a humoral response to P. falciparum peptide components. In the 
light of these considerations, immunization schedules will need special attention and 
careful evaluation to find the right balance between the presence of maternal 
antibodies, the infant’s ability to mount an immune response and the vaccine 
formulation. 
The phase 1 study with a virosomal vaccine candidate based on CSP and AMA-1 
described in this thesis was a proof of concept that synthetic peptides delivered on 
IRIVs are safe and highly immunogenic. The final goal for a multivalent virosomal 
malaria vaccine is the inclusion of five or more peptide components from different 
life-stages of the parasite. In addition to the CSP, AMA-1 and SERA5 peptides 
characterized in this thesis we have other peptide components in development, 
including peptides-derived from blood-stage proteins MSP-1 (James et al. accepted), 
MSP-3, and D1337. Most of these candidates have completed preclinical optimization 
and characterization and are now ready for safety and immunogenicity studies in 
humans. The availability of genome information38 together with techniques for 
identification of novel antigens from genome-wide analysis is currently yielding many 
new potential targets39. 
As mentioned before, induction of both humoral and cellular immune responses to 
antigens from different life-stages of the parasite might be crucial for good vaccine 
efficacy. All above described peptide antigens are used as B cell epitopes but the 
IRIV technology is also suitable for the induction of cytotoxic T cell responses40,41. 
For a multi-component multi-stage vaccine approach it would be desirable to include 
T cell epitopes of liver-stage antigens for the induction of cytotoxic T cell responses 
in addition to B cell epitopes of blood-stage and sporozoite antigens. 
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9.1.6 Comparison with other malaria vaccine candidates 
One big advantage of the IRIV system compared to other malaria vaccine 
approaches is the principle of single building blocks, which can be combined into a 
multi-component subunit vaccine. Each building block, i.e. peptide derived from a P. 
falciparum antigen presented on virosomes, can be developed and evaluated 
separately before combining the components in one vaccine. Combined delivery of 
two different virosomally-formulated antigens did not interfere with the 
immunogenicity of single components in the phase 1a clinical trial described in this 
thesis. 
RTS,S/AS02A, the most advanced malaria vaccine is based on one sporozoite 
antigen only. It is a fusion protein containing the repeat region and flanking 
sequences of CSP fused to hepatitis B surface antigen (HBsAg) and is expressed 
together with unfused HBsAg in Saccharomyces cerevisiae (reviewed in Heppner et 
al., 2004)42. A phase 2b efficacy trial with RTS,S/AS02A in African children gave 
promising results: The vaccine showed 35% efficacy for time to first clinical episode 
and 49% efficacy for incidence of severe malaria for at least 18 month4. Although 
RTS,S/AS02A is the first pre-erythrocytic vaccine showing efficacy in the field it will 
probably need more development to be introduced as a standard vaccination. The 
mechanisms of protection are incompletely understood and it is generally agreed that 
a successful malaria vaccine should combine several antigens from different life-
stages of the parasite42,43. To include more components into RTS,S one has to face 
all the problems associated with recombinant protein production. High A/T content of 
the genome, high molecular weight, protein disorder, basic isoelectric points and 
unusual repeat motifs make the heterologous expression of recombinant P. 
falciparum proteins very difficult44. Moreover new vaccine constructs have to go 
through all the steps of clinical profiling again, whereas with IRIVs it can be argued 
that the substitution of short defined peptides on the virosome surface are minor 
changes and should not affect safety of the vaccine. Another advantage of IRIVs 
over the other experimental adjuvants is that they are already registered and used in 
many countries. More than 20 million doses of the two marketed virosomal vaccines 
Inflexal®V (influenza) and Epaxal® (hepatitis A) have been given so far45.  IRIVs are 
delivery system and adjuvant at the same time and have an excellent safety and 
immunogenicity profile. There are only two human compatible adjuvants on the 
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market. Alum, the most widespread adjuvant based on aluminium salts, is inferior to 
IRIVs in terms of immunogenicity and quality of induced antibodies10,46. 
RTS,S/AS02A is based on an experimental oil-in-water formulation with the 
additional adjuvants Monophosphoryl lipid A (MPL) and QS21 not yet registered for 
use in humans. MPL, the lipid moiety of bacterial LPS, and the saponin derivative 
QS21 (extracted from the plant Quillaja saponaria) are very potent 
immunostimulatory adjuvants47. Some of the researchers in the field have argued 
that some of the observed effects of the vaccine might be mediated by an unspecific 
stimulation of the immune system by the adjuvant and not by a sporozoite-specific 
immune response48. 
Another promising approach, which has entered clinical development is a DNA-
based heterologous prime-boost regimen developed at the University of Oxford 
(reviewed in Moore and Hill, 2004; Hill 2006)20,49. It is also a building block system 
based on plasmid DNA or recombinant attenuated live viral vectors such as 
adenovirus, fowlpox (FP9), and modified vaccinia Ankara (MVA) for prime-boost 
studies50. The most advanced of these studies involve a multi-epitope (ME) string 
fused to TRAP. The ME portion contains two B cell, 14 CD8, and three CD4 T cell 
epitopes from six sporozoite and/or liver stage antigens, including CSP, liver-stage 
antigen 1 (LSA-1), and LSA-3. Several Phase 1 and Phase 2a sporozoite challenge 
studies have been conducted in healthy malaria-naive adults to identify prime-boost 
vaccination regimens that optimize the cell-mediated immune response and generate 
protective immune responses. These regimens induce very high T cell responses in 
ex vivo ELISPOT assays24. Some of the tested regimens provided a prolongation of 
the pre-patent period, while other regimens completely protected a portion of 
volunteers against heterologous strain sporozoite challenge. The same vaccine 
candidates were safe and highly immunogenic in a series of phase 1 trials in adults 
and children in The Gambia51. Despite this initial success, a subsequent phase 2b 
proof of concept trial of a DNA/MVA prime-boost regimen in The Gambia failed to 
show a reduction of the natural infection rate23. A series of new FP-9 and MVA 
constructs was developed and was superior in eliciting cytotoxic T cell responses 
compared to the above described constructs in a series of phase 1 trials in the UK52. 
The new constructs were safe and immunogenic in Gambian53 and Kenyan adults 
and Kenyan children54 and will now be evaluated in phase 2 efficacy trials. The 
heterologous prime-boost system was also used with DNA encoding full-length CSP. 
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Various prime-boost combinations, doses, and application routes were safe and 
immunogenic in the UK55, and The Gambia56 but failed to show evidence of efficacy 
in phase 2a laboratory sporozoite challenge of malaria-naïve volunteers55. Although 
the building block system of this DNA approach is comparable to the IRIV system 
described in this thesis, DNA-immunization is focused on the induction of cellular 
immune responses, which is not suitable for blood-stage vaccine development. In the 
case of a malaria vaccine relying on cellular immunity against pre-erythrocytic stages 
only, one sporozoite escaping the immune response, successfully infecting a 
hepatocyte and developing into merozoites can be enough to cause full disease. For 
that reason a combination of T and B cell responses against pre-erythrocytic 
antigens with B cell responses against blood-stage antigens might be crucial for 
efficient protection against infection and/or disease. IRIVs can induce cytotoxic T cell 
responses against encapsulated antigens40. However the development and 
evaluation of a virosome-based malaria vaccine inducing both humoral and cellular 
immune responses will be very expensive and time-consuming. Therefore a 
combination of advanced approaches for the stimulation of different arms of the 
immune system against both parasite stages seems to be the most rational approach 
for the swift development of an efficient malaria vaccine. First clinical trials with 
combinations of two types of antigen delivery systems and different vaccine 
candidates have already begun. The above described ME-TRAP DNA-based prime-
boost approach was combined with the IRIV-based delivery of UK-39 and AMA49-
CPE in an ongoing clinical trial. Another combination including RTS,S/AS02A and 
MVA-CSP was safe and immunogenic in malaria-naïve subjects and showed 
protection against sporozoite challenge in some volunteers57. Taking into account 
these latest developments and findings, combination of promising and already 
advanced vaccine candidates seems to be the best solution for the fast development 
of an efficient malaria vaccine. 
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9.2 Concluding remarks 
We have presented in this thesis the establishment and use of a technology platform 
for the development and evaluation of synthetic peptides derived from P. falciparum 
epitopes for inclusion in a virosomal malaria vaccine candidate. We have shown that 
it is possible to improve immunogenic properties of lead peptides in a medicinal 
chemistry type stepwise optimization process and highlighted the importance of a 
detailed pre-clinical profiling of candidate peptides. A close to natural conformation of 
peptides appears to be crucial for the induction of parasite-binding antibodies and 
was achieved in some cases by conformational restriction of the peptide. A crucial 
advantage of IRIVs over alum as antigen delivery system seems to be that IRIVs do 
not disturb the conformation of the peptide antigens hooked via a PE-anchor to the 
virosomal membrane10. A phase 1 proof of concept study confirmed the potential of 
IRIVs as a human-compatible adjuvant and delivery system for easy to synthesize 
peptides. Both peptides tested were safe and immunogenic at appropriate doses and 
no serious adverse events were reported. Immunogenicity results from this phase 1 
clinical trial also confirmed the value of the animal models used during the pre-clinical 
profiling stage to predict the antibody responses elicited in humans. Detailed studies 
on the functional activity of the induced humoral responses in animal models and 
humans should help broadening our understanding of mechanisms underlying 
potential vaccine efficacy in the field. 
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